CA2697370A1 - Hiv env proteins with modifications in the v3 loop - Google Patents
Hiv env proteins with modifications in the v3 loop Download PDFInfo
- Publication number
- CA2697370A1 CA2697370A1 CA2697370A CA2697370A CA2697370A1 CA 2697370 A1 CA2697370 A1 CA 2697370A1 CA 2697370 A CA2697370 A CA 2697370A CA 2697370 A CA2697370 A CA 2697370A CA 2697370 A1 CA2697370 A1 CA 2697370A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- env
- loop
- hiv
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004048 modification Effects 0.000 title abstract description 10
- 238000012986 modification Methods 0.000 title abstract description 10
- 108010078428 env Gene Products Proteins 0.000 title description 11
- 102100034353 Integrase Human genes 0.000 title description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 212
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 209
- 229920001184 polypeptide Polymers 0.000 claims abstract description 207
- 239000000203 mixture Substances 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 40
- 230000035772 mutation Effects 0.000 claims abstract description 35
- 239000012634 fragment Substances 0.000 claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 claims description 97
- 101710149951 Protein Tat Proteins 0.000 claims description 77
- 238000012217 deletion Methods 0.000 claims description 32
- 230000037430 deletion Effects 0.000 claims description 32
- 230000008569 process Effects 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 10
- 239000012646 vaccine adjuvant Substances 0.000 claims description 6
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 210000005220 cytoplasmic tail Anatomy 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000027455 binding Effects 0.000 abstract description 28
- 101710121417 Envelope glycoprotein Proteins 0.000 abstract description 3
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 68
- 229940024606 amino acid Drugs 0.000 description 66
- 239000002671 adjuvant Substances 0.000 description 47
- 241000725303 Human immunodeficiency virus Species 0.000 description 38
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 35
- -1 aromatic amino acids Chemical class 0.000 description 31
- 239000000839 emulsion Substances 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 229960005486 vaccine Drugs 0.000 description 23
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 22
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 20
- 229920000053 polysorbate 80 Polymers 0.000 description 20
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 239000004094 surface-active agent Substances 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 14
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
- 208000031886 HIV Infections Diseases 0.000 description 12
- 229910019142 PO4 Inorganic materials 0.000 description 12
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 229930182490 saponin Natural products 0.000 description 12
- 235000017709 saponins Nutrition 0.000 description 12
- 150000007949 saponins Chemical class 0.000 description 12
- 229940031439 squalene Drugs 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 235000021317 phosphate Nutrition 0.000 description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 10
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 9
- 229920004890 Triton X-100 Polymers 0.000 description 9
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000004132 cross linking Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000010452 phosphate Substances 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000013504 Triton X-100 Substances 0.000 description 8
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 8
- 229940001007 aluminium phosphate Drugs 0.000 description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 229920000136 polysorbate Polymers 0.000 description 8
- 229940068968 polysorbate 80 Drugs 0.000 description 8
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 229920002113 octoxynol Polymers 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 229930003799 tocopherol Natural products 0.000 description 6
- 239000011732 tocopherol Substances 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 125000001475 halogen functional group Chemical group 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 5
- 239000007764 o/w emulsion Substances 0.000 description 5
- 229940066429 octoxynol Drugs 0.000 description 5
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- 235000010384 tocopherol Nutrition 0.000 description 5
- 229960001295 tocopherol Drugs 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 4
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 229920002114 octoxynol-9 Polymers 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 229920002884 Laureth 4 Polymers 0.000 description 3
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 3
- 241001644525 Nastus productus Species 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 238000012382 advanced drug delivery Methods 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940062711 laureth-9 Drugs 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920000056 polyoxyethylene ether Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- AXTGOJVKRHFYBT-XAZAIFFQSA-N (1r,2r,3r,6s,7s,8r)-3-(hydroxymethyl)-2,3,5,6,7,8-hexahydro-1h-pyrrolizine-1,2,6,7-tetrol Chemical compound O[C@@H]1[C@@H](O)CN2[C@H](CO)[C@@H](O)[C@H](O)[C@H]21 AXTGOJVKRHFYBT-XAZAIFFQSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 2
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229910003827 NRaRb Inorganic materials 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000219287 Saponaria Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- AXTGOJVKRHFYBT-UHFFFAOYSA-N causarine Natural products OC1C(O)CN2C(CO)C(O)C(O)C21 AXTGOJVKRHFYBT-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008876 conformational transition Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940042396 direct acting antivirals thiosemicarbazones Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 229940098514 octoxynol-9 Drugs 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010845 search algorithm Methods 0.000 description 2
- 239000010686 shark liver oil Substances 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003584 thiosemicarbazones Chemical class 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- IELOKBJPULMYRW-UHFFFAOYSA-N α-tocopherol succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-UHFFFAOYSA-N 0.000 description 2
- AXTGOJVKRHFYBT-PPOMMRCSSA-N (1r,2r,3r,6s,7r,8r)-3-(hydroxymethyl)-2,3,5,6,7,8-hexahydro-1h-pyrrolizine-1,2,6,7-tetrol Chemical compound O[C@H]1[C@@H](O)CN2[C@H](CO)[C@@H](O)[C@H](O)[C@H]21 AXTGOJVKRHFYBT-PPOMMRCSSA-N 0.000 description 1
- AXTGOJVKRHFYBT-JKVYXWIHSA-N (1r,2r,3s,6s,7s,8r)-3-(hydroxymethyl)-2,3,5,6,7,8-hexahydro-1h-pyrrolizine-1,2,6,7-tetrol Chemical compound O[C@@H]1[C@@H](O)CN2[C@@H](CO)[C@@H](O)[C@H](O)[C@H]21 AXTGOJVKRHFYBT-JKVYXWIHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NNWQLZWAZSJGLY-VKHMYHEASA-N (2s)-2-azaniumyl-4-azidobutanoate Chemical compound OC(=O)[C@@H](N)CCN=[N+]=[N-] NNWQLZWAZSJGLY-VKHMYHEASA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- UGXDVELKRYZPDM-XLXQKPBQSA-N (4r)-4-[[(2s,3r)-2-[[(2r)-2-[(2r,3r,4r,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O UGXDVELKRYZPDM-XLXQKPBQSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- NCNYEGJDGNOYJX-NSCUHMNNSA-N (e)-2,3-dibromo-4-oxobut-2-enoic acid Chemical compound OC(=O)C(\Br)=C(/Br)C=O NCNYEGJDGNOYJX-NSCUHMNNSA-N 0.000 description 1
- LUMLZKVIXLWTCI-NSCUHMNNSA-N (e)-2,3-dichloro-4-oxobut-2-enoic acid Chemical compound OC(=O)C(\Cl)=C(/Cl)C=O LUMLZKVIXLWTCI-NSCUHMNNSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LOAOIHRUSGLJNH-UHFFFAOYSA-N 1-[4-amino-2-(propylamino)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C(N(C(NCCC)=N3)CC(C)(C)O)C3=C(N)N=C21 LOAOIHRUSGLJNH-UHFFFAOYSA-N 0.000 description 1
- UAZGXHNQEPLRQL-UHFFFAOYSA-N 1-[4-amino-2-[methyl(propyl)amino]imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol;4-n,4-n-dibenzyl-2-n,2-n-dimethyl-1-(2-methylpropyl)imidazo[4,5-c]quinoline-2,4-diamine Chemical compound C1=CC=CC2=C(N(C(N(C)CCC)=N3)CC(C)(C)O)C3=C(N)N=C21.N1=C2C=CC=CC2=C2N(CC(C)C)C(N(C)C)=NC2=C1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 UAZGXHNQEPLRQL-UHFFFAOYSA-N 0.000 description 1
- HCQFIHRPZXGXCK-UHFFFAOYSA-N 1h-benzimidazol-2-amine;1h-quinolin-2-one Chemical compound C1=CC=C2NC(N)=NC2=C1.C1=CC=C2NC(=O)C=CC2=C1 HCQFIHRPZXGXCK-UHFFFAOYSA-N 0.000 description 1
- FKMHSNTVILORFA-UHFFFAOYSA-N 2-[2-(2-dodecoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCO FKMHSNTVILORFA-UHFFFAOYSA-N 0.000 description 1
- LTFBJORFHSIIDF-UHFFFAOYSA-N 2-[[4-amino-1-(2-methylpropyl)imidazo[4,5-c]quinolin-2-yl]-methylamino]ethanol;1-(2-methylpropyl)-2-propylsulfanylimidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(SCCC)=N3)CC(C)C)C3=C(N)N=C21.C1=CC=CC2=C3N(CC(C)C)C(N(C)CCO)=NC3=C(N)N=C21 LTFBJORFHSIIDF-UHFFFAOYSA-N 0.000 description 1
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
- CKURPKAGDUSTMO-UHFFFAOYSA-N 2-methoxy-2,4-dimethylpentanedial Chemical compound COC(C)(C=O)CC(C)C=O CKURPKAGDUSTMO-UHFFFAOYSA-N 0.000 description 1
- QBZUNKUEGZZDKZ-UHFFFAOYSA-N 2-n,2-n-dimethyl-1-(2-methylpropyl)imidazo[4,5-c]quinoline-2,4-diamine Chemical compound C1=CC=CC2=C3N(CC(C)C)C(N(C)C)=NC3=C(N)N=C21 QBZUNKUEGZZDKZ-UHFFFAOYSA-N 0.000 description 1
- NPZAROHMGGHDPW-UHFFFAOYSA-N 2-n-butyl-1-(2-methylpropyl)imidazo[4,5-c]quinoline-2,4-diamine Chemical compound C1=CC=CC2=C(N(C(NCCCC)=N3)CC(C)C)C3=C(N)N=C21 NPZAROHMGGHDPW-UHFFFAOYSA-N 0.000 description 1
- XWBPYBCOIBWQGA-UHFFFAOYSA-N 2-n-butyl-2-n-methyl-1-(2-methylpropyl)imidazo[4,5-c]quinoline-2,4-diamine Chemical compound C1=CC=CC2=C(N(C(N(C)CCCC)=N3)CC(C)C)C3=C(N)N=C21 XWBPYBCOIBWQGA-UHFFFAOYSA-N 0.000 description 1
- NVRJEKABHZWCLT-UHFFFAOYSA-N 2-n-ethyl-2-n-methyl-1-(2-methylpropyl)imidazo[4,5-c]quinoline-2,4-diamine Chemical compound C1=CC=CC2=C(N(C(N(C)CC)=N3)CC(C)C)C3=C(N)N=C21 NVRJEKABHZWCLT-UHFFFAOYSA-N 0.000 description 1
- NHENDFIAUHZKHD-UHFFFAOYSA-N 2-n-methyl-1-(2-methylpropyl)-2-n-pentylimidazo[4,5-c]quinoline-2,4-diamine Chemical compound C1=CC=CC2=C(N(C(N(C)CCCCC)=N3)CC(C)C)C3=C(N)N=C21 NHENDFIAUHZKHD-UHFFFAOYSA-N 0.000 description 1
- KASGFUACLOECDL-UHFFFAOYSA-N 2-n-methyl-1-(2-methylpropyl)-2-n-propylimidazo[4,5-c]quinoline-2,4-diamine;1-(2-methylpropyl)-2-n-propylimidazo[4,5-c]quinoline-2,4-diamine Chemical compound C1=CC=CC2=C(N(C(NCCC)=N3)CC(C)C)C3=C(N)N=C21.C1=CC=CC2=C(N(C(N(C)CCC)=N3)CC(C)C)C3=C(N)N=C21 KASGFUACLOECDL-UHFFFAOYSA-N 0.000 description 1
- BWIQMBLDRUXPEN-UHFFFAOYSA-N 2-n-methyl-1-(2-methylpropyl)imidazo[4,5-c]quinoline-2,4-diamine Chemical compound C1=CC=CC2=C(N(C(NC)=N3)CC(C)C)C3=C(N)N=C21 BWIQMBLDRUXPEN-UHFFFAOYSA-N 0.000 description 1
- LYFYWXLKKQIOKO-UHFFFAOYSA-N 3,3-diaminopentan-1-ol Chemical compound CCC(N)(N)CCO LYFYWXLKKQIOKO-UHFFFAOYSA-N 0.000 description 1
- RNPNPRNZMIAEOB-UHFFFAOYSA-N 3-methoxy-2,4-dimethylpentanedial Chemical compound O=CC(C)C(OC)C(C)C=O RNPNPRNZMIAEOB-UHFFFAOYSA-N 0.000 description 1
- LUNMJPAJHJAGIS-UHFFFAOYSA-N 3-methylpentanedial Chemical compound O=CCC(C)CC=O LUNMJPAJHJAGIS-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- BBLLLLZSENOJNX-UHFFFAOYSA-N 4-amino-1-(2-methylpropyl)-3h-imidazo[4,5-c]quinolin-2-one;2-[[4-amino-1-(2-methylpropyl)imidazo[4,5-c]quinolin-2-yl]-methylamino]ethyl acetate Chemical compound NC1=NC2=CC=CC=C2C2=C1NC(=O)N2CC(C)C.C1=CC=CC2=C3N(CC(C)C)C(N(C)CCOC(C)=O)=NC3=C(N)N=C21 BBLLLLZSENOJNX-UHFFFAOYSA-N 0.000 description 1
- LFSSQJVAUYCMJC-UHFFFAOYSA-N 4-n,4-n-dibenzyl-1-(2-methoxy-2-methylpropyl)-2-n-propylimidazo[4,5-c]quinoline-2,4-diamine Chemical compound N1=C2C=CC=CC2=C2N(CC(C)(C)OC)C(NCCC)=NC2=C1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 LFSSQJVAUYCMJC-UHFFFAOYSA-N 0.000 description 1
- LWEOGJDQDPSCLA-UHFFFAOYSA-N 4-n,4-n-dibenzyl-2-n-butyl-1-(2-methylpropyl)imidazo[4,5-c]quinoline-2,4-diamine Chemical compound N1=C2C=CC=CC2=C2N(CC(C)C)C(NCCCC)=NC2=C1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 LWEOGJDQDPSCLA-UHFFFAOYSA-N 0.000 description 1
- GYSNQANFUBOXHG-UHFFFAOYSA-N 4-n,4-n-dibenzyl-2-n-butyl-2-n-methyl-1-(2-methylpropyl)imidazo[4,5-c]quinoline-2,4-diamine Chemical compound N1=C2C=CC=CC2=C2N(CC(C)C)C(N(C)CCCC)=NC2=C1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 GYSNQANFUBOXHG-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- PXBWLHQLSCMJEM-IOSLPCCCSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC2=C(O)N=CN=C2N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O PXBWLHQLSCMJEM-IOSLPCCCSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- UMHJEEQLYBKSAN-UHFFFAOYSA-N Adipaldehyde Chemical compound O=CCCCCC=O UMHJEEQLYBKSAN-UHFFFAOYSA-N 0.000 description 1
- 229910017089 AlO(OH) Inorganic materials 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- DQYBRTASHMYDJG-UHFFFAOYSA-N Bisindolylmaleimide Chemical class C1=CC=C2C(C=3C(=O)NC(C=3C=3C4=CC=CC=C4NC=3)=O)=CNC2=C1 DQYBRTASHMYDJG-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- LHCCCGMHSKUILO-UHFFFAOYSA-N CC(CN1C(=NC=2C(=NC=3C=CC=CC3C21)N)SCC2=CC=CC=C2)C.CN(C=2N(C1=C(C(=NC=3C=CC=CC13)N)N2)CC(C)C)CC=C Chemical compound CC(CN1C(=NC=2C(=NC=3C=CC=CC3C21)N)SCC2=CC=CC=C2)C.CN(C=2N(C1=C(C(=NC=3C=CC=CC13)N)N2)CC(C)C)CC=C LHCCCGMHSKUILO-UHFFFAOYSA-N 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 101100041687 Drosophila melanogaster san gene Proteins 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 244000140063 Eragrostis abyssinica Species 0.000 description 1
- 235000014966 Eragrostis abyssinica Nutrition 0.000 description 1
- 241001337814 Erysiphe glycines Species 0.000 description 1
- 108010000227 GP 140 Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical group NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 230000005154 HIV tropism Effects 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
- GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical group CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- GOWLTLODGKPXMN-MEKRSRHXSA-N OM-174 Chemical compound O1[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1CO[C@H]1[C@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 GOWLTLODGKPXMN-MEKRSRHXSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 240000002493 Smilax officinalis Species 0.000 description 1
- 235000008981 Smilax officinalis Nutrition 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- VQQVWGVXDIPORV-UHFFFAOYSA-N Tryptanthrine Natural products C1=CC=C2C(=O)N3C4=CC=CC=C4C(=O)C3=NC2=C1 VQQVWGVXDIPORV-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- ZBNRGEMZNWHCGA-PDKVEDEMSA-N [(2r)-2-[(2r,3r,4s)-3,4-bis[[(z)-octadec-9-enoyl]oxy]oxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC ZBNRGEMZNWHCGA-PDKVEDEMSA-N 0.000 description 1
- ZWELIJXAKMASLK-UGKPPGOTSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-2-(hydroxymethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@@H](CO)O[C@H]1N1C(=O)SC2=CN=C(N)N=C21 ZWELIJXAKMASLK-UGKPPGOTSA-N 0.000 description 1
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4ar,5r,6as,6br,9s,10s,12ar)-10-[(2r,3r,4s, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001399 aluminium compounds Chemical class 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940077746 antacid containing aluminium compound Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- HMPYIUYVCATRNB-XFQQQPONSA-L disodium;2-[2-[[(2r)-3-[(3r)-3-dodecanoyloxydecoxy]-2-(tetradecanoylamino)propoxy]-oxidophosphoryl]oxyethylcarbamoylamino]ethyl [(2r)-3-[(3r)-3-dodecanoyloxydecoxy]-2-(tetradecanoylamino)propyl] phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCC(=O)O[C@H](CCCCCCC)CCOC[C@@H](NC(=O)CCCCCCCCCCCCC)COP([O-])(=O)OCCNC(=O)NCCOP([O-])(=O)OC[C@@H](COCC[C@@H](CCCCCCC)OC(=O)CCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC HMPYIUYVCATRNB-XFQQQPONSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000002195 fatty ethers Chemical class 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229910001679 gibbsite Inorganic materials 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229940124669 imidazoquinoline Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical class C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- ZLVYMPOQNJTFSG-QMMMGPOBSA-N monoiodotyrosine Chemical compound OC(=O)[C@@H](NI)CC1=CC=C(O)C=C1 ZLVYMPOQNJTFSG-QMMMGPOBSA-N 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- PKDBSOOYVOEUQR-UHFFFAOYSA-N mucobromic acid Natural products OC1OC(=O)C(Br)=C1Br PKDBSOOYVOEUQR-UHFFFAOYSA-N 0.000 description 1
- ZAKLKBFCSHJIRI-UHFFFAOYSA-N mucochloric acid Natural products OC1OC(=O)C(Cl)=C1Cl ZAKLKBFCSHJIRI-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- SCIFESDRCALIIM-UHFFFAOYSA-N n-methylphenylalanine Chemical compound CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical class CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- NKXSJFUIFJMXED-UHFFFAOYSA-N quinoline-2,4-diamine Chemical compound C1=CC=CC2=NC(N)=CC(N)=C21 NKXSJFUIFJMXED-UHFFFAOYSA-N 0.000 description 1
- 150000003252 quinoxalines Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention concerns modification of the V3 loop of the HIV envelope glycoprotein in order to alter its Tat--binding properties. The invention provides a mixture of (i) a HIV Tat polypeptide and (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. Also a method comprising a step of: combining a HIV Env polypeptide with a HIV Tat polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. Also a mixture of (i) a HIV Tat polypeptide and (ii) a polypeptide comprising a fragment of a V3 loop of a HIV
Env polypeptide.
Env polypeptide.
Description
This application claims priority from US provisional application 60/966,048, the full contents of which are incorporated herein by reference.
GOVERNMENT SUPPORT
The application was made with support from the United States NIAID-NIH HIVRAD
under Grant No. 5P01 A148225-03. Thus, the U.S. Government may have certain rights in this invention.
TECHNICAL FIELD
This invention is in the field of human immunodeficiency virus (HIV) and, in particular, the viral envelope glycoproteins and their manipulation.
BACKGROUND OF THE INVENTION
The various proteins encoded within the HIV genome include the envelope glycoprotein (Env) and the trans-activating transcriptional factor (Tat).
In both HIV-1 and HIV-2 the Env protein is initially expressed as a long precursor protein that is subsequently cleaved to give an exterior membrane glycoprotein and a transmembrane glycoprotein. For convenience, these proteins are hereafter referred to by the standard HIV-1 nomenclature i.e. the precursor is `gp160', the membrane glycoprotein is `gp120' and the transmembrane glycoprotein is 'gp4l'. These names are based on approximate molecular weights of the HIV-1 glycoproteins.
Situated on the surface of HIV virions, gp120 can interact with the host cell CD4 receptor. This interaction induces a conformational transition in gp120, leading to the exposure of its `V3' loop.
Deletion studies have suggested that accessibility of the V3 region is influenced by the 'Vl' and `V2' loops, see, Sourial et al. (2006) Curr HIV Res. 4(2):229-37. For example, Srivastava et al.
(2003) J Virol 77(4):2310-20 reports that deletion of the V2 loop can alter the immunogenicity of the V 1 and V3 loops.
Because of its surface exposure, gp120 has been the main focus of HIV vaccine research over the last 20 years. While anti-Env antibodies that arise during natural infection have been found to neutralize primary HIV isolates, however, the same has not been true of antibodies elicited by Env-based subunit vaccines. Improvements to Env-based vaccines are therefore required.
Tat protein is important in regulating HIV gene expression. Although it is a transcription factor, it has also been found to be released by infected cells and has been proposed as a vaccine antigen.
W02005/090391 discloses that Env and Tat proteins can interact to form a complex. The interaction is said to require the presence of the V3 loop in the Env protein.
A vaccine based on a combination of Env and Tat polypeptides is also disclosed in e.g., Ensoli et al. (2005) Microbes Infect 7:1392-9.
It is an object to provide Env-derived polypeptides with altered Tat-binding properties.
SUMMARY OF THE INVENTION
The present invention is directed to a mixture of (i) a HIV Tat polypeptide and (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. In one embodiment, the HIV Tat polypeptide and the HIV Env polypeptide form a complex. In certain embodiments, the HIV Tat polypeptide and the HIV Env polypeptide are covalently linked to each other.
The present invention is also directed to a process for preparing a mixture of (i) a HIV Tat polypeptide and (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. In one embodiment, the process comprises mixing (i) a HIV Tat polypeptide with (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. In other embodiments, the process comprises combining a HIV Env polypeptide with a HIV Tat polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. In certain embodiments, the process comprises a further step of: determining if the Env and Tat polypeptides have formed a complex.
The present invention is also directed to a HIV Env polypeptide having a mutant V3 loop sequence, wherein the mutant sequence is selected from the group consisting of SEQ IDs 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24.
In certain embodiments, the Env polypeptide of the mixtures, processes or polypeptides of the invention includes one or more mutation(s) outside the V3 loop. In other embodiments, the Env polypeptide lacks the wild-type transmembrane domain and cytoplasmic tail. In still other embodiments, the Env polypeptide includes one or more deletion(s) within the V2 loop. In certain embodiments, the Env polypeptide has a V3 loop with an amino acid sequence selected from the group consisting of SEQ ID NOs: 15 to 24. In other embodiments, the Env polypeptide has a V3 loop with amino acid sequence SEQ ID NO: 29.
The invention is also directed to a mixture of (i) a HIV Tat polypeptide and (ii) a polypeptide comprising a fragment of a V3 loop of a HIV Env polypeptide, wherein the polypeptide of (ii) is no longer than 100 amino acids and includes at least 5 consecutive amino acids from a HIV Env polypeptide V3 loop. In certain embodiments, the polypeptide of (ii) is <30 amino acids long. In other embodiments, the polypeptide of (ii) is cyclic. In further embodiments, the fragment of (ii) has an amino acid sequence selected from group consisting of SEQ ID NOs: 30 to 37.
In certain embodiments, the Tat polypeptide of the mixtures, processes or polypeptides of the invention has amino acid sequence SEQ ID NO: 12.
GOVERNMENT SUPPORT
The application was made with support from the United States NIAID-NIH HIVRAD
under Grant No. 5P01 A148225-03. Thus, the U.S. Government may have certain rights in this invention.
TECHNICAL FIELD
This invention is in the field of human immunodeficiency virus (HIV) and, in particular, the viral envelope glycoproteins and their manipulation.
BACKGROUND OF THE INVENTION
The various proteins encoded within the HIV genome include the envelope glycoprotein (Env) and the trans-activating transcriptional factor (Tat).
In both HIV-1 and HIV-2 the Env protein is initially expressed as a long precursor protein that is subsequently cleaved to give an exterior membrane glycoprotein and a transmembrane glycoprotein. For convenience, these proteins are hereafter referred to by the standard HIV-1 nomenclature i.e. the precursor is `gp160', the membrane glycoprotein is `gp120' and the transmembrane glycoprotein is 'gp4l'. These names are based on approximate molecular weights of the HIV-1 glycoproteins.
Situated on the surface of HIV virions, gp120 can interact with the host cell CD4 receptor. This interaction induces a conformational transition in gp120, leading to the exposure of its `V3' loop.
Deletion studies have suggested that accessibility of the V3 region is influenced by the 'Vl' and `V2' loops, see, Sourial et al. (2006) Curr HIV Res. 4(2):229-37. For example, Srivastava et al.
(2003) J Virol 77(4):2310-20 reports that deletion of the V2 loop can alter the immunogenicity of the V 1 and V3 loops.
Because of its surface exposure, gp120 has been the main focus of HIV vaccine research over the last 20 years. While anti-Env antibodies that arise during natural infection have been found to neutralize primary HIV isolates, however, the same has not been true of antibodies elicited by Env-based subunit vaccines. Improvements to Env-based vaccines are therefore required.
Tat protein is important in regulating HIV gene expression. Although it is a transcription factor, it has also been found to be released by infected cells and has been proposed as a vaccine antigen.
W02005/090391 discloses that Env and Tat proteins can interact to form a complex. The interaction is said to require the presence of the V3 loop in the Env protein.
A vaccine based on a combination of Env and Tat polypeptides is also disclosed in e.g., Ensoli et al. (2005) Microbes Infect 7:1392-9.
It is an object to provide Env-derived polypeptides with altered Tat-binding properties.
SUMMARY OF THE INVENTION
The present invention is directed to a mixture of (i) a HIV Tat polypeptide and (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. In one embodiment, the HIV Tat polypeptide and the HIV Env polypeptide form a complex. In certain embodiments, the HIV Tat polypeptide and the HIV Env polypeptide are covalently linked to each other.
The present invention is also directed to a process for preparing a mixture of (i) a HIV Tat polypeptide and (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. In one embodiment, the process comprises mixing (i) a HIV Tat polypeptide with (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. In other embodiments, the process comprises combining a HIV Env polypeptide with a HIV Tat polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. In certain embodiments, the process comprises a further step of: determining if the Env and Tat polypeptides have formed a complex.
The present invention is also directed to a HIV Env polypeptide having a mutant V3 loop sequence, wherein the mutant sequence is selected from the group consisting of SEQ IDs 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24.
In certain embodiments, the Env polypeptide of the mixtures, processes or polypeptides of the invention includes one or more mutation(s) outside the V3 loop. In other embodiments, the Env polypeptide lacks the wild-type transmembrane domain and cytoplasmic tail. In still other embodiments, the Env polypeptide includes one or more deletion(s) within the V2 loop. In certain embodiments, the Env polypeptide has a V3 loop with an amino acid sequence selected from the group consisting of SEQ ID NOs: 15 to 24. In other embodiments, the Env polypeptide has a V3 loop with amino acid sequence SEQ ID NO: 29.
The invention is also directed to a mixture of (i) a HIV Tat polypeptide and (ii) a polypeptide comprising a fragment of a V3 loop of a HIV Env polypeptide, wherein the polypeptide of (ii) is no longer than 100 amino acids and includes at least 5 consecutive amino acids from a HIV Env polypeptide V3 loop. In certain embodiments, the polypeptide of (ii) is <30 amino acids long. In other embodiments, the polypeptide of (ii) is cyclic. In further embodiments, the fragment of (ii) has an amino acid sequence selected from group consisting of SEQ ID NOs: 30 to 37.
In certain embodiments, the Tat polypeptide of the mixtures, processes or polypeptides of the invention has amino acid sequence SEQ ID NO: 12.
The present invention is also directed to a pharmaceutical composition comprising a mixture of the invention. In certain embodiments, the pharmaceutical composition of the invention includes a vaccine adjuvant.
The present invention is also directed to a method of raising an immune response in a patient, comprising the step of administering a composition of the invention the patient.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 shows the results of a Far-Western assay. Lanes are: (1) markers at 35, 50, 75, 105, 160 and 250 kDa; (2) gpl40AV2; (3) gpl400V2 + CD4; (4) gpl40dV3-22; (5) gpl40dV3-22 + CD4;
(6) gp120; (7) gp120 + CD4; and (8) CD4.
DETAILED DESCRIPTION OF THE INVENTION
In general terms, the invention concerns modification of the V3 loop of the HIV envelope glycoprotein in order to alter its Tat-binding properties.
The invention provides a mixture of (i) a HIV Tat polypeptide and (ii) a HIV
Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. The Tat and Env polypeptides may form a complex and may, as described in more detail below, be covalently linked.
The invention also provides a process for preparing a polypeptide mixture, comprising a step of mixing (i) a HIV Tat polypeptide with (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop.
The invention also provides a method comprising a step of: combining a HIV Env polypeptide with a HIV Tat polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. The method may comprise a further step of: determining if the Env and Tat polypeptides have formed a complex. This further step allows the effect of different V3 mutations on Tat-binding activity to be determined. Any complexes formed by the V3 mutants can be compared to complexes formed by wild-type Env. The mutants may form weaker or stronger complexes than wild-type Env (e.g. tighter association constant), or may form complexes more quickly or slowly, etc. The invention also provides an Env polypeptide with one or more mutations in its V3 loop, identified by such methods as having a higher affinity for Tat than wild-type Env.
The invention also provides a HIV Env polypeptide having a V3 loop sequence selected from the group consisting of SEQ IDs 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 29.
The invention also provides a mixture of (i) a HIV Tat polypeptide and (ii) a polypeptide comprising a fragment of a V3 loop of a HIV Env polypeptide. The polypeptide of (ii) will usually be no longer than 100 amino acids, but the fragment will usually have at least 5 amino acids from a V3 loop (usually 5 consecutive amino acids from a V3 loop). The two polypeptides may form a complex, and may be covalently linked.
The Env polypeptide In some embodiments, mixtures of the invention include a HIV Env polypeptide that has one or more mutations in its V3 loop.
Various forms of Env polypeptide can be used, from HIV-1 or HIV-2. For example, the mixture may include a full-length gp160 Env polypeptide with V3 mutation(s), a gp120 Env polypeptide with V3 mutation(s), a truncated gp120 or gp160 Env polypeptide with V3 mutation(s), gp160 or gp120 polypeptide with V3 mutation(s) and one or more deletions outside V3, a fusion protein including a gp120 or gp160 polypeptide with V3 mutation(s), etc. Rather than being a full-length Env precursor with V3 mutation(s), however, the invention will typically use a shortened protein.
The amino acid sequence of the full-length HIV-1 Env precursor from the REFSEQ
database (GI:9629363) is a 856mer shown below (SEQ ID NO: 1 herein; V3 loop underlined):
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWA
THACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNT
NSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSF
EPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPWSTQLLLNGSLAEEEWIRSVNFTDN
AKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRI
KQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVK
IEPLGVAPTKAKRRWQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIE
AQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWME
WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHR
LRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEWQGACRAI
RHIPRRIRQGLERILL
This wild-type HIV-1 precursor protein is cleaved to give the surface glycoprotein gp120 (e.g.
amino acids 29-511 of SEQ ID NO: 1; SEQ ID NO: 2 herein) and the transmembrane domain gp4l (e.g. amino acids 512-856 of SEQ ID NO: 1; SEQ ID NO: 3 herein):
MRVKEKYQHLWRWGWRWGTMLLGMLMIC/SATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVW
ATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTN
TNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVS
FEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPWSTQLLLNGSLAEEEWIRSVNFTD
NAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKL
REQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCR
IKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVV
KIEPLGVAPTKAKRRWQREKR/AVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRA
IEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTW
MEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIV
FAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSY
HRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEWQGACR
AIRHIPRRIRQGLERILL
The hypervariable regions within the gp120 region are located as follows, numbered according to SEQ ID NO: 1: V1 = 131-157; V2 = 157-196; V3 = 296-331; V4 = 385-418; and V5 =
461-471.
The present invention is also directed to a method of raising an immune response in a patient, comprising the step of administering a composition of the invention the patient.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 shows the results of a Far-Western assay. Lanes are: (1) markers at 35, 50, 75, 105, 160 and 250 kDa; (2) gpl40AV2; (3) gpl400V2 + CD4; (4) gpl40dV3-22; (5) gpl40dV3-22 + CD4;
(6) gp120; (7) gp120 + CD4; and (8) CD4.
DETAILED DESCRIPTION OF THE INVENTION
In general terms, the invention concerns modification of the V3 loop of the HIV envelope glycoprotein in order to alter its Tat-binding properties.
The invention provides a mixture of (i) a HIV Tat polypeptide and (ii) a HIV
Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. The Tat and Env polypeptides may form a complex and may, as described in more detail below, be covalently linked.
The invention also provides a process for preparing a polypeptide mixture, comprising a step of mixing (i) a HIV Tat polypeptide with (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop.
The invention also provides a method comprising a step of: combining a HIV Env polypeptide with a HIV Tat polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop. The method may comprise a further step of: determining if the Env and Tat polypeptides have formed a complex. This further step allows the effect of different V3 mutations on Tat-binding activity to be determined. Any complexes formed by the V3 mutants can be compared to complexes formed by wild-type Env. The mutants may form weaker or stronger complexes than wild-type Env (e.g. tighter association constant), or may form complexes more quickly or slowly, etc. The invention also provides an Env polypeptide with one or more mutations in its V3 loop, identified by such methods as having a higher affinity for Tat than wild-type Env.
The invention also provides a HIV Env polypeptide having a V3 loop sequence selected from the group consisting of SEQ IDs 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 29.
The invention also provides a mixture of (i) a HIV Tat polypeptide and (ii) a polypeptide comprising a fragment of a V3 loop of a HIV Env polypeptide. The polypeptide of (ii) will usually be no longer than 100 amino acids, but the fragment will usually have at least 5 amino acids from a V3 loop (usually 5 consecutive amino acids from a V3 loop). The two polypeptides may form a complex, and may be covalently linked.
The Env polypeptide In some embodiments, mixtures of the invention include a HIV Env polypeptide that has one or more mutations in its V3 loop.
Various forms of Env polypeptide can be used, from HIV-1 or HIV-2. For example, the mixture may include a full-length gp160 Env polypeptide with V3 mutation(s), a gp120 Env polypeptide with V3 mutation(s), a truncated gp120 or gp160 Env polypeptide with V3 mutation(s), gp160 or gp120 polypeptide with V3 mutation(s) and one or more deletions outside V3, a fusion protein including a gp120 or gp160 polypeptide with V3 mutation(s), etc. Rather than being a full-length Env precursor with V3 mutation(s), however, the invention will typically use a shortened protein.
The amino acid sequence of the full-length HIV-1 Env precursor from the REFSEQ
database (GI:9629363) is a 856mer shown below (SEQ ID NO: 1 herein; V3 loop underlined):
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWA
THACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNT
NSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSF
EPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPWSTQLLLNGSLAEEEWIRSVNFTDN
AKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRI
KQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVK
IEPLGVAPTKAKRRWQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIE
AQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWME
WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHR
LRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEWQGACRAI
RHIPRRIRQGLERILL
This wild-type HIV-1 precursor protein is cleaved to give the surface glycoprotein gp120 (e.g.
amino acids 29-511 of SEQ ID NO: 1; SEQ ID NO: 2 herein) and the transmembrane domain gp4l (e.g. amino acids 512-856 of SEQ ID NO: 1; SEQ ID NO: 3 herein):
MRVKEKYQHLWRWGWRWGTMLLGMLMIC/SATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVW
ATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTN
TNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVS
FEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPWSTQLLLNGSLAEEEWIRSVNFTD
NAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKL
REQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCR
IKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVV
KIEPLGVAPTKAKRRWQREKR/AVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRA
IEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTW
MEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIV
FAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSY
HRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEWQGACR
AIRHIPRRIRQGLERILL
The hypervariable regions within the gp120 region are located as follows, numbered according to SEQ ID NO: 1: V1 = 131-157; V2 = 157-196; V3 = 296-331; V4 = 385-418; and V5 =
461-471.
Within the overall CI-V1-V2-C2-V3-C3-V4-C4-V5-C5 arrangement of gp120, therefore, the subdomains are as follows (numbered according to SEQ ID NO: 2): 1-102; 103-129; 129-168;
169-267; 268-303; 304-356; 357-390; 391-432; 433-443; and 444-483. The coordinates of these subdomains can be identified in other HIV-1 Env sequences by performing a suitable sequence alignment. Pre-aligned sequences from numerous strains, annotated with these features, can also be found in the Los Alamos HIV Sequence Compendia http://hiv-web.lanl.gov For instance, the Env sequence (SEQ ID NO: 38) after removal of the leader is shown below for the SF162 strain (SEQ ID NO: 7; V3 loop underlined). It is cleaved after Arg-475 to give the mature proteins, including the gp120 (SEQ ID NO: 50 herein, namely amino acids 1-475 of SEQ
ID NO: 7):
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVTTSIRNKM
QKEYALFYKLDVVPIDNDNTSYKLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPC
TNVSTVQCTHGIRPVVSTQLLLNGSLAEEGWIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRKSITI
GPGRAFYATGDIIGDIRQAHCNISGEKWNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGGE
FFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTRD
GGKEISNTTEIFRPGGGDMRDNWRSELYKYKWKIEPLGVAPTKAKR.RWQREKRAVTLGAMFLGFLGAA
GSTMGARSLTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIW
GCSGKLICTTAVPWNASWSNKSLDQIWNNMTWMEWEREIDNYTNLIYTLIEESQNQQEKNEQELLELDKW
ASLWNWFDISKWLWYIKIFIMIVGGLVGLRIVFTVLSIVNRVRQGYSPLSFQTRFPAPRGPDRPEGIEEE
GGERDRDRSSPLVHGLLALIWDDLRSLCLFSYHRLRDLILIAARIVELLGRRGWEALKYWGNLLQYWIQE
LKNSAVSLFDAIAIAVAEGTDRIIEVAQRIGRAFLHIPRRIRQGFERALL
The hypervariable regions in the SF162 strain, numbered according to SEQ ID
NO: 7, are:
V1 = 98-128; V2 = 128-167; V3 = 267-301; V4 = 354-381; and V5 = 423-435.
The amino acid sequence of a full-length HIV-2 Env precursor (GI:2144996) is a 852mer shown below (SEQ ID NO: 4 herein; V3 loop underlined):
MCGKSLLCVASLLASAYLVYCTQYVTVFYGVPVWRNASIPLFCATKNRDTWGTIQCKPDNDDYQEITLNV
TEAFDAWDNTVTEQAVEDVWSLFETSIKPCVKLTPLCVAMSCNSTTNNTTTTGSTTGMSEINETSPSYSD
NCTGLGKEEIVNCQFYMTGLERDKKKQYNETWYSKDVVCESNNTKDGKNRCYMNHCNTSVITESCDKHYW
DAIKFRYCAPPGYALLRCNDTNYSGFEPKCSKWASTCTRMMETQTSTWFGFNGTRAENRTYIYWHGRDN
RTIISLNKYYNLSIHCKRPGNKTVVPITLMSGLVFHSQPINTRPRQAWCWFKGKWREAMQEVKQTLIKHP
RYKGTNDTKNINFTKPGRGSDPEVAYMWTNCRGEFLYCNMTWFLNWVENRPNQTQHNYAPCHIRQIINTW
HKVGKNVYLPPREGQLTCNSTVTSIIANIDVNSNQTNITFSAEVAELYRLELGDYKLIEVTPIGFAPTRE
KRYSSAPVRNKRGVFVLGFLGFLATAGSAMGAASLTLSAQSRTLLAGIVQQQQQLLDVVKRQQEMLRLTV
WGTKNLQARVTAIEKYLKDQAQLNSWGCAFRQVCHTTVPWVNDSLSPDWNNMTWQEWEKQVRYLEANISQ
SLEQAQIQQEKNMYELQKLNSWDVFGNWFDLTSWIKYIQYGVYIWGVIVLRIAIYIVQLLSRLRKGYRP
VFSSPPGYLQQIHIHTDRGQPANEGTEEDDRDDDGYDLXPWPINYIHFLIHLLTRLLTGLYKICRDLLST
NSPTHRLISQNLTAIRDWLRLKAAYLQYGGEWIQEAFQAFAKTTRETLASAWGGLCAAVQRVGRGILAVP
RRIRQGAEIALL
The HIV-2 Env precursor protein is cleaved to give the surface glycoprotein (e.g. amino acids 20-502 of SEQ ID NO: 4; SEQ ID NO: 5 herein) and the transmembrane domain (e.g. amino acids 503-852 of SEQ ID NO: 4; SEQ ID NO: 6 herein):
MCGKSLLCVASLLASAYLV/YCTQYVTVFYGVPVWRNASIPLFCATKNRDTWGTIQCKPDNDDYQEITLN
VTEAFDAWDNTVTEQAVEDVWSLFETSIKPCVKLTPLCVAMSCNSTTNNTTTTGSTTGMSEINETSPSYS
DNCTGLGKEEIVNCQFYMTGLERDKKKQYNETWYSKDWCESNNTKDGKNRCYMNHCNTSVITESCDKHY
WDAIKFRYCAPPGYALLRCNDTNYSGFEPKCSKWASTCTRMMETQTSTWFGFNGTRAENRTYIYWHGRD
169-267; 268-303; 304-356; 357-390; 391-432; 433-443; and 444-483. The coordinates of these subdomains can be identified in other HIV-1 Env sequences by performing a suitable sequence alignment. Pre-aligned sequences from numerous strains, annotated with these features, can also be found in the Los Alamos HIV Sequence Compendia http://hiv-web.lanl.gov For instance, the Env sequence (SEQ ID NO: 38) after removal of the leader is shown below for the SF162 strain (SEQ ID NO: 7; V3 loop underlined). It is cleaved after Arg-475 to give the mature proteins, including the gp120 (SEQ ID NO: 50 herein, namely amino acids 1-475 of SEQ
ID NO: 7):
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVTTSIRNKM
QKEYALFYKLDVVPIDNDNTSYKLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPC
TNVSTVQCTHGIRPVVSTQLLLNGSLAEEGWIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRKSITI
GPGRAFYATGDIIGDIRQAHCNISGEKWNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGGE
FFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTRD
GGKEISNTTEIFRPGGGDMRDNWRSELYKYKWKIEPLGVAPTKAKR.RWQREKRAVTLGAMFLGFLGAA
GSTMGARSLTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIW
GCSGKLICTTAVPWNASWSNKSLDQIWNNMTWMEWEREIDNYTNLIYTLIEESQNQQEKNEQELLELDKW
ASLWNWFDISKWLWYIKIFIMIVGGLVGLRIVFTVLSIVNRVRQGYSPLSFQTRFPAPRGPDRPEGIEEE
GGERDRDRSSPLVHGLLALIWDDLRSLCLFSYHRLRDLILIAARIVELLGRRGWEALKYWGNLLQYWIQE
LKNSAVSLFDAIAIAVAEGTDRIIEVAQRIGRAFLHIPRRIRQGFERALL
The hypervariable regions in the SF162 strain, numbered according to SEQ ID
NO: 7, are:
V1 = 98-128; V2 = 128-167; V3 = 267-301; V4 = 354-381; and V5 = 423-435.
The amino acid sequence of a full-length HIV-2 Env precursor (GI:2144996) is a 852mer shown below (SEQ ID NO: 4 herein; V3 loop underlined):
MCGKSLLCVASLLASAYLVYCTQYVTVFYGVPVWRNASIPLFCATKNRDTWGTIQCKPDNDDYQEITLNV
TEAFDAWDNTVTEQAVEDVWSLFETSIKPCVKLTPLCVAMSCNSTTNNTTTTGSTTGMSEINETSPSYSD
NCTGLGKEEIVNCQFYMTGLERDKKKQYNETWYSKDVVCESNNTKDGKNRCYMNHCNTSVITESCDKHYW
DAIKFRYCAPPGYALLRCNDTNYSGFEPKCSKWASTCTRMMETQTSTWFGFNGTRAENRTYIYWHGRDN
RTIISLNKYYNLSIHCKRPGNKTVVPITLMSGLVFHSQPINTRPRQAWCWFKGKWREAMQEVKQTLIKHP
RYKGTNDTKNINFTKPGRGSDPEVAYMWTNCRGEFLYCNMTWFLNWVENRPNQTQHNYAPCHIRQIINTW
HKVGKNVYLPPREGQLTCNSTVTSIIANIDVNSNQTNITFSAEVAELYRLELGDYKLIEVTPIGFAPTRE
KRYSSAPVRNKRGVFVLGFLGFLATAGSAMGAASLTLSAQSRTLLAGIVQQQQQLLDVVKRQQEMLRLTV
WGTKNLQARVTAIEKYLKDQAQLNSWGCAFRQVCHTTVPWVNDSLSPDWNNMTWQEWEKQVRYLEANISQ
SLEQAQIQQEKNMYELQKLNSWDVFGNWFDLTSWIKYIQYGVYIWGVIVLRIAIYIVQLLSRLRKGYRP
VFSSPPGYLQQIHIHTDRGQPANEGTEEDDRDDDGYDLXPWPINYIHFLIHLLTRLLTGLYKICRDLLST
NSPTHRLISQNLTAIRDWLRLKAAYLQYGGEWIQEAFQAFAKTTRETLASAWGGLCAAVQRVGRGILAVP
RRIRQGAEIALL
The HIV-2 Env precursor protein is cleaved to give the surface glycoprotein (e.g. amino acids 20-502 of SEQ ID NO: 4; SEQ ID NO: 5 herein) and the transmembrane domain (e.g. amino acids 503-852 of SEQ ID NO: 4; SEQ ID NO: 6 herein):
MCGKSLLCVASLLASAYLV/YCTQYVTVFYGVPVWRNASIPLFCATKNRDTWGTIQCKPDNDDYQEITLN
VTEAFDAWDNTVTEQAVEDVWSLFETSIKPCVKLTPLCVAMSCNSTTNNTTTTGSTTGMSEINETSPSYS
DNCTGLGKEEIVNCQFYMTGLERDKKKQYNETWYSKDWCESNNTKDGKNRCYMNHCNTSVITESCDKHY
WDAIKFRYCAPPGYALLRCNDTNYSGFEPKCSKWASTCTRMMETQTSTWFGFNGTRAENRTYIYWHGRD
NRTIISLNKYYNLSIHCKRPGNKTWPITLMSGLVFHSQPINTRPRQAWCWFKGKWREAMQEVKQTLIKH
PRYKGTNDTKNINFTKPGRGSDPEVAYMWTNCRGEFLYCNMTWFLNWVENRPNQTQHNYAPCHIRQIINT
WHKVGKNVYLPPREGQLTCNSTVTSIIANIDVNSNQTNITFSAEVAELYRLELGDYKLIEVTPIGFAPTR
EKRYSSAPVRNKR/GVFVLGFLGFLATAGSAMGAASLTLSAQSRTLLAGIVQQQQQLLDVVKRQQEMLRL
TVWGTKNLQARVTAIEKYLKDQAQLNSWGCAFRQVCHTTVPWVNDSLSPDWNNMTWQEWEKQVRYLEANI
SQSLEQAQIQQEKNMYELQKLNSWDVFGNWFDLTSWIKYIQYGVYIVVGVIVLRIAIYIVQLLSRLRKGY
RPVFSSPPGYLQQIHIHTDRGQPANEGTEEDDRDDDGYDLXPWPINYIHFLIHLLTRLLTGLYKICRDLL
STNSPTHRLISQNLTAIRDWLRLKAAYLQYGGEWIQEAFQAFAKTTRETLASAWGGLCAAVQRVGRGILA
VPRRIRQGAEIALL
The hypervariable regions etc. can, again, be identified by sequence alignment and by reference to the alignments in the Los Alamos HIV Sequence Compendia Other specific Env sequences that can be used include those disclosed in W000/39302, W003/020876, WO2005/007808, W003/004620, W000/39304 Env polypeptides used with the invention will have, relative to a wild-type sequence, a V3 loop having one or more mutations. Such V3 mutations are described in more detail below.
An Env polypeptide used with the invention may further include mutations outside the V3 loop.
For example, the invention will typically use a shortened Env polypeptide. The shortening will involve the removal of one of more amino acids from the full-length sequence e.g. truncation at the C-terminus and/or N-terminus, deletion of internal residues, removal of subdomains other than V3 US patent 5,792,459, and combinations of these approaches.
For instance, it is known to make a soluble form of the Env precursor by removing its transmembrane domain and cytoplasmic tail. This polypeptide, which includes the gp120 sequence and the ectodomain of gp4l, is known as `gp140' (Zhang et al. (2001) J. Biol. Chem.
276:39577-85), and has been reported to be a better immunogen than gp120 (Earl et al. (2001) J
Virol 75:645-53). Thus the precursor is truncated at its C-terminus e.g. after Ile-682 of SEQ ID
NO:1 (giving a gp140 sequence having amino acids Ser-29 to Ile-682 of SEQ ID
NO: 1; SEQ ID
NO: 49 herein), or after Ile-673 of SEQ ID NO: 38 (giving a gp140 sequence having amino acids Ser-28 to Ile-673 of SEQ ID NO: 38; SEQ ID NO: 39 herein,). Thus an Env polypeptide used with the invention may include a portion of gp4l but not include its transmembrane domain.
It is also known to make deletions within the V2 loop of the Env precursor, to give 'AV2' mutants. For instance, one or more amino acids within the 40-mer V2 loop can be deleted (e.g. at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or more amino acids). Deletions within the V2 loop have been reported to improve immunogenicity of Env polypeptides (Barnett et al. (2001) J Virol 75:5526-40; Srivastava et al.
(2003) J Virol 77:2310-20). Env polypeptides with deletions and/or substitutions in the V2 loop have been found to be useful in forming Env/Tat complexes. In particular, Env/Tat complexes may not be seen with monomeric gp120 unless its V2 loop is mutated. Amino acids deleted from the V2 loop may be substituted with other amino acids e.g. it is known to replace the central portion of the V2 loop with a Gly-Ala-Gly tripeptide. For example, a AV2 mutant may have the following sequence (SEQ ID NO: 8):
SATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKN
DMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCXCNTSVITQAC
PKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSV
NFTDNAKTIIVQLNTSVEINXNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGG
EFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNIT
GLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR
where: (i) the `X' at position 130 represents a mutant V2 loop e.g. with between 4 and 15 amino acids; and (ii) the `X' at position 231 represents a mutant V3 loop.
Another useful AV2 mutant, based on SF162, may have the following sequence (SEQ ID NO:
45):
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCXCNTSVITQACP
KVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEGVVIRSEN
FTDNAKTIIVQLKESVEINCXCNISGEKWNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGG
EFFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTR
DGGKEISNTTEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR
where: (i) the `X' at position 129 represents a mutant V2 loop e.g. with between 4 and 15 amino acids; and (ii) the `X' at position 231 represents a mutant V3 loop.
A particularly preferred Env polypeptide for use with the invention is a gp140 protein with a AV2 mutation from HIV-1 strain SF162. In its mature form, after cleavage of a signal sequence and secretion (see, e.g., Figure 24 of W000/39302), this polypeptide has the following amino acid sequence (SEQ ID NO: 9):
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVGAGKLINC
NTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPWSTQLLLNGSLA
EEGVVIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHCNISGEK
WNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNTIGPNNTNGTI
TLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGKEISNTTEIFRPGGGDMRDNWRSEL
YKYKWKIEPLGVAPTKAISSWQSEKSAVTLGAMFLGFLGAAGSTMGARSLTLTVQARQLLSGIVQQQN
NLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLDQIW
NNMTWMEWEREIDNYTNLIYTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYI
In the present invention, the wild-type SF162 V3 loop (underlined; SEQ ID NO:
44) will be replaced by a mutant V3 loop as described elsewhere herein.
Env polypeptides used with the invention may retain the ability of natural Env to bind to CD4.
Residues that have been identified as important for CD4 binding include (numbered according to SEQ ID NO: 1) Asp-368, Glu-370, Trp-427, Val-430 and Pro-438.
As the HIV genome is in a state of constant flux, and contains several domains that exhibit relatively high degrees of variability between isolates, the invention is not limited to the use of Env polypeptides having the exact sequence of a known HIV polypeptide. Thus the Env polypeptide used according to the invention may be selected from one of the following, provided that it includes a mutant V3 loop:
(i) a polypeptide comprising an amino acid sequence selected from SEQ ID NOs:
1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50;
(ii) a polypeptide comprising an amino acid sequence that has sequence identity to an amino acid sequence selected from SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50;
(iii) a polypeptide comprising an amino acid sequence that, compared to an amino acid sequence selected from SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50, has one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) substitutions and/or deletions and/or insertions (inside and, optionally, outside the V3 loop);
(iv) a polypeptide comprising an amino acid sequence comprising a fragment of at least n consecutive amino acids from an amino acid sequence selected from SEQ ID NOs:
1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50, where n is 7 or more; or (v) a polypeptide comprising a sequence of p amino acids that, when aligned with an amino acid sequence selected from SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50 using a pairwise alignment algorithm, has at least x=y identical aligned monomers in each window of x amino acids moving from N-terminus to C-terminus, where: p>x; there are p-x+l windows; x is selected from 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800 or 850; y is selected from 0.50, 0.60, 0.70, 0.75, 0.80, 0.85, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, or 0.99; and, ifx=y is not an integer, it is rounded up to the nearest integer.
These polypeptides include homologs, orthologs, allelic variants and mutants of SEQ ID NOs 1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50. For instance, it is known to mutate natural Env sequences to improve resistance to proteases. The polypeptides also include fusion polypeptides, in which the Env sequence is fused to non-Env sequence. For instance, it is known to fuse Env sequences without the native leader peptide to leader peptides from non-Env proteins e.g. from tissue plasminogen activator.
Within category (ii), the degree of sequence identity may be greater than 50%
(e.g. 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more).
Identity between polypeptides is preferably determined by the Smith-Watennan homology search algorithm as implemented in the MPSRCH program (Oxford Molecular), using an affine gap search with parameters gap open penalty=12 and gap extension penalty=l.
Within category (iii), each substitution involves a single amino acid, each deletion preferably involves a single amino acid, and each insertion preferably involves a single amino acid. These changes may arise deliberately (e.g. by site-directed mutagenesis) or naturally (e.g. through virus evolution or through spontaneous mutation). The polypeptides in category (iii) may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid substitutions relative to SEQ ID NO:
1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 or 50. These polypeptides may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid deletions relative to SEQ ID NO:
1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 or 50. These polypeptides may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid insertion relative to SEQ ID NO: 1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 or 50. The substitutions, insertions and/or deletions may be at separate locations or may be contiguous. Substitutions may be conservative i.e. replacements of one amino acid with another which has a related side chain. Genetically-encoded amino acids are generally divided into four families: (1) acidic i.e. aspartate, glutamate; (2) basic i.e. lysine, arginine, histidine; (3) non-polar i.e. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar i.e. glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine.
Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids.
In general, substitution of single amino acids within these families does not have a major effect on the biological activity. Various substitutions have been described for use with Env polypeptides e.g. it is known to inactivate the cleavage site between gp120 and gp4l (e.g. by a Lys--*Ser substitution) in order to provide a polypeptide that remains in full-length form, or to remove the `clipping' site in the V3 loop (W091/15238), or to delete or substitute glycosylation sites, particularly N-glycosylation sites (i.e. asparagine residues).
Within category (iv), the value of n may be greater than 7 e.g. 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850 or more. The fragment may comprise at least one T-cell and/or B-cell epitope of the sequence. T- and B-cell epitopes can be identified empirically (e.g.
using PEPSCAN
Geysen et al. (1984) PNAS USA 81:3998-4002; Carter (1994) Methods Mol Biol 36:207-223) or similar methods), or they can be predicted (e.g. using the Jameson-Wolf antigenic index (Jameson, BA et al. 1988, CABIOS 4(1):181-186), matrix-based approaches (Raddrizzani &
Hammer (2000) Brief Bioinform 1(2):179-189), TEPITOPE (De Lalla et al. (1999) J. Immunol.
163:1725-1729), neural networks (Brusic et al. (1998) Bioinformatics 14(2):121-130), OptiMer &
EpiMer (Meister et al. (1995) Vaccine 13(6):581-591; Roberts et al. (1996) AIDS Res Hum Retroviruses 12(7):593-610), ADEPT (Maksyutov & Zagrebelnaya (1993) Comput Appl Biosci 9(3):291-297), Tsites (Feller & de la Cruz (1991) Nature 349(6311):720-1), hydrophilicity (Hopp (1993) Peptide Research 6:183-190), antigenic index (Welling et al. (1985) FEBS Lett. 188:215-218) or the methods disclosed in Davenport et al. (1995) Immunogenetics 42:392-297).
Within category (v), the preferred pairwise alignment algorithm is the Needleman-Wunsch global alignment algorithm (Needleman& Wunsch (1970) J. Mol. Biol. 48:443-453), using default parameters (e.g. with Gap opening penalty = 10.0, and with Gap extension penalty = 0.5, using the EBLOSUM62 scoring matrix). This algorithm is conveniently implemented in the needle tool in the EMBOSS package (Rice et al. (2000) Trends Genet 16:276-277).
Env polypeptide is found in oligomeric form on the HIV virion, and preferred Env polypeptides used with the invention can also form oligomers, and in particular trimers.
For instance, AV2 mutants of gp140 have been shown to form trimers (Barnett et al. (2001) J
Virol 75:5526-40).
Env/Tat complexes generally do not form when using monomeric gp120, unless its V2 loop is mutated, but are formed from trimeric gp 140 without requiring any V2 mutation.
Preferred Env polypeptides used with the invention have, in addition to a mutant V3 loop, a mutant V2 loop (e.g. a mutant V2 as in SEQ ID NO: 9).
Mutant V3 loops The wild-type V3 loop in Env has cysteine residues at both termini, which may be covalently linked in a disulfide bridge. As mentioned above, Env polypeptides in mixtures of the invention will have one or more mutations in the V3 loop relative to a wild-type Env sequence.
In wild-type HIV-1 Env sequence SEQ ID NO: 2, the V3 loop consists of amino acids Cys-268 to Cys-303 (SEQ ID NO: 13):
CTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHC
In wild-type HIV-1 Env sequence from strain SF162 (SEQ ID NO: 7), the V3 loop consists of amino acids Cys-267 to Cys-301 (SEQ ID NO: 46):
CTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHC
In wild-type HIV-2 Env sequence SEQ ID NO: 4, the V3 loop consists of amino acids Cys-296 to Cys-329 (SEQ ID NO: 14):
CKRPGNKTVVPITLMSGLVFHSQPINTRPRQAWC
The location of the V3 loop in other Env sequences can readily be identified by performing a suitable sequence alignment and, as mentioned above, pre-aligned sequences from numerous strains annotated to show the V3 loop can also be found in the Los Alamos HIV
Sequence Compendia. For instance, the wild-type V3 loops of five specific strains from different subtypes are aligned below, together with a consensus sequence:
SF162 CTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHC (SEQ ID NO: 44) TV1 CTRPNNNTRKSVRIGPGQAFYATNDVIGNIRQAHC (SEQ ID NO: 25) MJ4 CTRPGNNTRRSVRIGPGQAFYATGDIIGDIRAAHC (SEQ ID NO: 26) CM235 CTRPSNNTRTSITIGPGQVFYRTGDIIGDIRKAYC (SEQ ID NO: 27) Q461 CIRPGNNTRKSVRIGPGQAFYATGDITGDIRNAHC (SEQ ID NO: 28) Consensus CTRPNNNTRKSVRIGPGQAFYATGDIIGDIRQAHC (SEQ ID NO: 29) A mutation in the V3 loop may independently be a deletion of a single amino acid, the substitution of a single amino acid with a single amino acid, or the insertion of one or more amino acids. An Env polypeptide used with the invention may have one or more of such mutations e.g.
one or more deletions and/or one or more substitutions and/or one or more insertions. Mutant V3 loops with at least one deletion are typical e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or more deletion(s). Where there is more than one deletion, it is possible to group them (i.e. two or more neighboring wild-type amino acids may both be deleted) and/or separate them (i.e. two deleted amino acids are separated by at least one wild-type amino acid).
Mutations in the V3 loop of Env have previously been reported, and any of these can be used with invention. For instance, Su et al. (2000) AIDS Res Hum Retroviruses.
16(1):37-48 reports viruses with deletion of the conserved Gly-Pro-Gly motif from the centre of the V3 loop.
Kmieciak et al. (1998) J Immunol. 160(11):5676-83 analyzed the effect of deletion of the V3 loop, and the AV3 mutants showed increased CTL activities in vitro against conserved epitopes of the env protein. The authors of Jagodzinski et al. (1996) Virology 226(2):217-27 deleted the V3 loop and also transplanted V3 loops between different HIV strains. Hansen et al. (1996) Arch Virol 141(2):291-300 mutated Thr and Ser residues in the V3 loop to prevent 0-glycosylation, substituting Ala residues instead. Similarly, Kang et al. (2005) Virology 331(1):20-32 mutated glycosylation sites in the V3 loop. Chiou et al. (1992) AIDS Res Hum Retroviruses 8(9):1611-8 prepared Env proteins with a series of deletions in the V3 loop. Pollard et al. (1992) EMBO J.
PRYKGTNDTKNINFTKPGRGSDPEVAYMWTNCRGEFLYCNMTWFLNWVENRPNQTQHNYAPCHIRQIINT
WHKVGKNVYLPPREGQLTCNSTVTSIIANIDVNSNQTNITFSAEVAELYRLELGDYKLIEVTPIGFAPTR
EKRYSSAPVRNKR/GVFVLGFLGFLATAGSAMGAASLTLSAQSRTLLAGIVQQQQQLLDVVKRQQEMLRL
TVWGTKNLQARVTAIEKYLKDQAQLNSWGCAFRQVCHTTVPWVNDSLSPDWNNMTWQEWEKQVRYLEANI
SQSLEQAQIQQEKNMYELQKLNSWDVFGNWFDLTSWIKYIQYGVYIVVGVIVLRIAIYIVQLLSRLRKGY
RPVFSSPPGYLQQIHIHTDRGQPANEGTEEDDRDDDGYDLXPWPINYIHFLIHLLTRLLTGLYKICRDLL
STNSPTHRLISQNLTAIRDWLRLKAAYLQYGGEWIQEAFQAFAKTTRETLASAWGGLCAAVQRVGRGILA
VPRRIRQGAEIALL
The hypervariable regions etc. can, again, be identified by sequence alignment and by reference to the alignments in the Los Alamos HIV Sequence Compendia Other specific Env sequences that can be used include those disclosed in W000/39302, W003/020876, WO2005/007808, W003/004620, W000/39304 Env polypeptides used with the invention will have, relative to a wild-type sequence, a V3 loop having one or more mutations. Such V3 mutations are described in more detail below.
An Env polypeptide used with the invention may further include mutations outside the V3 loop.
For example, the invention will typically use a shortened Env polypeptide. The shortening will involve the removal of one of more amino acids from the full-length sequence e.g. truncation at the C-terminus and/or N-terminus, deletion of internal residues, removal of subdomains other than V3 US patent 5,792,459, and combinations of these approaches.
For instance, it is known to make a soluble form of the Env precursor by removing its transmembrane domain and cytoplasmic tail. This polypeptide, which includes the gp120 sequence and the ectodomain of gp4l, is known as `gp140' (Zhang et al. (2001) J. Biol. Chem.
276:39577-85), and has been reported to be a better immunogen than gp120 (Earl et al. (2001) J
Virol 75:645-53). Thus the precursor is truncated at its C-terminus e.g. after Ile-682 of SEQ ID
NO:1 (giving a gp140 sequence having amino acids Ser-29 to Ile-682 of SEQ ID
NO: 1; SEQ ID
NO: 49 herein), or after Ile-673 of SEQ ID NO: 38 (giving a gp140 sequence having amino acids Ser-28 to Ile-673 of SEQ ID NO: 38; SEQ ID NO: 39 herein,). Thus an Env polypeptide used with the invention may include a portion of gp4l but not include its transmembrane domain.
It is also known to make deletions within the V2 loop of the Env precursor, to give 'AV2' mutants. For instance, one or more amino acids within the 40-mer V2 loop can be deleted (e.g. at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or more amino acids). Deletions within the V2 loop have been reported to improve immunogenicity of Env polypeptides (Barnett et al. (2001) J Virol 75:5526-40; Srivastava et al.
(2003) J Virol 77:2310-20). Env polypeptides with deletions and/or substitutions in the V2 loop have been found to be useful in forming Env/Tat complexes. In particular, Env/Tat complexes may not be seen with monomeric gp120 unless its V2 loop is mutated. Amino acids deleted from the V2 loop may be substituted with other amino acids e.g. it is known to replace the central portion of the V2 loop with a Gly-Ala-Gly tripeptide. For example, a AV2 mutant may have the following sequence (SEQ ID NO: 8):
SATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKN
DMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCXCNTSVITQAC
PKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSV
NFTDNAKTIIVQLNTSVEINXNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGG
EFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNIT
GLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR
where: (i) the `X' at position 130 represents a mutant V2 loop e.g. with between 4 and 15 amino acids; and (ii) the `X' at position 231 represents a mutant V3 loop.
Another useful AV2 mutant, based on SF162, may have the following sequence (SEQ ID NO:
45):
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCXCNTSVITQACP
KVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEGVVIRSEN
FTDNAKTIIVQLKESVEINCXCNISGEKWNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGG
EFFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTR
DGGKEISNTTEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR
where: (i) the `X' at position 129 represents a mutant V2 loop e.g. with between 4 and 15 amino acids; and (ii) the `X' at position 231 represents a mutant V3 loop.
A particularly preferred Env polypeptide for use with the invention is a gp140 protein with a AV2 mutation from HIV-1 strain SF162. In its mature form, after cleavage of a signal sequence and secretion (see, e.g., Figure 24 of W000/39302), this polypeptide has the following amino acid sequence (SEQ ID NO: 9):
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVGAGKLINC
NTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPWSTQLLLNGSLA
EEGVVIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHCNISGEK
WNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNTIGPNNTNGTI
TLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGKEISNTTEIFRPGGGDMRDNWRSEL
YKYKWKIEPLGVAPTKAISSWQSEKSAVTLGAMFLGFLGAAGSTMGARSLTLTVQARQLLSGIVQQQN
NLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLDQIW
NNMTWMEWEREIDNYTNLIYTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYI
In the present invention, the wild-type SF162 V3 loop (underlined; SEQ ID NO:
44) will be replaced by a mutant V3 loop as described elsewhere herein.
Env polypeptides used with the invention may retain the ability of natural Env to bind to CD4.
Residues that have been identified as important for CD4 binding include (numbered according to SEQ ID NO: 1) Asp-368, Glu-370, Trp-427, Val-430 and Pro-438.
As the HIV genome is in a state of constant flux, and contains several domains that exhibit relatively high degrees of variability between isolates, the invention is not limited to the use of Env polypeptides having the exact sequence of a known HIV polypeptide. Thus the Env polypeptide used according to the invention may be selected from one of the following, provided that it includes a mutant V3 loop:
(i) a polypeptide comprising an amino acid sequence selected from SEQ ID NOs:
1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50;
(ii) a polypeptide comprising an amino acid sequence that has sequence identity to an amino acid sequence selected from SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50;
(iii) a polypeptide comprising an amino acid sequence that, compared to an amino acid sequence selected from SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50, has one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) substitutions and/or deletions and/or insertions (inside and, optionally, outside the V3 loop);
(iv) a polypeptide comprising an amino acid sequence comprising a fragment of at least n consecutive amino acids from an amino acid sequence selected from SEQ ID NOs:
1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50, where n is 7 or more; or (v) a polypeptide comprising a sequence of p amino acids that, when aligned with an amino acid sequence selected from SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50 using a pairwise alignment algorithm, has at least x=y identical aligned monomers in each window of x amino acids moving from N-terminus to C-terminus, where: p>x; there are p-x+l windows; x is selected from 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800 or 850; y is selected from 0.50, 0.60, 0.70, 0.75, 0.80, 0.85, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, or 0.99; and, ifx=y is not an integer, it is rounded up to the nearest integer.
These polypeptides include homologs, orthologs, allelic variants and mutants of SEQ ID NOs 1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 and 50. For instance, it is known to mutate natural Env sequences to improve resistance to proteases. The polypeptides also include fusion polypeptides, in which the Env sequence is fused to non-Env sequence. For instance, it is known to fuse Env sequences without the native leader peptide to leader peptides from non-Env proteins e.g. from tissue plasminogen activator.
Within category (ii), the degree of sequence identity may be greater than 50%
(e.g. 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more).
Identity between polypeptides is preferably determined by the Smith-Watennan homology search algorithm as implemented in the MPSRCH program (Oxford Molecular), using an affine gap search with parameters gap open penalty=12 and gap extension penalty=l.
Within category (iii), each substitution involves a single amino acid, each deletion preferably involves a single amino acid, and each insertion preferably involves a single amino acid. These changes may arise deliberately (e.g. by site-directed mutagenesis) or naturally (e.g. through virus evolution or through spontaneous mutation). The polypeptides in category (iii) may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid substitutions relative to SEQ ID NO:
1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 or 50. These polypeptides may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid deletions relative to SEQ ID NO:
1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 or 50. These polypeptides may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid insertion relative to SEQ ID NO: 1, 2, 4, 5, 7, 8, 9, 38, 39, 43, 45, 49 or 50. The substitutions, insertions and/or deletions may be at separate locations or may be contiguous. Substitutions may be conservative i.e. replacements of one amino acid with another which has a related side chain. Genetically-encoded amino acids are generally divided into four families: (1) acidic i.e. aspartate, glutamate; (2) basic i.e. lysine, arginine, histidine; (3) non-polar i.e. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar i.e. glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine.
Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids.
In general, substitution of single amino acids within these families does not have a major effect on the biological activity. Various substitutions have been described for use with Env polypeptides e.g. it is known to inactivate the cleavage site between gp120 and gp4l (e.g. by a Lys--*Ser substitution) in order to provide a polypeptide that remains in full-length form, or to remove the `clipping' site in the V3 loop (W091/15238), or to delete or substitute glycosylation sites, particularly N-glycosylation sites (i.e. asparagine residues).
Within category (iv), the value of n may be greater than 7 e.g. 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850 or more. The fragment may comprise at least one T-cell and/or B-cell epitope of the sequence. T- and B-cell epitopes can be identified empirically (e.g.
using PEPSCAN
Geysen et al. (1984) PNAS USA 81:3998-4002; Carter (1994) Methods Mol Biol 36:207-223) or similar methods), or they can be predicted (e.g. using the Jameson-Wolf antigenic index (Jameson, BA et al. 1988, CABIOS 4(1):181-186), matrix-based approaches (Raddrizzani &
Hammer (2000) Brief Bioinform 1(2):179-189), TEPITOPE (De Lalla et al. (1999) J. Immunol.
163:1725-1729), neural networks (Brusic et al. (1998) Bioinformatics 14(2):121-130), OptiMer &
EpiMer (Meister et al. (1995) Vaccine 13(6):581-591; Roberts et al. (1996) AIDS Res Hum Retroviruses 12(7):593-610), ADEPT (Maksyutov & Zagrebelnaya (1993) Comput Appl Biosci 9(3):291-297), Tsites (Feller & de la Cruz (1991) Nature 349(6311):720-1), hydrophilicity (Hopp (1993) Peptide Research 6:183-190), antigenic index (Welling et al. (1985) FEBS Lett. 188:215-218) or the methods disclosed in Davenport et al. (1995) Immunogenetics 42:392-297).
Within category (v), the preferred pairwise alignment algorithm is the Needleman-Wunsch global alignment algorithm (Needleman& Wunsch (1970) J. Mol. Biol. 48:443-453), using default parameters (e.g. with Gap opening penalty = 10.0, and with Gap extension penalty = 0.5, using the EBLOSUM62 scoring matrix). This algorithm is conveniently implemented in the needle tool in the EMBOSS package (Rice et al. (2000) Trends Genet 16:276-277).
Env polypeptide is found in oligomeric form on the HIV virion, and preferred Env polypeptides used with the invention can also form oligomers, and in particular trimers.
For instance, AV2 mutants of gp140 have been shown to form trimers (Barnett et al. (2001) J
Virol 75:5526-40).
Env/Tat complexes generally do not form when using monomeric gp120, unless its V2 loop is mutated, but are formed from trimeric gp 140 without requiring any V2 mutation.
Preferred Env polypeptides used with the invention have, in addition to a mutant V3 loop, a mutant V2 loop (e.g. a mutant V2 as in SEQ ID NO: 9).
Mutant V3 loops The wild-type V3 loop in Env has cysteine residues at both termini, which may be covalently linked in a disulfide bridge. As mentioned above, Env polypeptides in mixtures of the invention will have one or more mutations in the V3 loop relative to a wild-type Env sequence.
In wild-type HIV-1 Env sequence SEQ ID NO: 2, the V3 loop consists of amino acids Cys-268 to Cys-303 (SEQ ID NO: 13):
CTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHC
In wild-type HIV-1 Env sequence from strain SF162 (SEQ ID NO: 7), the V3 loop consists of amino acids Cys-267 to Cys-301 (SEQ ID NO: 46):
CTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHC
In wild-type HIV-2 Env sequence SEQ ID NO: 4, the V3 loop consists of amino acids Cys-296 to Cys-329 (SEQ ID NO: 14):
CKRPGNKTVVPITLMSGLVFHSQPINTRPRQAWC
The location of the V3 loop in other Env sequences can readily be identified by performing a suitable sequence alignment and, as mentioned above, pre-aligned sequences from numerous strains annotated to show the V3 loop can also be found in the Los Alamos HIV
Sequence Compendia. For instance, the wild-type V3 loops of five specific strains from different subtypes are aligned below, together with a consensus sequence:
SF162 CTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHC (SEQ ID NO: 44) TV1 CTRPNNNTRKSVRIGPGQAFYATNDVIGNIRQAHC (SEQ ID NO: 25) MJ4 CTRPGNNTRRSVRIGPGQAFYATGDIIGDIRAAHC (SEQ ID NO: 26) CM235 CTRPSNNTRTSITIGPGQVFYRTGDIIGDIRKAYC (SEQ ID NO: 27) Q461 CIRPGNNTRKSVRIGPGQAFYATGDITGDIRNAHC (SEQ ID NO: 28) Consensus CTRPNNNTRKSVRIGPGQAFYATGDIIGDIRQAHC (SEQ ID NO: 29) A mutation in the V3 loop may independently be a deletion of a single amino acid, the substitution of a single amino acid with a single amino acid, or the insertion of one or more amino acids. An Env polypeptide used with the invention may have one or more of such mutations e.g.
one or more deletions and/or one or more substitutions and/or one or more insertions. Mutant V3 loops with at least one deletion are typical e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or more deletion(s). Where there is more than one deletion, it is possible to group them (i.e. two or more neighboring wild-type amino acids may both be deleted) and/or separate them (i.e. two deleted amino acids are separated by at least one wild-type amino acid).
Mutations in the V3 loop of Env have previously been reported, and any of these can be used with invention. For instance, Su et al. (2000) AIDS Res Hum Retroviruses.
16(1):37-48 reports viruses with deletion of the conserved Gly-Pro-Gly motif from the centre of the V3 loop.
Kmieciak et al. (1998) J Immunol. 160(11):5676-83 analyzed the effect of deletion of the V3 loop, and the AV3 mutants showed increased CTL activities in vitro against conserved epitopes of the env protein. The authors of Jagodzinski et al. (1996) Virology 226(2):217-27 deleted the V3 loop and also transplanted V3 loops between different HIV strains. Hansen et al. (1996) Arch Virol 141(2):291-300 mutated Thr and Ser residues in the V3 loop to prevent 0-glycosylation, substituting Ala residues instead. Similarly, Kang et al. (2005) Virology 331(1):20-32 mutated glycosylation sites in the V3 loop. Chiou et al. (1992) AIDS Res Hum Retroviruses 8(9):1611-8 prepared Env proteins with a series of deletions in the V3 loop. Pollard et al. (1992) EMBO J.
11(2):585-91 used deletions to show that 62 N- and 20 C-terminal residues along with the V1, V2 and V3 variable regions of gp 120 were unnecessary for CD4 binding. Sanders et al. (2000) J
Virol 74(11):5091-100 characterized gp140 variants with deletions in the Vl, V2 and/or V3 loops. Yang et al. (2004) J Virol. 78(8):4029-36 shortened the stem of the V3 loop by selective deletions, and progressive shortening of the stem abolished immunogenicity and functional activity of HIV Env, suggesting that highly conserved subregions within V3 may be relevant targets for eliciting neutralizing antibody responses, for affecting HIV
tropism, and for increasing the immunogenicity of vaccines. Gzyl et al. (2004) Virology 318(2):493-506 reports that partial deletions in the VI, V2 and/or V3 loops may facilitate approaches for boosting cross-reactive cellular and antibody responses to the Env glycoprotein.
Examples of mutant V3 loop sequences for use in Env polypeptides of the invention, each including several consecutive amino acid deletions, are shown below as SEQ ID
NOS: 15 to 22:
CTRPNNNGAGDIRQAHC (SEQ ID NO: 15) CTITIGPGRAFYATGDIIGDIRQAHC (SEQ ID NO: 16) CTRPNNNTRKSITIGPGRAFYATQAHC (SEQ ID NO: 17) CTRPNNNTRFYATGDIIGDIRQAHC (SEQ ID NO: 18) CTRPNNNTRGDIIGDIRQAHC (SEQ ID NO: 19) CTFYATGDIIGDIRQAHC (SEQ ID NO: 20) CTRPNNNTRQAHC (SEQ ID NO: 21) CTGAGHC (SEQ ID NO: 22) CTRPNNNTRGAGQAHC (SEQ ID NO: 23) A further example of a V3 loop sequence for use in Env polypeptides of the invention, with three substitutions relative to the wild-type SF162 V3 sequence, is shown below (SEQ
ID NO: 24):
CTRPNNNTRKSITIGPGRAFYATGDIIGNMRQAHC (SEQ ID NO: 24) The consensus sequence (SEQ ID NO: 29) may also be used in place of a wild-type V3 loop.
Preferred mutant V3 loops retain the ability to interact with a Tat polypeptide. The interaction may be weaker/stronger, quicker/slower, etc. than seen with the wild-type V3 sequence V3fragments In some embodiments, a mixture of the invention includes a polypeptide comprising a fragment of a V3 loop of a HIV Env polypeptide. This polypeptide will usually be no longer than 100 amino acids (e.g. <90, <80, <70, <60, <50, <40, <30, <20 amino acids). The V3 loop fragment will include at least 5 amino acids from a wild-type V3 loop (e.g. 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more amino acids from a V3 loop). The polypeptide may include amino acids to the C-terminus and/or N-terminus of a V3 loop fragment.
The polypeptide may be linear and/or branched. Cyclic polypeptides may be used (e.g. DTIC
report ADA322181 (1994) http://handle.dtic.mil/100.2/ADA322181 discloses a cyclic 35mer peptide formed from a V3 loop). If a polypeptide includes more than one cysteine residue, these may be linked to form a disulfide bridge.
Eight specific V3-derived polypeptides for use with the invention are shown below:
TRKSITIGPGRAFYATGD (SEQ ID NO: 30) RPNNNTRKS (SEQ ID NO: 31) GDIIGDIR (SEQ ID NO: 32) KSITIGPGRA (SEQ ID NO: 33) KSITIGPGRAFYAT (SEQ ID NO: 34) RPNNNTRKSITIGPGRA (SEQ ID NO: 35) KSITIGPGRAFYATGDIIGDIR (SEQ ID NO: 36) RPNNNTRKSITIGPGRAFYATGDIIGDIRQA (SEQ ID NO: 37) The Tat polypeptide Mixtures of the invention include a HIV Tat polypeptide, and various forms of Tat polypeptide can be used from HIV-1 or HIV-2. The length of the Tat polypeptide varies depending on virus strain. The amino acid sequence of the full-length HIV-1 Tat polypeptide from the REFSEQ
database (GI:9629358) is a 86mer shown below (SEQ ID NO: 10 herein):
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLS
KQPTSQPRGDPTGPKE
Within the various HIV-1 Tat polypeptide sequences, Cys-22 and Cys-37 are conserved and form an intramolecular disulfide bond. The RKKRRQRRR 9-mer (SEQ ID NO: 51) is a nuclear localization signal. These features can be identified in other HIV-1 Env sequences by performing a suitable sequence alignment. Pre-aligned sequences from numerous strains, annotated with these features, can also be found in the Los Alamos HIV Sequence Compendia.
The amino acid sequence of a full-length HIV-2 Tat polypeptide (GI:41056781) is a 130mer shown below (SEQ ID NO: 11 herein):
METPLKAPESSLMSYNEPSSCTSERDVGSQELAKQGEELLSQLHRPLEPCNNKCYCKGCCFHCQLCFLNK
GLGICYDRKGRRRRTPKKTKAHSSSASDKSISTRTGNSQPEKKQKKTLETTLETARGLGR
An alignment of this and other HIV-2 Tat sequences can be found in the Los Alamos HIV
Sequence Compendia.
Other specific tat sequences that can be used include those disclosed in references W000/39302, W003/020876, W02005/007808, W003/004620 and W099/27958.
A particularly useful Tat polypeptide for use with the invention is from HIV-1 strain BH10. This polypeptide has the following amino acid sequence (SEQ ID NO: 12;
GI:62291022):
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRPPQGSQTHQVSLS
KQPTSQSRGDPTGPKE
As the HIV genome is in a state of constant flux, and contains several domains that exhibit relatively high degrees of variability between isolates, the invention is not limited to the use of Tat polypeptides having the exact sequence of a known HIV polypeptide. Thus the Tat polypeptide used according to the invention may be selected from:
(i) a polypeptide comprising an amino acid sequence selected from SEQ ID NOs:
10, 11 and 12;
(ii) a polypeptide comprising an amino acid sequence that has sequence identity to an amino acid sequence selected from SEQ ID NOs: 10, 11 and 12;
(iii) a polypeptide comprising an amino acid sequence that, compared to an amino acid sequence selected from SEQ ID NOs: 10, 11 and 12, has one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) substitutions and/or deletions and/or insertions;
(iv) a polypeptide comprising an amino acid sequence comprising a fragment of at least n consecutive amino acids from an amino acid sequence selected from SEQ ID NOs:
10, 11 and 12, where n is 7 or more; or (v) a polypeptide comprising a sequence of p amino acids that, when aligned with an amino acid sequence selected from SEQ ID NOs: 10, 11 and 12 using a pairwise alignment algorithm, has at least x=y identical aligned monomers in each window of x amino acids moving from N-terminus to C-terminus, where: p>x; there are p-x+1 windows; x is selected from 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 or 85; y is selected from 0.50, 0.60, 0.70, 0.75, 0.80, 0.85, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, or 0.99; and, if x=y is not an integer, it is rounded up to the nearest integer.
Virol 74(11):5091-100 characterized gp140 variants with deletions in the Vl, V2 and/or V3 loops. Yang et al. (2004) J Virol. 78(8):4029-36 shortened the stem of the V3 loop by selective deletions, and progressive shortening of the stem abolished immunogenicity and functional activity of HIV Env, suggesting that highly conserved subregions within V3 may be relevant targets for eliciting neutralizing antibody responses, for affecting HIV
tropism, and for increasing the immunogenicity of vaccines. Gzyl et al. (2004) Virology 318(2):493-506 reports that partial deletions in the VI, V2 and/or V3 loops may facilitate approaches for boosting cross-reactive cellular and antibody responses to the Env glycoprotein.
Examples of mutant V3 loop sequences for use in Env polypeptides of the invention, each including several consecutive amino acid deletions, are shown below as SEQ ID
NOS: 15 to 22:
CTRPNNNGAGDIRQAHC (SEQ ID NO: 15) CTITIGPGRAFYATGDIIGDIRQAHC (SEQ ID NO: 16) CTRPNNNTRKSITIGPGRAFYATQAHC (SEQ ID NO: 17) CTRPNNNTRFYATGDIIGDIRQAHC (SEQ ID NO: 18) CTRPNNNTRGDIIGDIRQAHC (SEQ ID NO: 19) CTFYATGDIIGDIRQAHC (SEQ ID NO: 20) CTRPNNNTRQAHC (SEQ ID NO: 21) CTGAGHC (SEQ ID NO: 22) CTRPNNNTRGAGQAHC (SEQ ID NO: 23) A further example of a V3 loop sequence for use in Env polypeptides of the invention, with three substitutions relative to the wild-type SF162 V3 sequence, is shown below (SEQ
ID NO: 24):
CTRPNNNTRKSITIGPGRAFYATGDIIGNMRQAHC (SEQ ID NO: 24) The consensus sequence (SEQ ID NO: 29) may also be used in place of a wild-type V3 loop.
Preferred mutant V3 loops retain the ability to interact with a Tat polypeptide. The interaction may be weaker/stronger, quicker/slower, etc. than seen with the wild-type V3 sequence V3fragments In some embodiments, a mixture of the invention includes a polypeptide comprising a fragment of a V3 loop of a HIV Env polypeptide. This polypeptide will usually be no longer than 100 amino acids (e.g. <90, <80, <70, <60, <50, <40, <30, <20 amino acids). The V3 loop fragment will include at least 5 amino acids from a wild-type V3 loop (e.g. 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more amino acids from a V3 loop). The polypeptide may include amino acids to the C-terminus and/or N-terminus of a V3 loop fragment.
The polypeptide may be linear and/or branched. Cyclic polypeptides may be used (e.g. DTIC
report ADA322181 (1994) http://handle.dtic.mil/100.2/ADA322181 discloses a cyclic 35mer peptide formed from a V3 loop). If a polypeptide includes more than one cysteine residue, these may be linked to form a disulfide bridge.
Eight specific V3-derived polypeptides for use with the invention are shown below:
TRKSITIGPGRAFYATGD (SEQ ID NO: 30) RPNNNTRKS (SEQ ID NO: 31) GDIIGDIR (SEQ ID NO: 32) KSITIGPGRA (SEQ ID NO: 33) KSITIGPGRAFYAT (SEQ ID NO: 34) RPNNNTRKSITIGPGRA (SEQ ID NO: 35) KSITIGPGRAFYATGDIIGDIR (SEQ ID NO: 36) RPNNNTRKSITIGPGRAFYATGDIIGDIRQA (SEQ ID NO: 37) The Tat polypeptide Mixtures of the invention include a HIV Tat polypeptide, and various forms of Tat polypeptide can be used from HIV-1 or HIV-2. The length of the Tat polypeptide varies depending on virus strain. The amino acid sequence of the full-length HIV-1 Tat polypeptide from the REFSEQ
database (GI:9629358) is a 86mer shown below (SEQ ID NO: 10 herein):
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLS
KQPTSQPRGDPTGPKE
Within the various HIV-1 Tat polypeptide sequences, Cys-22 and Cys-37 are conserved and form an intramolecular disulfide bond. The RKKRRQRRR 9-mer (SEQ ID NO: 51) is a nuclear localization signal. These features can be identified in other HIV-1 Env sequences by performing a suitable sequence alignment. Pre-aligned sequences from numerous strains, annotated with these features, can also be found in the Los Alamos HIV Sequence Compendia.
The amino acid sequence of a full-length HIV-2 Tat polypeptide (GI:41056781) is a 130mer shown below (SEQ ID NO: 11 herein):
METPLKAPESSLMSYNEPSSCTSERDVGSQELAKQGEELLSQLHRPLEPCNNKCYCKGCCFHCQLCFLNK
GLGICYDRKGRRRRTPKKTKAHSSSASDKSISTRTGNSQPEKKQKKTLETTLETARGLGR
An alignment of this and other HIV-2 Tat sequences can be found in the Los Alamos HIV
Sequence Compendia.
Other specific tat sequences that can be used include those disclosed in references W000/39302, W003/020876, W02005/007808, W003/004620 and W099/27958.
A particularly useful Tat polypeptide for use with the invention is from HIV-1 strain BH10. This polypeptide has the following amino acid sequence (SEQ ID NO: 12;
GI:62291022):
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRPPQGSQTHQVSLS
KQPTSQSRGDPTGPKE
As the HIV genome is in a state of constant flux, and contains several domains that exhibit relatively high degrees of variability between isolates, the invention is not limited to the use of Tat polypeptides having the exact sequence of a known HIV polypeptide. Thus the Tat polypeptide used according to the invention may be selected from:
(i) a polypeptide comprising an amino acid sequence selected from SEQ ID NOs:
10, 11 and 12;
(ii) a polypeptide comprising an amino acid sequence that has sequence identity to an amino acid sequence selected from SEQ ID NOs: 10, 11 and 12;
(iii) a polypeptide comprising an amino acid sequence that, compared to an amino acid sequence selected from SEQ ID NOs: 10, 11 and 12, has one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) substitutions and/or deletions and/or insertions;
(iv) a polypeptide comprising an amino acid sequence comprising a fragment of at least n consecutive amino acids from an amino acid sequence selected from SEQ ID NOs:
10, 11 and 12, where n is 7 or more; or (v) a polypeptide comprising a sequence of p amino acids that, when aligned with an amino acid sequence selected from SEQ ID NOs: 10, 11 and 12 using a pairwise alignment algorithm, has at least x=y identical aligned monomers in each window of x amino acids moving from N-terminus to C-terminus, where: p>x; there are p-x+1 windows; x is selected from 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 or 85; y is selected from 0.50, 0.60, 0.70, 0.75, 0.80, 0.85, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, or 0.99; and, if x=y is not an integer, it is rounded up to the nearest integer.
These polypeptides include homologs, orthologs, allelic variants and mutants of SEQ ID NOs 10, 11 and 12. They also include fusion polypeptides, in which the Tat sequence is fused to non-Tat sequence.
Within category (ii), the degree of sequence identity may be greater than 50%
(e.g. 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more).
Identity between polypeptides is preferably determined by the Smith-Watennan homology search algorithm as implemented in the MPSRCH program (Oxford Molecular), using an affine gap search with parameters gap open penalty=12 and gap extension penalty=l.
Within category (iii), each substitution involves a single amino acid, each deletion preferably involves a single amino acid, and each insertion preferably involves a single amino acid. These changes may arise deliberately (e.g. by site-directed mutagenesis) or naturally (e.g. through virus evolution or through spontaneous mutation). The polypeptides in category (iii) may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid substitutions relative to SEQ ID NO:
10, 11 or 12. These polypeptides may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid deletions relative to SEQ ID NO: 10, 11 or 12. These polypeptide s may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid insertion relative to SEQ ID
NO: 10, 11 or 12. The substitutions, insertions and/or deletions may be at separate locations or may be contiguous. As mentioned above, substitutions may be conservative.
Within category (iv), the value of n may be greater than 7 e.g. 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850 or more. The fragment may comprise at least one T-cell and/or B-cell epitope of the sequence. As described above, such epitopes can be identified empirically or can be predicted.
Within category (v), the preferred pairwise alignment algorithm is the Needleman-Wunsch global alignment algorithm as described above.
Env/Tat mixtures Mixtures of the invention include Env and Tat polypeptides. In the mixture, these may form complexes, in which the Env and Tat polypeptides may be associated non-covalently and/or covalently. Particularly useful complexes have essentially a 1:1 molar ratio of Env and Tat.
Where the Env is in the form of a trimer, therefore, the preferred complex includes three Tat monomers.
The Env and Tat polypeptides in a mixture may be from the same type if HIV
e.g. both are from HIV-1 or both are from HIV-2. Where the same HIV types are used, it is also useful to mix Env and Tat polypeptides from the same group e.g. within HIV-1, both are from group M, group N or group O. Within group M, it is useful to mix Env and Tat polypeptides from the same subtype (or clade) e.g. from subtype A, B, C, D, F, G, H, J or K. It is also possible to use Env or Tat from a CRF (circulating recombinant form) subtype, such as an A/B or A/E CRF. Where a subtype includes sub-subtypes then the Env and Tat polypeptides may be from the same sub-subtype.
Using Env and Tat from different groups, subtypes, sub-subtypes and/or clades is not, however, excluded. HIV-1 nomenclature is discussed in more detail in Robertson et al.
(2000) Science 288:55-6.
The use of Env and Tat from subtype B or C is preferred. Within a single subtype (or, where applicable, sub-subtype) it is possible to use Env and Tat from the same strain or from different strains. For instance, the Env and Tat polypeptides may both be from the SF162 strain (subtype B), or the invention may use Env from one strain (e.g. SF162) and Tat from another strain (e.g.
BH 10).
Env/Tat complexes of the invention may bind specifically to (a) CD4 and/or (b) a monoclonal antibody that specifically binds to HIV Tat polypeptide and/or (c) a monoclonal antibody that specifically binds to HIV Env polypeptide. Thus the complexes may retain the CD4-binding activity of the uncomplexed Env polypeptide and/or the mAb-binding activity of the uncomplexed Tat or Env polypeptide. Complexes with both of binding activities (a) and (b) are particularly useful. As described in US provisional patent application 60/786,947 filed March 28 2006, retaining these two activities in a covalent complex requires an appropriate degree of cross-linking between Env and Tat. Although this degree of cross-linking can vary within a fairly broad range, and thus does not need to be controlled with absolute precision, too little cross-linking leads to unstable complexes and too much cross-linking leads to a loss of binding activity.
Where a complex binds specifically to CD4, this binding activity can be assessed using known assays e.g. as described in W091/13906. The assay does not need to use native CD4, however, and it is more typical to use a purified soluble form of CD4 based on its external domain (e.g. see example 5 of W091/13906). The CD4 may also be labeled to facilitate the assay.
The CD4 is preferably human CD4. At least 250 SNPs have so far been described for CD4, and any of these polypeptides can be used, such as the REFSEQ CD4 (GI:10835167). The uncomplexed Env will specifically bind to CD4, and this specific binding activity can be retained in the Env/Tat complex. Although the binding activity is not removed, however, the actual binding affinity may change.
Where the complex binds specifically to an anti-Tat monoclonal antibody, a preferred monoclonal antibody is 8D1.8, which is available through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH
(http://www.aidsreagent.org/UploadDocs/ds4672_003.pdf ). The use of this antibody in Tat-binding assays has previously been disclosed e.g. in references Rohr et al.
(2003) J Virol.
77:5415-27, Avraham et al. (2004) J Immunol 173:6228-33, Liu et al. (2002) J
Virol 76:6689-700.
EnvlTat covalent cross-linking Env and Tat proteins may be covalently linked together in complexes of the invention. Various methods for covalently linking proteins are known in the art e.g. see references Wong (1991) Chemistry ofprotein conjugation and cross-linking. ISBN 0-8493-5886-8 and Hermanson (1996) Bioconjugate techniques. ISBN 0-12-342336-8. For example, covalent linking may involve the use of homobifunctional cross-linkers, heterobifunctional cross-linkers or zero-length cross-linkers. It may involve reagents directed to sulfhydryl groups in proteins, reagents directed to amino groups in proteins, reagents directed to carboxyl groups in proteins, tyrosine-selective reagents, arginine-specific reagents, histidine-specific reagents, methionine-alkylating reagents, tryptophan-specific reagents, serine-modifying reagents, etc.
A preferred group of cross-linking reagents for use with the invention includes aldehydes, and in particular includes formaldehyde and the dialdehydes. Suitable dialdehydes include glyoxal, malondialdehyde, succinialdehyde, adipaldehyde, a-hydroxyadipaldehyde, glutaraldehyde and phthalaldehyde. Glutaraldehyde and its derivatives are particularly preferred, including 2-methoxy-2,4-dimethylglutaraldehyde, 3-methoxy-2,4-dimethylglutaraldehyde and 3-methylglutar-aldehyde, Pyridoxal phosphates can also be used. Other amino group-directed cross-linkers include bis-imidoesters, bis-succinimidyl derivatives (e.g.
bis(sulfosuccinimidyl)suberate, or `BS3'), bifunctional aryl halides, bifunctional acylating agents (including di-isocyanates, di-isothiocyanates, bifunctional sulfonyl halides, bis-nitrophenyl esters and bifunctional acylazides), diketones, p-benzoquinone, 2-iminothiolane, erythritolbiscarbonate, mucobromic acid, mucochloric acid, ethylchloroformate and multidiazonium compounds.
Methods for cross-linking proteins using these reagents are known in the art.
Generally, the invention will involve mixing Env polypeptide, Tat polypeptide and a linking reagent under conditions that permit the covalent linking reaction to proceed. In some two-step procedures, however, such as those using a heterobifunctional reagent, one of the two polypeptides will be reacted with the linking reagent first, to form an activated polypeptide, and then the activated polypeptide will be reacted with the second polypeptide.
Heterobifunctional linkers with a photoreactive group are also useful. If a linker has one thermoreactive group and one photoreactive group then a first step can involve attachment via the thermoreactive group, and then conjugation to make the complex can be initiated by the use of e.g. UV light. As an alternative, the photoreactive group can be used first.
As mentioned above, the cross-linking reaction may be performed to an extent that is not so great as to eliminate critical binding activities of the Env and Tat proteins. Thus the concentration of the Env and Tat proteins, the concentration of the cross-linking reagent(s), the pH, the reaction temperature and the reaction time can be controlled to give the desired degree of cross-linking.
When testing a particular combination of Env, Tat and cross-linking reagent then an initial series of reactions can be performed to evaluate suitable reaction conditions.
Pharmaceutical compositions Mixtures of the invention can be used as active ingredients in immunogenic compositions. These compositions can be administered to animals in order to elicit an immune response. The immune response preferably includes a humoral (e.g. an antibody response, such as a neutralizing antibody response) and/or a cellular response against Env and/or Tat. In a patient already infected with HIV, the immune response may reduce the severity of the infection (e.g.
reduce viral load) and may even result in clearance of HIV infection. In a patient who is not infected with HIV, the immune response may reduce the risk of future HIV infection and may even be protective against future HIV infection. These effects arising from administration of the immunogenic composition of may be augmented by, or also require, the use of other anti-HIV strategies e.g. the administration of antivirals, including but not limited to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, etc.
Immunogenic compositions will include an immunologically effective amount of a polypeptide.
By `immunologically effective amount', it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for the desired treatment or prevention. This amount can vary depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non-human primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials, and a typical quantity of complex per dose is between 1 g and 10mg per antigen.
Immunogenic compositions of the invention are pharmaceutically acceptable.
They usually include components in addition to the complexes e.g. they typically include one or more pharmaceutical carrier(s) and/or excipient(s). A thorough discussion of such components is available in Gennaro (2000) Remington: The Science and Practice of Pharmacy.
20th edition, ISBN: 0683306472.
Compositions will generally be in aqueous form.
To control tonicity, it is preferred to include a physiological salt, such as a sodium salt. Sodium chloride (NaCI) is preferred, which may be present at between 1 and 20 mg/ml.
Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, etc.
Compositions will generally have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, preferably between 240-3 60 mOsm/kg, and will more preferably fall within the range of 290-310 mOsm/kg.
Compositions may include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer; or a citrate buffer. Buffers will typically be included in the 5-20mM range.
The pH of a composition will generally be between 5 and 8, and more typically between 6 and 7.
The composition is preferably sterile. The composition is preferably non-pyrogenic e.g.
containing <1 EU (endotoxin unit, a standard measure) per dose, and preferably <0.1 EU per dose. The composition is preferably gluten free.
Compositions of the invention may include detergent e.g. a polyoxyethylene sorbitan ester surfactant (known as `Tweens'), an octoxynol (such as octoxynol-9 (Triton X-100) or t-octylphenoxypolyethoxy-ethanol), etc.
Vaccines may be administered in a dosage volume of about 0.5m1.
Vaccine adjuvants Compositions of the invention may advantageously include an adjuvant, which can function to enhance the immune responses (humoral and/or cellular) elicited in a patient who receives the composition. Adjuvants that can be used with the invention include, but are not limited to:
= A mineral-containing composition, including calcium salts and aluminum salts (or mixtures thereof). Calcium salts include calcium phosphate (e.g. the "CAP"
particles disclosed in US patent 6355271). Aluminum salts include hydroxides, phosphates, sulfates, etc., with the salts taking any suitable form (e.g. gel, crystalline, amorphous, etc.). Adsorption to these salts is preferred. The mineral containing compositions may also be formulated as a particle of metal salt W000/23105. Aluminum salt adjuvants are described in more detail below.
= An oil-in-water emulsion, as described in more detail below.
= An immunostimulatory oligonucleotide, such as one containing a CpG motif (a dinucleotide sequence containing an unmethylated cytosine linked by a phosphate bond to a guanosine), a TpG motif WO01/22972,a double-stranded RNA, an oligonucleotide containing a palindromic sequence, or an oligonucleotide containing a poly(dG) sequence. Immunostimulatory oligonucleotides can include nucleotide modifications/analogs such as phosphorothioate modifications and can be double-stranded or (except for RNA) single-stranded. Kandimalla et al. (2003) Nucleic Acids Research 31:2393-2400, W002/26757 and W099/62923 disclose possible analog substitutions e.g. replacement of guanosine with 2'-deoxy-7-deazaguanosine.
The adjuvant effect of CpG oligonucleotides is further discussed in Krieg (2003) Nature Medicine 9:831-835, McCluskie et al. (2002) FEMS Immunology and Medical Microhiology 32:179-185, W098/40100, US patents 6,207,646, 6,239,116 and 6,429,199.
A CpG sequence may be directed to TLR9, such as the motif GTCGTT or TTCGTT
(Kandimalla et al. (2003) Biochemical Society Transactions 31 (part 3):654-658). The CpG sequence may be specific for inducing a Thl immune response, such as a CpG-A
ODN (oligodeoxynucleotide), or it may be more specific for inducing a B cell response, such a CpG-B ODN. CpG-A and CpG-B ODNs are discussed in Blackwell et al.
(2003) J
Immunol 170:4061-4068, Krieg (2002) Trends Immunol 23:64-65, WO01/95935.
Preferably, the CpG is a CpG-A ODN. Preferably, the CpG oligonucleotide is constructed so that the 5' end is accessible for receptor recognition. Optionally, two CpG
oligonucleotide sequences may be attached at their 3' ends to form "immunomers". See, for example, Kandimalla et al. (2003) Biochemical Society Transactions 31 (part 3):654-658, Kandimalla et al. (2003) BBRC 306:948-953, Bhagat et al. (2003) BBRC
300:853-861 and W003/035836. A useful CpG adjuvant is CpG7909, also known as ProMuneTM
(Coley Pharmaceutical Group, Inc.). Immunostimulatory oligonucleotides will typically comprise at least 20 nucleotides. They may comprise fewer than 100 nucleotides.
= 3-0-deacylated monophosphoryl lipid A(`3dMPL', also known as `MPLTM') (Myers et al. (1990) pages 145-156 of Cellular and molecular aspects of endotoxin reaction, Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan pages 282, Johnson et al. (1999) JMed Chem 42:4640-9 and Baldrick et al. (2002) Regulatory Toxicol Pharmacol 35:398-413). 3dMPL has been prepared from a heptoseless mutant of Salmonella minnesota, and is chemically similar to lipid A but lacks an acid-labile phosphoryl group and a base-labile acyl group. Preparation of 3dMPL was originally described in UK patent application GB-A-2220211. 3dMPL can take the form of a mixture of related molecules, varying by their acylation (e.g. having 3, 4, 5 or 6 acyl chains, which may be of different lengths). The two glucosamine (also known as 2-deoxy-2-amino-glucose) monosaccharides are N-acylated at their 2-position carbons (i.e. at positions 2 and 2'), and there is also 0-acylation at the 3' position.
= An imidazoquinoline compound, such as Imiquimod ("R-837") (US patents 4,680,338;
4,988,815) Resiquimod ("R-848") (W092/15582), and their analogs; and salts thereof (e.g. the hydrochloride salts). Further details about immunostimulatory imidazoquinolines can be found in Stanley (2002) Clin Exp Dermatol 27:571-577, Wu et al. (2004) Antiviral Res. 64(2):79-83, Vasilakos et al. (2000) Cell Immunol. 204(1):64-74, US
patents 4689338, 4929624, 5238944, 5266575, 5268376, 5346905, 5352784, 5389640, 5395937, 5482936, 5494916, 5525612, 6083505, 6440992, 6627640, 6656938, 6660735, 6660747, 6664260, 6664264, 6664265, 6667312, 6670372, 6677347, 6677348, 6677349, 6683088, 6703402, 6743920, 6800624, 6809203, 6888000 and 6924293 and Jones (2003) Curr Opin Investig Drugs 4:214-218.
= A thiosemicarbazone compound, such as those disclosed in W02004/060308.
Methods of formulating, manufacturing, and screening for active compounds are also described in W02004/060308. The thiosemicarbazones are particularly effective in the stimulation of human peripheral blood mononuclear cells for the production of cytokines, such as TNF-a.
= A tryptanthrin compound, such as those disclosed in W02004/064759. Methods of formulating, manufacturing, and screening for active compounds are also described in reference W02004/064759. The thiosemicarbazones are particularly effective in the stimulation of human peripheral blood mononuclear cells for the production of cytokines, such as TNF-a.
= A nucleoside analog, such as: (a) Isatorabine (ANA-245; 7-thia-8-oxoguanosine):
O
S
J~ ~
N N N
O
OO
and prodrugs thereof; (b) ANA975; (c) ANA-025-1; (d) ANA380; (e) the compounds disclosed in US patents 6,924,271, 5,658,731 and US2005/0070556; (f) a compound having the formula:
R, R~N R4 wherein:
Rl and R2 are each independently H, halo, -NRaR, -OH, C1_6 alkoxy, substituted C1_6 alkoxy, heterocyclyl, substituted heterocyclyl, C6_10 aryl, substituted C6_1o aryl, C1_6 alkyl, or substituted C1_6 alkyl;
R3 is absent, H, C1_6 alkyl, substituted C1_6 alkyl, C6_10 aryl, substituted C6_10 aryl, heterocyclyl, or substituted heterocyclyl;
R4 and R5 are each independently H, halo, heterocyclyl, substituted heterocyclyl, -C(O)-Rd, C1-6 alkyl, substituted C1_6 alkyl, or bound together to form a 5 membered ring as in R4-5:
,MXj DrRa the binding being achieved at the bonds indicated by a X1 and X2 are each independently N, C, 0, or S;
R8 is H, halo, -OH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -OH, -NRaRb, -(CH2)n-0-Rc, -O-(C1-6 alkyl), -S(O)pRe, or -C(O)-Rd;
R9 is H, C1-6 alkyl, substituted C1-6 alkyl, heterocyclyl, substituted heterocyclyl or R9a, wherein R9a is:
RfO R9a Rlo R11 the binding being achieved at the bond indicated by a Rlo and Ril are each independently H, halo, C1_6 alkoxy, substituted C1-6 alkoxy, -NRaRb, or -OH;
each Ra and Rb is independently H, C1-6 alkyl, substituted CI-6 alkyl, -C(O)Rd, C6-10 aryl;
each R, is independently H, phosphate, diphosphate, triphosphate, C1-6 alkyl, or substituted C1-6 alkyl;
each Rd is independently H, halo, C1-6 alkyl, substituted C1_6 alkyl, C1-6 alkoxy, substituted C1-6 alkoxy, -NH2, -NH(C1_6 alkyl), -NH(substituted CI-6 alkyl), -N(CI-6 alkyl)2, -N(substituted C1-6 alkyl)2, C6-1o aryl, or heterocyclyl;
each Re is independently H, C1-6 alkyl, substituted C1-6 alkyl, C6_10 aryl, substituted C6-10 aryl, heterocyclyl, or substituted heterocyclyl;
each Rf is independently H, C1-6 alkyl, substituted C1_6 alkyl, -C(O)Rd, phosphate, diphosphate, or triphosphate;
each n is independently 0, 1, 2, or 3;
each p is independently 0, 1, or 2; or or (g) a pharmaceutically acceptable salt of any of (a) to (f), a tautomer of any of (a) to (f), or a pharmaceutically acceptable salt of the tautomer.
= Loxoribine (7-allyl-8-oxoguanosine) (US patent 5,011,828).
= Compounds disclosed in W02004/87153, including: Acylpiperazine compounds, Indoledione compounds, Tetrahydraisoquinoline (THIQ) compounds, Benzocyclodione compounds, Aminoazavinyl compounds, Aminobenzimidazole quinolinone (ABIQ) compounds (US 6,605,617, W002/18383), Hydrapthalamide compounds, Benzophenone compounds, Isoxazole compounds, Sterol compounds, Quinazilinone compounds, Pyrrole compounds (W02004/018455), Anthraquinone compounds, Quinoxaline compounds, Triazine compounds, Pyrazalopyrimidine compounds, and Benzazole compounds (W003/082272).
= Compounds disclosed in W02006/00242, including 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, and nucleoside analogs.
= An aminoalkyl glucosaminide phosphate derivative, such as RC-529 (Johnson et al.
(1999) Bioorg Med Chem Lett 9:2273-227, Evans et al. (2003) Expert Rev Vaccines 2:219-22).
= A phosphazene, such as poly[di(carboxylatophenoxy)phosphazene] ("PCPP") as described, for example, in Andrianov et al. (1998) Biomaterials 19:109-115 and Payne et al. (1998) Adv Drug Delivery Review 31:185-196.
= Small molecule immunopotentiators (SMIPs) such as:
N2-methyl-l-(2-methylpropyl)-1 H-imidazo[4,5-c]quinoline-2,4-diamine N2,N2-dimethyl-l-(2-methylpropyl)-1 H-imidazo [4,5-c]quinoline-2,4-diamine N2-ethyl-N2-methyl- l -(2-methylpropyl)-1 H-imidazo[4,5-c]quinoline-2,4-diamine N2-methyl-l-(2-methylpropyl)-N2-propyl-1 H-imidazo[4,5-c]quinoline-2,4-diamine 1-(2-methylpropyl)-N2-propyl-1 H-imidazo [4,5-c]quinoline-2,4-diamine N2-butyl-l-(2-methylpropyl)-1 H-imidazo[4,5-c]quinoline-2,4-diamine N2-butyl-N2-methyl-l-(2-methylpropyl)-1 H-imidazo[4,5-c]quinoline-2,4-diamine N2-methyl-l-(2-methylpropyl)-N2-pentyl-1 H-imidazo [4,5-c]quinoline-2,4-diamine N2-methyl- l -(2-methylpropyl)-N2-prop-2-enyl-1 H-imidazo [4,5-c]quinoline-2,4-diamine 1-(2-methylpropyl)-2-[(phenylmethyl)thio]-1 H-imidazo[4,5-c]quinolin-4-amine 1-(2-methylpropyl)-2-(propylthio)-1 H-imidazo[4,5-c]quinolin-4-amine 2-[[4-amino-l-(2-methylpropyl)-1 H-imidazo[4,5-c]quinolin-2-yl] (methyl)amino]ethano l 2-[[4-amino-l-(2-methylpropyl)-1 H-imidazo[4,5-c]quinolin-2-yl](methyl)amino]ethyl acetate 4-amino-l-(2-methylpropyl)-1,3-dihydro-2H-imidazo [4, 5-c]quinolin-2-one N2-butyl-l-(2-methylpropyl)-N4,N4-bis(phenylmethyl)-1 H-imidazo[4,5-c]quinoline-2,4-diamine N2-butyl-N2-methyl-l-(2-methylpropyl)-N4,N4-bis(phenylmethyl)-1 H-imidazo [4,5-c]quinoline-2,4-diamine N2-methyl-l-(2-methylpropyl)-N4,N4-bis(phenylmethyl)-1 H-imidazo[4,5-c] quinol ine-2,4-diamine N2,N2-dimethyl-l-(2-methylpropyl)-N4,N4-bis(phenylmethyl)-1 H-imidazo [4,5-c]quinoline-2,4-diamine 1-{4-amino-2-[methyl(propyl)amino]-1 H-imidazo[4,5-c]quinolin-l-yl} -2-methylpropan-2-ol 1-[4-amino-2-(propylamino)-1 H-imidazo[4,5-c]quinolin-l-yl]-2-methylpropan-2-ol N4,N4-dibenzyl-l-(2-methoxy-2-methylpropyl)-N2-propyl-1 H-imidazo [4, 5-c]quinoline-2,4-diamine.
= Saponins [chapter 22 of Vaccine Design: The Subunit and Adjuvant Approach (eds.
Powell & Newman) Plenum Press 1995 ISBN 0-306-44867-X], which are a heterologous group of sterol glycosides and triterpenoid glycosides that are found in the bark, leaves, stems, roots and even flowers of a wide range of plant species. Saponin from the bark of the Quillaia saponaria Molina tree have been widely studied as adjuvants.
Saponin can also be commercially obtained from Smilax ornata (sarsaprilla), Gypsophilla paniculata (brides veil), and Saponaria officianalis (soap root). Saponin adjuvant formulations include purified formulations, such as QS21, as well as lipid formulations, such as ISCOMs. QS21 is marketed as StimulonTM. Saponin compositions have been purified using HPLC and RP-HPLC. Specific purified fractions using these techniques have been identified, including QS7, QS17, QS18, QS21, QH-A, QH-B and QH-C. Preferably, the saponin is QS21. A method of production of QS21 is disclosed in US 5,057,540.
Saponin formulations may also comprise a sterol, such as cholesterol (W096/33739).
Combinations of saponins and cholesterols can be used to form unique particles called immunostimulating complexes (ISCOMs) [chapter 23 of Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN 0-306-44867-X)]. ISCOMs typically also include a phospholipid such as phosphatidylethanolamine or phosphatidylcholine. Any known saponin can be used in ISCOMs. Preferably, the ISCOM includes one or more of QuilA, QHA & QHC. ISCOMs are further described in W096/33739, EP-A-0 109942 and W096/1 1 71 1.
Optionally, the ISCOMS may be devoid of additional detergent (W000/07621). A review of the development of saponin based adjuvants can be found in Barr et al. (1998) Advanced Drug Delivery Reviews 32:247-271 and Sjolanderet et al. (1998) Advanced Drug Delivery Reviews 32:321-338.
= Bacterial ADP-ribosylating toxins (e.g. the E.coli heat labile enterotoxin "LT", cholera toxin "CT", or pertussis toxin "PT") and detoxified derivatives thereof, such as the mutant toxins known as LT-K63 and LT-R72 (Sjolanderet et al. (1998) Advanced Drug Delivery Reviews 32:321-338). The use of detoxified ADP-ribosylating toxins as mucosal adjuvants is described in W095/1721 and as parenteral adjuvants in W098/42375.
= Bioadhesives and mucoadhesives, such as esterified hyaluronic acid microspheres (Singh et al] (2001) JCont Release 70:267-276) or chitosan and its derivatives (W099/2796).
= Microparticles (i.e. a particle of -100nm to -150gm in diameter, more preferably -200nm to -30 m in diameter, or -500nm to -10 m in diameter) formed from materials that are biodegradable and non-toxic (e.g. a poly(a-hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone, etc.), with poly(lactide-co-glycolide) being preferred, optionally treated to have a negatively-charged surface (e.g. with SDS) or a positively-charged surface (e.g. with a cationic detergent, such as CTAB).
= Liposomes (Chapters 13 & 14 of Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN 0-306-44867-X)). Examples of liposome formulations suitable for use as adjuvants are described in US
5,916,588, 6,090,406 and EP-A-0626169.
= Polyoxyethylene ethers and polyoxyethylene esters (W099/52549). Such formulations further include polyoxyethylene sorbitan ester surfactants in combination with an octoxynol (WO01/21207) as well as polyoxyethylene alkyl ethers or ester surfactants in combination with at least one additional non-ionic surfactant such as an octoxynol (WO01/2115). Preferred polyoxyethylene ethers are selected from the following group:
polyoxyethylene-9-lauryl ether (laureth 9), polyoxyethylene-9-steoryl ether, polyoxytheylene-8-steoryl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether.
= Muramyl peptides, such as N-acetylmuramyl-L-threonyl-D-isoglutamine ("thr-MDP"), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylglucsaminyl-N-acetylmuramyl-L-Al-D-isoglu-L-Ala-dipalmitoxy propylamide ("DTP-DPP", or "TheramideTM), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine ("MTP-PE").
= An outer membrane protein proteosome preparation prepared from a first Gram-negative bacterium in combination with a liposaccharide (LPS) preparation derived from a second Gram-negative bacterium, wherein the outer membrane protein proteosome and LPS
preparations form a stable non-covalent adjuvant complex. Such complexes include "IVX- 908", a complex comprised of Neisseria meningitidis outer membrane and LPS.
= Methyl inosine 5'-monophosphate ("MIMP") (Signorelli & Hadden (2003) Int Immunopharmacol 3(8):1177-86).
= A polyhydroxlated pyrrolizidine compound (W02004/064715), such as one having formula:
HO ~ ~Jw Ra....._.~ OH
cHZcaH
where R is selected from the group comprising hydrogen, straight or branched, unsubstituted or substituted, saturated or unsaturated acyl, alkyl (e.g.
cycloalkyl), alkenyl, alkynyl and aryl groups, or a pharmaceutically acceptable salt or derivative thereof.
Examples include, but are not limited to: casuarine, casuarine-6-a-D-glucopyranose, 3-epi-casuarine, 7-epi-casuarine, 3,7-diepi-casuarine, etc.
= A gamma inulin (Cooper (1995) Pharm Biotechnol 6:559-80) or derivative thereof, such as algammulin.
= A compound of formula I, II or III, or a salt thereof:
xt~~,--Y~ /X~~"Y~
( HE)a ~CHZIo 0-P-OH X.~ -0 O=P-O' 1! Z2 A: \N
WO ~-0 mm R= ~ ~ b=
1 Ctl~jq tw. a X ~
NT' ~ Fi2)C ~~ 2)a` F+~' p2 fif ~ Rz W\ rowy~. t 5~ ~
R2 Ff ~~ [ a3c \~~~ a ~~(~Hz1a (GW2}e' ir da' ~
~, 4 pa G2 !_ C'`pa ~ pa He y as defined in W003/011223, such as `ER 803058', `ER 803732', `ER 804053', ER
804058', `ER 804059', `ER 804442', `ER 804680', `ER .804764', ER 803022 or `ER
804057' e.g.:
o" 'Cõ[1zs a =
p- I1-C)~(T
/_j () Na [Iti ,,[IJ,3 ~ (:
HN
O-P-QO' v `G,H~s [23 () Va [iN Y-Y C;i.F
( ) 0 N
A
J _O(O 0 0 O 1~~ ER-803022:
p, A
= Derivatives of lipid A from Escherichia coli such as OM-174 (described in Meraldi et al.
(2003) Vaccine 21:2485-2491, Pajak et al. (2003) Vaccine 21:836-84.
= A formulation of a cationic lipid and a (usually neutral) co-lipid, such as aminopropyl-dimethyl-myri stoleyloxy-propanaminiumbromide-diphytanoylphosphatidyl-ethanolamine ("VaxfectinTM") or aminopropyl-dimethyl-bis-dodecyloxy-propanaminiumbromide-dioleoylphosphatidyl-ethanolamine ("GAP-DLRIE:DOPE"). Formulations containing ( )-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradeceneyloxy)-1-propanaminium salts are preferred (US patent 6586409) = Compounds containing lipids linked to a phosphate-containing acyclic backbone, such as the TLR4 antagonist E5564 (Wong et al. (2003) J Clin Pharmacol 43(7):735-42, US2005/0215517):
0 0 0 ,oPO(orn, C1Ia(> U U
(CIIiIgCII.j - If These and other adjuvant-active substances are discussed in more detail in references Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN
0-306-44867-X) and Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan.
Compositions may include two or more of said adjuvants.
Antigens and adjuvants in a composition will typically be in admixture.
Oil-in-water emulsion adjuvants Oil-in-water emulsions are particularly useful as adjuvants. Various such emulsions are known, and they typically include at least one oil and at least one surfactant, with the oil(s) and surfactant(s) being biodegradable (metabolizable) and biocompatible. The oil droplets in the emulsion are generally less than 5 m in diameter, and may even have a sub-micron diameter, with these small sizes being achieved with a microfluidizer to provide stable emulsions. Droplets with a size less than 220nm are preferred as they can be subjected to filter sterilization.
The invention can be used with oils such as those from an animal (such as fish) or vegetable source. Sources for vegetable oils include nuts, seeds and grains. Peanut oil, soybean oil, coconut oil, and olive oil, the most commonly available, exemplify the nut oils.
Jojoba oil can be used e.g.
obtained from the jojoba bean. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil and the like. In the grain group, corn oil is the most readily available, but the oil of other cereal grains such as wheat, oats, rye, rice, teff, triticale and the like may also be used. 6-10 carbon fatty acid esters of glycerol and 1,2-propanediol, while not occurring naturally in seed oils, may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils. Fats and oils from mammalian milk are metabolizable and may therefore be used in the practice of this invention. The procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art. Most fish contain metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein. A number of branched chain oils are synthesized biochemically in 5-carbon isoprene units and are generally referred to as terpenoids.
Shark liver oil contains a branched, unsaturated terpenoids known as squalene, 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene, which is particularly preferred herein. Squalane, the saturated analog to squalene, is also a preferred oil. Fish oils, including squalene and squalane, are readily available from commercial sources or may be obtained by methods known in the art. Other preferred oils are the tocopherols (see below). Mixtures of oils can be used.
Surfactants can be classified by their `HLB' (hydrophile/lipophile balance).
Preferred surfactants of the invention have a HLB of at least 10, preferably at least 15, and more preferably at least 16.
The invention can be used with surfactants including, but not limited to: the polyoxyethylene sorbitan esters surfactants (commonly referred to as the Tweens), especially polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), and/or butylene oxide (BO), sold under the DOWFAXTM tradename, such as linear EO/PO block copolymers;
octoxynols, which can vary in the number of repeating ethoxy (oxy-1,2-ethanediyl) groups, with octoxynol-9 (Triton X-100, or t-octylphenoxypolyethoxyethanol) being of particular interest;
(octylphenoxy)polyethoxyethanol (IGEPAL CA-630/NP-40); phospholipids such as phosphatidylcholine (lecithin); polyoxyethylene fatty ethers derived from lauryl, cetyl, stearyl and oleyl alcohols (known as Brij surfactants), such as triethyleneglycol monolauryl ether (Brij 30); and sorbitan esters (commonly known as the SPANs), such as sorbitan trioleate (Span 85) and sorbitan monolaurate. Preferred surfactants for including in the emulsion are Tween 80 (polyoxyethylene sorbitan monooleate), Span 85 (sorbitan trioleate), lecithin and Triton X-100.
Mixtures of surfactants can be used e.g. Tween 80/Span 85 mixtures, or Tween80/Triton-X100 mixtures. A combination of a polyoxyethylene sorbitan ester such as polyoxyethylene sorbitan monooleate (Tween 80) and an octoxynol such as t-octylphenoxypolyethoxyethanol (Triton X-100) is also suitable. Another useful combination comprises laureth 9 plus a polyoxyethylene sorbitan ester and/or an octoxynol.
Preferred amounts of surfactants (% by weight) are: polyoxyethylene sorbitan esters (such as Tween 80) 0.01 to 1%, in particular about 0.1 %; octyl- or nonylphenoxy polyoxyethanols (such as Triton X-100, or other detergents in the Triton series) 0.001 to 0.1 %, in particular 0.005 to 0.02%; polyoxyethylene ethers (such as laureth 9) 0.1 to 20 %, preferably 0.1 to 10 % and in particular 0.1 to 1% or about 0.5%.
Specific oil-in-water emulsion adjuvants useful with the invention include, but are not limited to:
= A submicron emulsion of squalene, Tween 80, and Span 85. The composition of the emulsion by volume can be about 5% squalene, about 0.5% polysorbate 80 and about 0.5%
Span 85. In weight terms, these ratios become 4.3% squalene, 0.5% polysorbate 80 and 0.48% Span 85. This adjuvant is known as `MF59' (W090/14837, Podda & Del Giudice (2003) Expert Rev Vaccines 2:197-203, and Podda (2001) Vaccine 19: 2673-2680), as described in more detail in Chapter 10 of Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 of Vaccine Adjuvants:
Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series).
The MF59 emulsion advantageously includes citrate ions e.g. 10mM sodium citrate buffer.
= An emulsion of squalene, a tocopherol, and Tween 80. The emulsion may include phosphate buffered saline. It may also include Span 85 (e.g. at 1%) and/or lecithin. These emulsions may have from 2 to 10% squalene, from 2 to 10% tocopherol and from 0.3 to 3% Tween 80, and the weight ratio of squalene:tocopherol is preferably <1 as this provides a more stable emulsion. One such emulsion can be made by dissolving Tween 80 in PBS to give a 2% solution, then mixing 90m1 of this solution with a mixture of (5g of DL-a-tocopherol and 5ml squalene), then microfluidising the mixture. The resulting emulsion may have submicron oil droplets e.g. with an average diameter of between 100 and 250nm, preferably about 180nm.
= An emulsion of squalene, a tocopherol, and a Triton detergent (e.g. Triton X-100). The emulsion may also include a 3d-MPL (see below). The emulsion may contain a phosphate buffer.
= An emulsion comprising a polysorbate (e.g. polysorbate 80), a Triton detergent (e.g. Triton X-100) and a tocopherol (e.g. an a-tocopherol succinate). The emulsion may include these three components at a mass ratio of about 75:11:10 (e.g. 750 g/ml polysorbate 80, ll0 g/ml Triton X-100 and 100 g/ml a-tocopherol succinate), and these concentrations should include any contribution of these components from antigens. The emulsion may also include squalene. The emulsion may also include a 3d-MPL (see below). The aqueous phase may contain a phosphate buffer.
= An emulsion of squalane, polysorbate 80 and poloxamer 401 ("PluronicTM
L121"). The emulsion can be formulated in phosphate buffered saline, pH 7.4. This emulsion is a useful delivery vehicle for muramyl dipeptides, and has been used with threonyl-MDP
in the "SAF-1" adjuvant (Allison & Byars (1992) Res Immunol 143:519-25), (0.05-1% Thr-MDP, 5% squalane, 2.5% Pluronic L121 and 0.2% polysorbate 80). It can also be used without the Thr-MDP, as in the "AF" adjuvant (Hariharan et al. (1995) Cancer Res 55:3486-9) (5%
squalane, 1.25% Pluronic L121 and 0.2% polysorbate 80). Microfluidization is preferred.
= An emulsion having from 0.5-50% of an oil, 0.1-10% of a phospholipid, and 0.05-5% of a non-ionic surfactant. As described in W095/11700, preferred phospholipid components are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, sphingomyelin and cardiolipin.
Submicron droplet sizes are advantageous.
= A submicron oil-in-water emulsion of a non-metabolizable oil (such as light mineral oil) and at least one surfactant (such as lecithin, Tween 80 or Span 80). Additives may be included, such as QuilA saponin, cholesterol, a saponin-lipophile conjugate (such as GPI-0100, described in US patent 6,080,725, produced by addition of aliphatic amine to desacylsaponin via the carboxyl group of glucuronic acid), dimethyidioctadecylammonium bromide and/or N,N-dioctadecyl-N,N-bis (2-hydroxyethyl)propanediamine.
= An emulsion in which a saponin (e.g. QuilA or QS21) and a sterol (e.g. a cholesterol) are associated as helical micelles (W02005/09718).
= An emulsion comprising a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol, and a non-ionic hydrophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene-polyoxypropylene block copolymer) (W02006/113373).
= An emulsion comprising a mineral oil, a non-ionic hydrophilic ethoxylated fatty alcohol, and a non-ionic lipophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene-polyoxypropylene block copolymer) (W02006/11337).
The emulsions may be mixed with antigen extemporaneously, at the time of delivery. Thus the adjuvant and antigen may be kept separately in a packaged or distributed vaccine, ready for final formulation at the time of use. The antigen will generally be in an aqueous form, such that the vaccine is finally prepared by mixing two liquids. The volume ratio of the two liquids for mixing can vary (e.g. between 5:1 and 1:5) but is generally about 1:1.
Aluminum salt adjuvants The adjuvants known as aluminum hydroxide and aluminum phosphate may be used.
These names are conventional, but are used for convenience only, as neither is a precise description of the actual chemical compound which is present (e.g. see chapter 9 of Vaccine Design: The Subunit andAdjuvant Approach (eds. Powell & Newman) Plenum Press 1995). The invention can use any of the "hydroxide" or "phosphate" adjuvants that are in general use as adjuvants.
The adjuvants known as "aluminium hydroxide" are typically aluminium oxyhydroxide salts, which are usually at least partially crystalline. Aluminium oxyhydroxide, which can be represented by the formula AlO(OH), can be distinguished from other aluminium compounds, such as aluminium hydroxide Al(OH)3, by infrared (IR) spectroscopy, in particular by the presence of an adsorption band at 1070cm I and a strong shoulder at 3090-3100cm 1[chapter 9 of Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995]. The degree of crystallinity of an aluminium hydroxide adjuvant is reflected by the width of the diffraction band at half height (WHH), with poorly-crystalline particles showing greater line broadening due to smaller crystallite sizes. The surface area increases as WHH increases, and adjuvants with higher WHH values have been seen to have greater capacity for antigen adsorption. A fibrous morphology (e.g. as seen in transmission electron micrographs) is typical for aluminium hydroxide adjuvants. The pI of aluminium hydroxide adjuvants is typically about 11 i.e. the adjuvant itself has a positive surface charge at physiological pH.
Adsorptive capacities of between 1.8-2.6 mg protein per mg Al+' at pH 7.4 have been reported for aluminium hydroxide adjuvants.
The adjuvants known as "aluminium phosphate" are typically aluminium hydroxyphosphates, often also containing a small amount of sulfate (i.e. aluminium hydroxyphosphate sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt.
Hydroxyphosphates generally have a P04/Al molar ratio between 0.3 and 1.2.
Hydroxyphosphates can be distinguished from strict A1PO4 by the presence of hydroxyl groups.
For example, an IR spectrum band at 3164cm'1 (e.g. when heated to 200 C) indicates the presence of structural hydroxyls [ch.9 of Vaccine Design: The Subunit and Adjuvant Approach (eds.
Powell & Newman) Plenum Press 1995.
The PO4/A13+ molar ratio of an aluminium phosphate adjuvant will generally be between 0.3 and 1.2, preferably between 0.8 and 1.2, and more preferably 0.95+0.1. The aluminium phosphate will generally be amorphous, particularly for hydroxyphosphate salts. A
typical adjuvant is amorphous aluminium hydroxyphosphate with PO4/Al molar ratio between 0.84 and 0.92, included at 0.6mg A13+/ml. The aluminium phosphate will generally be particulate (e.g. plate-like morphology as seen in transmission electron micrographs). Typical diameters of the particles are in the range 0.5-20 m (e.g. about 5-l04m) after any antigen adsorption.
Adsorptive capacities of between 0.7-1.5 mg protein per mg Al at pH 7.4 have been reported for aluminium phosphate adjuvants.
The point of zero charge (PZC) of aluminium phosphate is inversely related to the degree of substitution of phosphate for hydroxyl, and this degree of substitution can vary depending on reaction conditions and concentration of reactants used for preparing the salt by precipitation.
PZC is also altered by changing the concentration of free phosphate ions in solution (more phosphate = more acidic PZC) or by adding a buffer such as a histidine buffer (makes PZC more basic). Aluminium phosphates used according to the invention will generally have a PZC of between 4.0 and 7.0, more preferably between 5.0 and 6.5 e.g. about 5.7.
Suspensions of aluminium salts used to prepare compositions of the invention may contain a buffer (e.g. a phosphate or a histidine or a Tris buffer), but this is not always necessary. The suspensions are preferably sterile and pyrogen-free. A suspension may include free aqueous phosphate ions e.g. present at a concentration between 1.0 and 20 mM, preferably between 5 and 15 mM, and more preferably about 10 mM. The suspensions may also comprise sodium chloride.
The invention can use a mixture of both an aluminium hydroxide and an aluminium phosphate. In this case there may be more aluminium phosphate than hydroxide e.g. a weight ratio of at least 2:1 e.g. >5:1, >6:1, >7:1, >8:1, >9:1, etc.
The concentration of AI~ in a composition for administration to a patient is preferably less than 10mg/ml e.g. <5 mg/ml, <4 mg/ml, <3 mg/mi, <2 mg/ml, <1 mg/ml, etc. A
preferred range is between 0.3 and 1 mg/ml.
Kits of the invention Where a composition includes two components for delivery to a patient, such as an Env/Tat mixture and an adjuvant, these may be mixed during manufacture, or they may be mixed extemporaneously, at the time of delivery. Thus the invention provides kits including the various components ready for mixing. The kit allows the adjuvant and the complex to be kept separately until the time of use. This arrangement is particularly useful when using an oil-in-water emulsion adjuvant.
The components are physically separate from each other within the kit, and this separation can be achieved in various ways. For instance, the two components may be in two separate containers, such as vials. The contents of the two vials can then be mixed e.g. by removing the contents of one vial and adding them to the other vial, or by separately removing the contents of both vials and mixing them in a third container.
In a preferred arrangement, one of the kit components is in a syringe and the other is in a container such as a vial. The syringe can be used (e.g. with a needle) to insert its contents into the second container for mixing, and the mixture can then be withdrawn into the syringe. The mixed contents of the syringe can then be administered to a patient, typically through a new sterile needle. Packing one component in a syringe eliminates the need for using a separate syringe for patient administration.
In another preferred arrangement, the two kit components are held together but separately in the same syringe e.g. a dual-chamber syringe, such as those disclosed in W02005/089837, W000/07647, W099/17820, EP-A-0520618, W098/01174, US patents 6,692,468, 5,971,953, 4,060,082. When the syringe is actuated (e.g. during administration to a patient) then the contents of the two chambers are mixed. This arrangement avoids the need for a separate mixing step at the time of use.
The kit components will generally be in aqueous form. In some arrangements, a component (typically the antigen component rather than the adjuvant component) is in dry form (e.g. in a lyophilised form), with the other component being in aqueous form. The two components can be mixed in order to reactivate the dry component and give an aqueous composition for administration to a patient. A lyophilised component will typically be located within a vial rather than a syringe. Dried components may include stabilizers such as lactose, sucrose or mannitol, as well as mixtures thereof e.g. lactose/sucrose mixtures, sucrose/mannitol mixtures, etc. One possible arrangement uses an aqueous adjuvant component in a pre-filled syringe and a lyophilised antigen component in a vial.
Methods of treatment, and administration of vaccines The invention provides a method of raising an immune response in a patient, comprising the step of administering a composition of the invention to the patient. The compositions of the invention are particularly suitable for administration to human patients, but can also be administered to other mammals for investigational purposes, for raising antisera, etc.
The invention also provides a kit or composition of the invention for use as a medicament.
The invention also provides the use of an Env/Tat mixture of the invention in the manufacture of a medicament for raising an immune response in a patient.
Compositions of the invention can be administered in various ways. The most preferred immunization route is by injection (e.g. intramuscular, subcutaneous, intravenous), but other available routes include, but are not limited to, intranasal, oral, intradermal, transcutaneous, transdermal, pulmonary, etc.
Treatment can be by a single dose schedule or a multiple dose schedule.
Multiple doses may be used in a primary immunization schedule and/or in a booster immunization schedule. In a multiple dose schedule the various doses may be given by the same or different routes e.g. a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, etc.
Administration of more than one dose (typically two doses) is typical. Multiple doses will typically be administered at least 1 week apart (e.g. about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, etc.).
General The term "comprising" encompasses "including" as well as "consisting" e.g. a composition "comprising" X may consist exclusively of X or may include something additional e.g. X + Y.
The word "substantially" does not exclude "completely" e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.
The term "about" in relation to a numerical value x means, for example, x+10 /a.
Unless specifically stated, a process comprising a step of mixing two or more components does not require any specific order of mixing. Thus components can be mixed in any order. Where there are three components then two components can be combined with each other, and then the combination may be combined with the third component, etc.
Where animal (and particularly bovine) materials are used in the culture of cells, they should be obtained from sources that are free from transmissible spongiform encaphalopathies (TSEs), and in particular free from bovine spongiform encephalopathy (BSE). Overall, it is preferred to culture cells in the total absence of animal-derived materials.
Where a protein or a complex "binds specifically" to a particular target (e.g.
to CD4 or to a monoclonal antibody), it will typically bind to that.target with at least 10-fold greater affinity than to a control protein e.g. than to CD3 or than to an anti-Rev antibody.
Specific binding and non-specific binding can be distinguished by standard techniques e.g. by checking the effect of control proteins on the interaction, by checking dose-responsiveness, etc.
The term "polypeptide" refers to amino acid polymers of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acid components. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. Polypeptides can occur as single chains or associated chains. Polypeptides of the invention can be naturally or non-naturally glycosylated (i.e. the polypeptide has a glycosylation pattern that differs from the glycosylation pattern found in the corresponding naturally occurring polypeptide).
Env and Tat polypeptides for use with the invention can be prepared in many ways e.g. by chemical synthesis (in whole or in part), by digesting longer polypeptides using proteases, by translation from RNA, by purification from cell culture (e.g. from recombinant expression), from the organism itself (e.g. after bacterial culture, or direct from patients), etc. A preferred method for production of peptides <40 amino acids long involves in vitro chemical synthesis (Bodanszky (1993) Principles of Peptide Synthesis (ISBN: 0387564314), Fields et al.
(1997) Meth Enzymol 289: Solid-Phase Peptide Synthesis. ISBN: 0121821900). Solid-phase peptide synthesis is particularly preferred, such as methods based on tBoc or Fmoc (Chan & White (2000) Fmoc Solid Phase Peptide Synthesis. ISBN: 0199637245) chemistry. Enzymatic synthesis (Kullmann (1987) Enzymatic Peptide Synthesis. ISBN: 0849368413) may also be used in part or in full. As an alternative to chemical synthesis, biological synthesis may be used e.g:
the polypeptides may be produced by translation. This may be carried out in vitro or in vivo.
Biological methods are in general restricted to the production of polypeptides based on L-amino acids, but manipulation of translation machinery (e.g. of aminoacyl tRNA molecules) can be used to allow the introduction of D-amino acids (or of other non natural amino acids, such as iodotyrosine or methylphenylalanine, azidohomoalanine, etc.) (Ibba (1996) Biotechnol Genet Eng Rev 13:197-216). Where D-amino acids are included, however, it is preferred to use chemical synthesis.
Polypeptides of the invention may have covalent modifications at the C-terminus and/or N-terminus.
Env and Tat polypeptides can take various forms (e.g. native, fusions, glycosylated, non-glycosylated, lipidated, non-lipidated, phosphorylated, non-phosphorylated, myristoylated, non-myristoylated, monomeric, multimeric, particulate, denatured, etc.). For Env, oligomeric glycosylated polypeptides are preferred.
Env and Tat polypeptides are preferably provided in purified or substantially purified form i.e. substantially free from other polypeptides (e.g. free from naturally-occurring polypeptides), particularly from other HIV or host cell polypeptides, and are generally at least about 50% pure (by weight), and usually at least about 90% pure i.e. less than about 50%, and more preferably less than about 10% (e.g. 5% or less) of a composition is made up of other expressed polypeptides.
EXAMPLES
The full-length SF162 strain Env sequence has the following amino acid sequence (SEQ ID NO:
38):
MRVKGIRKNYQHLWRGGTLLLGMLMICSAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWAT
HACVPTDPNPQEIVLENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTK
SSNWKEMDRGEIKNCSFKVTTSIRNKMQKEYALFYKLDWPIDNDNTSYKLINCNTSVITQACPKVSFEP
IPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEGWIRSENFTDNAK
TIIVQLKESVEINCTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHCNISGEKWNNTLKQIVTKLQAQF
GNKTIVFKQSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEV
GKAMYAPPIRGQIRCSSNITGLLLTRDGGKEISNTTEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPT
KAKRRVVQREKRAVTLGAMFLGFLGAAGSTMGARSLTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT
VWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLDQIWNNMTWMEWEREIDNYT
NLIYTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYIKIFIMIVGGLVGLRIVFTVLSIVNRVR
QGYSPLSFQTRFPAPRGPDRPEGIEEEGGERDRDRSSPLVHGLLALIWDDLRSLCLFSYHRLRDLILIAA
RIVELLGRRGWEALKYWGNLLQYWIQELKNSAVSLFDAIAIAVAEGTDRIIEVAQRIGRAFLHIPRRIRQ
GFERALL
For expression purposes, the leader (amino acids 1-27; SEQ ID NO: 47) can be replaced by a leader sequence from tpa (SEQ ID NO: 48, MDAMKRGLCCVLLLCGAVFVSP).
The gp160 sequence can be modified to a gp140 form (SEQ ID NO: 39):
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWAT
HACVPTDPNPQEIVLENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTK
SSNWKEMDRGEIKNCSFKVTTSIRNKMQKEYALFYKLDVVPIDNDNTSYKLINCNTSVITQACPKVSFEP
IPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPWSTQLLLNGSLAEEGVVIRSENFTDNAK
TIIVQLKESVEINCTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHCNISGEKWNNTLKQIVTKLQAQF
GNKTIVFKQSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEV
GKAMYAPPIRGQIRCSSNITGLLLTRDGGKEISNTTEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPT
KAKRRVVQREKRAVTLGAMFLGFLGAAGSTMGARSLTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT
VWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLDQIWNNMTWMEWEREIDNYT
NLIYTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYIT"'T''T""TV^^T "^T DTT' '"VT
nrWrnsro GFEP.A.Lb It can be further modified to include five amino acid mutations at the cleavage site, to produce oligomeric gp140. This sequence (SEQ ID NO: 43) is known as `gp140mut7':
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVTTSIRNKM
QKEYALFYKLDWPIDNDNTSYKLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPC
TNVSTVQCTHGIRPWSTQLLLNGSLAEEGVVIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRKSITI
GPGRAFYATGDIIGDIRQAHCNISGEKWNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGGE
FFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTRD
GGKEISNTTEIFRPGGGDMRDNWRSELYKYKWKIEPLGVAPTKAISSVVQSEKSAVTLGAMFLGFLGAA
GSTMGARSLTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIW
GCSGKLICTTAVPWNASWSNKSLDQIWNNMTWMEWEREIDNYTNLIYTLIEESQNQQEKNEQELLELDKW
ASLWNWFDISKWLWYI
The V3 loop of SEQ ID NO: 39 can be replaced with SEQ ID NO: 23, in which a central 22mer has been deleted and a flexible sequence inserted (SEQ ID NO: 40; 627mer):
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVTTSIRNKM
QKEYALFYKLDVVPIDNDNTSYKLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPC
TNVSTVQCTHGIRPVVSTQLLLNGSLAEEGVVIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRGAGQA
HCNISGEKWNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNTIG
PNNTNGTITLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGKEISNTTEIFRPGGGDM
RDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVTLGAMFLGFLGAAGSTMGARSLTLTVQARQLL
SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWS
NKSLDQIWNNMTWMEWEREIDNYTNLIYTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYI
A construct encoding SEQ ID NO: 40 (`gp140dV3-22') can be expressed in 293T
cells and purified. Proteins are initially purified using GNA lectin, and are then re-purified using a ceramic hydroxyapatite column (CHAP). Small-scale and large-scale purifications are performed.
A modified form of SEQ ID NO: 40 (`gp1400V2dv3-22') in which the V2 loop is replaced by SEQ ID NO: 42 (CSFKVGAGKLINC) is prepared in the same way. Its sequence is SEQ
ID NO:
41:
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVGAGKLINC
NTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLA
EEGVVIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRGAGQAHCNISGEKWNNTLKQIVTKLQAQFGNK
TIVFKQSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEVGKA
MYAPPIRGQIRCSSNITGLLLTRDGGKEISNTTEIFRPGGGDMRDNWRSELYKYKWKIEPLGVAPTKAI
SSWQSEKSAVTLGAMFLGFLGAAGSTMGARSLTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG
IKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLDQIWNNMTWMEWEREIDNYTNLI
YTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYI
This protein is purified in the same manner as described above.
Equivalent Env-derivatives re also made for strain TV 1.
Example 1 After confirming purity, oligomerization and CD4-binding activity for both gp140dV3-22 and gp1400V2dv3-22 proteins using HPLC, are assayed for both CD4- and tat-binding activity using the BIACORETM system. Results using immobilized CD4, immobilized tat or immobilized tat-cys (a mutant of tat that still binds to env (Ensoli et al. (2005) Microbes Infect 7:1392-9) are summarized below:
Parameter Off rate (s-1 x 10=5) Half life (hours) Ligand CD4 Tat Tat-cys CD4 Tat Tat-cys 9p140sF162 5.30 + 0.76% 3.88 + 3.13% 0.13 + 96.4% 3.64 4.96 150.1 gp140AV2sF162 7.60 + 0.67% 5.50 + 1.37% 4.02 + 1.80% 2.53 3.50 4.79 gp140dV3-22sF162 5.48 + 0.63% 6.24 + 2.03% 4.61 + 1.82% 3.51 3.08 4.17 gp140Tv, 6.48 + 0.82% 10.0 + 1.22% 7.38 + 1.69% 2.97 1.92 2.61 gp140dV3-22Tvj 3.47 + 0.67% 6.98 + 2.82% 3.84 + 4.35% 5.55 2.76 5.01 Thus all the trimeric variants of Env bound to both CD4 and the tat polypeptide. Monomeric gp120 binds to CD4 as expected, but binding to tat is not observed.
BIACORETM can also be used to test binding of the SF162-derived proteins to (i) CD4, (ii) neutralizing antibody b12, which binds to gp120's CD4-binding site (Zwick et al. (2003) J Virol 77:5863-76), and (iii) non-neutralizing antibody 4.8d, which binds to a conformational epitope on gp120. Dissociation constants (M-1 x 10-10) and Rmax values (using 4.8d & CD4) are as follows:
CD4 Kd b1 Kd 4.8d Kd x Up-reg 4.8d* Rmax gp120 770 970 40 1.7 416 gp140AV2 160 34 3.8 2.6 281 gp140dV3-22 180 200 75 1.4 660 gp140 AV2 dV3-22 650 1000 79 1.8 602 4.8d is a CD4 inducible epitope antibody. It recognizes env alone at a low level, once env has undergone its conformational change due to CD4 binding. The `x 4.8d up-reg' figure indicates the BlAcore signal observed for env mixed with CD4 as a function of the signal observed for env without CD4, on the 4.8d antibody.
Thus the modifications that are introduced into Env do not substantially alter its CD4-binding properties. Moreover, monoclonal antibody binding remained at reasonable levels for all variants.
Example 2 Tat-binding for the SF162-derived proteins (with or without CD4) is also tested by a Far-Western assay. Results are shown in Figure 1. Thus both in a kinetic experimental environment (i.e.
BlAcore) and under conditions of equilibrium (i.e. Far Western analysis), trimeric envelope and its variants are able to bind to tat. Monomeric gpl20 does not generally show any evidence of binding to the tat polyprotein in either experiment, unless the V2 loop is deleted as in gpI20AV2.
Overall, the data show no significant difference between the magnitude of binding of Tat to the AV2 and dV3-22 forms of Env. However, the off rate for the dV3-22 trimeric Env was faster (i.e.
shorter half-life) when compared to the AV2 trimeric protein.
Example 3 Alternative V3 loop substitutions may be designed. Alignment of SEQ ID NO: 44 with SEQ ID
NOS: 25 to 29 suggests that the middle of the V3 loop is more variable than the outer flanking regions. In mutant loop SEQ ID NO: 15, the middle portion is deleted and the flanking regions remain intact. In SEQ ID NOs: 16 and 17 the N- or C- terminus flanking region is deleted. In SEQ ID NOs: 18 to 21 contact sites for monoclonal antibody 447D are removed.
In SEQ ID NO:
22, the loop is replaced with a flexible Gly-Ala-Gly sequence. In SEQ ID NO:
23 this flexible sequence is also inserted into the SEQ ID NO: 21 loop. In SEQ ID NO: 24, a different V3 loop is substituted into SF162.
SF162dV3-20 CTRPNNN------------------GAGDIRQAHC (SEQ ID NO: 15) SF162dV3-9 CT--------- ITIGPGRAFYATGDIIGDIRQAHC (SEQ ID NO: 16) SF162dV3-6 CTRPNNNTRKSITIGPGRAFYAT--------QAHC (SEQ ID NO: 17) SF162dV3-10 CTRPNNNTR----------FYATGDIIGDIRQAHC (SEQ ID NO: 18) SF162dV3-12 CTRPNNNTR--------------GDIIGDIRQAHC (SEQ ID NO: 19) SF162dv3-17 CT----------------- FYATGDIIGDIRQAHC (SEQ ID NO: 20) SF162dV3-22 CTRPNNNTR----------------------QAHC (SEQ ID NO: 21) SF162dV3-28sub CTRPNNNTR------------------- GAGQAHC (SEQ ID NO: 23) SF162dV3-28 CT----------------------------GAGHC (SEQ ID NO: 22) SF162V3sub CTRPNNNTRKSITIGPGRAFYATGDIIGNMRQAHC (SEQ ID NO: 24) The deleted peptide sequences (SEQ ID NOS: 30 to 37) are synthesized and evaluated for their ability to bind to Tat.
Example 4 Biologically active Tat binds the HIV Env through high affinity interactions with the V3 loop.
This requires exposure and/or conformational transitions of the V3 loop that are induced upon Env oligomerization or V2 loop deletion. Shortening of the Vl-V2 loop is a key feature of virus isolates emerging during early infection, which, however, are much more sensitive to neutralization. These data point to a key role of Tat in shielding these isolates from the mounting humoral immune response. Further, binding of the V3 loop of Env to Tat resembles the interaction of Env with the CCR5 co-receptor, a process that is also potentially enhanced by V1-V2 deletion or shortening. This indicates that the Tat-Env complex may impact virus entry and transmission to T cells, in particular the low CCR5 expressing CD4+ T cells that appear to be early targets of infection in mucosal tissues.
It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.
Within category (ii), the degree of sequence identity may be greater than 50%
(e.g. 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more).
Identity between polypeptides is preferably determined by the Smith-Watennan homology search algorithm as implemented in the MPSRCH program (Oxford Molecular), using an affine gap search with parameters gap open penalty=12 and gap extension penalty=l.
Within category (iii), each substitution involves a single amino acid, each deletion preferably involves a single amino acid, and each insertion preferably involves a single amino acid. These changes may arise deliberately (e.g. by site-directed mutagenesis) or naturally (e.g. through virus evolution or through spontaneous mutation). The polypeptides in category (iii) may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid substitutions relative to SEQ ID NO:
10, 11 or 12. These polypeptides may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid deletions relative to SEQ ID NO: 10, 11 or 12. These polypeptide s may have one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) single amino acid insertion relative to SEQ ID
NO: 10, 11 or 12. The substitutions, insertions and/or deletions may be at separate locations or may be contiguous. As mentioned above, substitutions may be conservative.
Within category (iv), the value of n may be greater than 7 e.g. 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850 or more. The fragment may comprise at least one T-cell and/or B-cell epitope of the sequence. As described above, such epitopes can be identified empirically or can be predicted.
Within category (v), the preferred pairwise alignment algorithm is the Needleman-Wunsch global alignment algorithm as described above.
Env/Tat mixtures Mixtures of the invention include Env and Tat polypeptides. In the mixture, these may form complexes, in which the Env and Tat polypeptides may be associated non-covalently and/or covalently. Particularly useful complexes have essentially a 1:1 molar ratio of Env and Tat.
Where the Env is in the form of a trimer, therefore, the preferred complex includes three Tat monomers.
The Env and Tat polypeptides in a mixture may be from the same type if HIV
e.g. both are from HIV-1 or both are from HIV-2. Where the same HIV types are used, it is also useful to mix Env and Tat polypeptides from the same group e.g. within HIV-1, both are from group M, group N or group O. Within group M, it is useful to mix Env and Tat polypeptides from the same subtype (or clade) e.g. from subtype A, B, C, D, F, G, H, J or K. It is also possible to use Env or Tat from a CRF (circulating recombinant form) subtype, such as an A/B or A/E CRF. Where a subtype includes sub-subtypes then the Env and Tat polypeptides may be from the same sub-subtype.
Using Env and Tat from different groups, subtypes, sub-subtypes and/or clades is not, however, excluded. HIV-1 nomenclature is discussed in more detail in Robertson et al.
(2000) Science 288:55-6.
The use of Env and Tat from subtype B or C is preferred. Within a single subtype (or, where applicable, sub-subtype) it is possible to use Env and Tat from the same strain or from different strains. For instance, the Env and Tat polypeptides may both be from the SF162 strain (subtype B), or the invention may use Env from one strain (e.g. SF162) and Tat from another strain (e.g.
BH 10).
Env/Tat complexes of the invention may bind specifically to (a) CD4 and/or (b) a monoclonal antibody that specifically binds to HIV Tat polypeptide and/or (c) a monoclonal antibody that specifically binds to HIV Env polypeptide. Thus the complexes may retain the CD4-binding activity of the uncomplexed Env polypeptide and/or the mAb-binding activity of the uncomplexed Tat or Env polypeptide. Complexes with both of binding activities (a) and (b) are particularly useful. As described in US provisional patent application 60/786,947 filed March 28 2006, retaining these two activities in a covalent complex requires an appropriate degree of cross-linking between Env and Tat. Although this degree of cross-linking can vary within a fairly broad range, and thus does not need to be controlled with absolute precision, too little cross-linking leads to unstable complexes and too much cross-linking leads to a loss of binding activity.
Where a complex binds specifically to CD4, this binding activity can be assessed using known assays e.g. as described in W091/13906. The assay does not need to use native CD4, however, and it is more typical to use a purified soluble form of CD4 based on its external domain (e.g. see example 5 of W091/13906). The CD4 may also be labeled to facilitate the assay.
The CD4 is preferably human CD4. At least 250 SNPs have so far been described for CD4, and any of these polypeptides can be used, such as the REFSEQ CD4 (GI:10835167). The uncomplexed Env will specifically bind to CD4, and this specific binding activity can be retained in the Env/Tat complex. Although the binding activity is not removed, however, the actual binding affinity may change.
Where the complex binds specifically to an anti-Tat monoclonal antibody, a preferred monoclonal antibody is 8D1.8, which is available through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH
(http://www.aidsreagent.org/UploadDocs/ds4672_003.pdf ). The use of this antibody in Tat-binding assays has previously been disclosed e.g. in references Rohr et al.
(2003) J Virol.
77:5415-27, Avraham et al. (2004) J Immunol 173:6228-33, Liu et al. (2002) J
Virol 76:6689-700.
EnvlTat covalent cross-linking Env and Tat proteins may be covalently linked together in complexes of the invention. Various methods for covalently linking proteins are known in the art e.g. see references Wong (1991) Chemistry ofprotein conjugation and cross-linking. ISBN 0-8493-5886-8 and Hermanson (1996) Bioconjugate techniques. ISBN 0-12-342336-8. For example, covalent linking may involve the use of homobifunctional cross-linkers, heterobifunctional cross-linkers or zero-length cross-linkers. It may involve reagents directed to sulfhydryl groups in proteins, reagents directed to amino groups in proteins, reagents directed to carboxyl groups in proteins, tyrosine-selective reagents, arginine-specific reagents, histidine-specific reagents, methionine-alkylating reagents, tryptophan-specific reagents, serine-modifying reagents, etc.
A preferred group of cross-linking reagents for use with the invention includes aldehydes, and in particular includes formaldehyde and the dialdehydes. Suitable dialdehydes include glyoxal, malondialdehyde, succinialdehyde, adipaldehyde, a-hydroxyadipaldehyde, glutaraldehyde and phthalaldehyde. Glutaraldehyde and its derivatives are particularly preferred, including 2-methoxy-2,4-dimethylglutaraldehyde, 3-methoxy-2,4-dimethylglutaraldehyde and 3-methylglutar-aldehyde, Pyridoxal phosphates can also be used. Other amino group-directed cross-linkers include bis-imidoesters, bis-succinimidyl derivatives (e.g.
bis(sulfosuccinimidyl)suberate, or `BS3'), bifunctional aryl halides, bifunctional acylating agents (including di-isocyanates, di-isothiocyanates, bifunctional sulfonyl halides, bis-nitrophenyl esters and bifunctional acylazides), diketones, p-benzoquinone, 2-iminothiolane, erythritolbiscarbonate, mucobromic acid, mucochloric acid, ethylchloroformate and multidiazonium compounds.
Methods for cross-linking proteins using these reagents are known in the art.
Generally, the invention will involve mixing Env polypeptide, Tat polypeptide and a linking reagent under conditions that permit the covalent linking reaction to proceed. In some two-step procedures, however, such as those using a heterobifunctional reagent, one of the two polypeptides will be reacted with the linking reagent first, to form an activated polypeptide, and then the activated polypeptide will be reacted with the second polypeptide.
Heterobifunctional linkers with a photoreactive group are also useful. If a linker has one thermoreactive group and one photoreactive group then a first step can involve attachment via the thermoreactive group, and then conjugation to make the complex can be initiated by the use of e.g. UV light. As an alternative, the photoreactive group can be used first.
As mentioned above, the cross-linking reaction may be performed to an extent that is not so great as to eliminate critical binding activities of the Env and Tat proteins. Thus the concentration of the Env and Tat proteins, the concentration of the cross-linking reagent(s), the pH, the reaction temperature and the reaction time can be controlled to give the desired degree of cross-linking.
When testing a particular combination of Env, Tat and cross-linking reagent then an initial series of reactions can be performed to evaluate suitable reaction conditions.
Pharmaceutical compositions Mixtures of the invention can be used as active ingredients in immunogenic compositions. These compositions can be administered to animals in order to elicit an immune response. The immune response preferably includes a humoral (e.g. an antibody response, such as a neutralizing antibody response) and/or a cellular response against Env and/or Tat. In a patient already infected with HIV, the immune response may reduce the severity of the infection (e.g.
reduce viral load) and may even result in clearance of HIV infection. In a patient who is not infected with HIV, the immune response may reduce the risk of future HIV infection and may even be protective against future HIV infection. These effects arising from administration of the immunogenic composition of may be augmented by, or also require, the use of other anti-HIV strategies e.g. the administration of antivirals, including but not limited to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, etc.
Immunogenic compositions will include an immunologically effective amount of a polypeptide.
By `immunologically effective amount', it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for the desired treatment or prevention. This amount can vary depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non-human primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials, and a typical quantity of complex per dose is between 1 g and 10mg per antigen.
Immunogenic compositions of the invention are pharmaceutically acceptable.
They usually include components in addition to the complexes e.g. they typically include one or more pharmaceutical carrier(s) and/or excipient(s). A thorough discussion of such components is available in Gennaro (2000) Remington: The Science and Practice of Pharmacy.
20th edition, ISBN: 0683306472.
Compositions will generally be in aqueous form.
To control tonicity, it is preferred to include a physiological salt, such as a sodium salt. Sodium chloride (NaCI) is preferred, which may be present at between 1 and 20 mg/ml.
Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, etc.
Compositions will generally have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, preferably between 240-3 60 mOsm/kg, and will more preferably fall within the range of 290-310 mOsm/kg.
Compositions may include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer; or a citrate buffer. Buffers will typically be included in the 5-20mM range.
The pH of a composition will generally be between 5 and 8, and more typically between 6 and 7.
The composition is preferably sterile. The composition is preferably non-pyrogenic e.g.
containing <1 EU (endotoxin unit, a standard measure) per dose, and preferably <0.1 EU per dose. The composition is preferably gluten free.
Compositions of the invention may include detergent e.g. a polyoxyethylene sorbitan ester surfactant (known as `Tweens'), an octoxynol (such as octoxynol-9 (Triton X-100) or t-octylphenoxypolyethoxy-ethanol), etc.
Vaccines may be administered in a dosage volume of about 0.5m1.
Vaccine adjuvants Compositions of the invention may advantageously include an adjuvant, which can function to enhance the immune responses (humoral and/or cellular) elicited in a patient who receives the composition. Adjuvants that can be used with the invention include, but are not limited to:
= A mineral-containing composition, including calcium salts and aluminum salts (or mixtures thereof). Calcium salts include calcium phosphate (e.g. the "CAP"
particles disclosed in US patent 6355271). Aluminum salts include hydroxides, phosphates, sulfates, etc., with the salts taking any suitable form (e.g. gel, crystalline, amorphous, etc.). Adsorption to these salts is preferred. The mineral containing compositions may also be formulated as a particle of metal salt W000/23105. Aluminum salt adjuvants are described in more detail below.
= An oil-in-water emulsion, as described in more detail below.
= An immunostimulatory oligonucleotide, such as one containing a CpG motif (a dinucleotide sequence containing an unmethylated cytosine linked by a phosphate bond to a guanosine), a TpG motif WO01/22972,a double-stranded RNA, an oligonucleotide containing a palindromic sequence, or an oligonucleotide containing a poly(dG) sequence. Immunostimulatory oligonucleotides can include nucleotide modifications/analogs such as phosphorothioate modifications and can be double-stranded or (except for RNA) single-stranded. Kandimalla et al. (2003) Nucleic Acids Research 31:2393-2400, W002/26757 and W099/62923 disclose possible analog substitutions e.g. replacement of guanosine with 2'-deoxy-7-deazaguanosine.
The adjuvant effect of CpG oligonucleotides is further discussed in Krieg (2003) Nature Medicine 9:831-835, McCluskie et al. (2002) FEMS Immunology and Medical Microhiology 32:179-185, W098/40100, US patents 6,207,646, 6,239,116 and 6,429,199.
A CpG sequence may be directed to TLR9, such as the motif GTCGTT or TTCGTT
(Kandimalla et al. (2003) Biochemical Society Transactions 31 (part 3):654-658). The CpG sequence may be specific for inducing a Thl immune response, such as a CpG-A
ODN (oligodeoxynucleotide), or it may be more specific for inducing a B cell response, such a CpG-B ODN. CpG-A and CpG-B ODNs are discussed in Blackwell et al.
(2003) J
Immunol 170:4061-4068, Krieg (2002) Trends Immunol 23:64-65, WO01/95935.
Preferably, the CpG is a CpG-A ODN. Preferably, the CpG oligonucleotide is constructed so that the 5' end is accessible for receptor recognition. Optionally, two CpG
oligonucleotide sequences may be attached at their 3' ends to form "immunomers". See, for example, Kandimalla et al. (2003) Biochemical Society Transactions 31 (part 3):654-658, Kandimalla et al. (2003) BBRC 306:948-953, Bhagat et al. (2003) BBRC
300:853-861 and W003/035836. A useful CpG adjuvant is CpG7909, also known as ProMuneTM
(Coley Pharmaceutical Group, Inc.). Immunostimulatory oligonucleotides will typically comprise at least 20 nucleotides. They may comprise fewer than 100 nucleotides.
= 3-0-deacylated monophosphoryl lipid A(`3dMPL', also known as `MPLTM') (Myers et al. (1990) pages 145-156 of Cellular and molecular aspects of endotoxin reaction, Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan pages 282, Johnson et al. (1999) JMed Chem 42:4640-9 and Baldrick et al. (2002) Regulatory Toxicol Pharmacol 35:398-413). 3dMPL has been prepared from a heptoseless mutant of Salmonella minnesota, and is chemically similar to lipid A but lacks an acid-labile phosphoryl group and a base-labile acyl group. Preparation of 3dMPL was originally described in UK patent application GB-A-2220211. 3dMPL can take the form of a mixture of related molecules, varying by their acylation (e.g. having 3, 4, 5 or 6 acyl chains, which may be of different lengths). The two glucosamine (also known as 2-deoxy-2-amino-glucose) monosaccharides are N-acylated at their 2-position carbons (i.e. at positions 2 and 2'), and there is also 0-acylation at the 3' position.
= An imidazoquinoline compound, such as Imiquimod ("R-837") (US patents 4,680,338;
4,988,815) Resiquimod ("R-848") (W092/15582), and their analogs; and salts thereof (e.g. the hydrochloride salts). Further details about immunostimulatory imidazoquinolines can be found in Stanley (2002) Clin Exp Dermatol 27:571-577, Wu et al. (2004) Antiviral Res. 64(2):79-83, Vasilakos et al. (2000) Cell Immunol. 204(1):64-74, US
patents 4689338, 4929624, 5238944, 5266575, 5268376, 5346905, 5352784, 5389640, 5395937, 5482936, 5494916, 5525612, 6083505, 6440992, 6627640, 6656938, 6660735, 6660747, 6664260, 6664264, 6664265, 6667312, 6670372, 6677347, 6677348, 6677349, 6683088, 6703402, 6743920, 6800624, 6809203, 6888000 and 6924293 and Jones (2003) Curr Opin Investig Drugs 4:214-218.
= A thiosemicarbazone compound, such as those disclosed in W02004/060308.
Methods of formulating, manufacturing, and screening for active compounds are also described in W02004/060308. The thiosemicarbazones are particularly effective in the stimulation of human peripheral blood mononuclear cells for the production of cytokines, such as TNF-a.
= A tryptanthrin compound, such as those disclosed in W02004/064759. Methods of formulating, manufacturing, and screening for active compounds are also described in reference W02004/064759. The thiosemicarbazones are particularly effective in the stimulation of human peripheral blood mononuclear cells for the production of cytokines, such as TNF-a.
= A nucleoside analog, such as: (a) Isatorabine (ANA-245; 7-thia-8-oxoguanosine):
O
S
J~ ~
N N N
O
OO
and prodrugs thereof; (b) ANA975; (c) ANA-025-1; (d) ANA380; (e) the compounds disclosed in US patents 6,924,271, 5,658,731 and US2005/0070556; (f) a compound having the formula:
R, R~N R4 wherein:
Rl and R2 are each independently H, halo, -NRaR, -OH, C1_6 alkoxy, substituted C1_6 alkoxy, heterocyclyl, substituted heterocyclyl, C6_10 aryl, substituted C6_1o aryl, C1_6 alkyl, or substituted C1_6 alkyl;
R3 is absent, H, C1_6 alkyl, substituted C1_6 alkyl, C6_10 aryl, substituted C6_10 aryl, heterocyclyl, or substituted heterocyclyl;
R4 and R5 are each independently H, halo, heterocyclyl, substituted heterocyclyl, -C(O)-Rd, C1-6 alkyl, substituted C1_6 alkyl, or bound together to form a 5 membered ring as in R4-5:
,MXj DrRa the binding being achieved at the bonds indicated by a X1 and X2 are each independently N, C, 0, or S;
R8 is H, halo, -OH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -OH, -NRaRb, -(CH2)n-0-Rc, -O-(C1-6 alkyl), -S(O)pRe, or -C(O)-Rd;
R9 is H, C1-6 alkyl, substituted C1-6 alkyl, heterocyclyl, substituted heterocyclyl or R9a, wherein R9a is:
RfO R9a Rlo R11 the binding being achieved at the bond indicated by a Rlo and Ril are each independently H, halo, C1_6 alkoxy, substituted C1-6 alkoxy, -NRaRb, or -OH;
each Ra and Rb is independently H, C1-6 alkyl, substituted CI-6 alkyl, -C(O)Rd, C6-10 aryl;
each R, is independently H, phosphate, diphosphate, triphosphate, C1-6 alkyl, or substituted C1-6 alkyl;
each Rd is independently H, halo, C1-6 alkyl, substituted C1_6 alkyl, C1-6 alkoxy, substituted C1-6 alkoxy, -NH2, -NH(C1_6 alkyl), -NH(substituted CI-6 alkyl), -N(CI-6 alkyl)2, -N(substituted C1-6 alkyl)2, C6-1o aryl, or heterocyclyl;
each Re is independently H, C1-6 alkyl, substituted C1-6 alkyl, C6_10 aryl, substituted C6-10 aryl, heterocyclyl, or substituted heterocyclyl;
each Rf is independently H, C1-6 alkyl, substituted C1_6 alkyl, -C(O)Rd, phosphate, diphosphate, or triphosphate;
each n is independently 0, 1, 2, or 3;
each p is independently 0, 1, or 2; or or (g) a pharmaceutically acceptable salt of any of (a) to (f), a tautomer of any of (a) to (f), or a pharmaceutically acceptable salt of the tautomer.
= Loxoribine (7-allyl-8-oxoguanosine) (US patent 5,011,828).
= Compounds disclosed in W02004/87153, including: Acylpiperazine compounds, Indoledione compounds, Tetrahydraisoquinoline (THIQ) compounds, Benzocyclodione compounds, Aminoazavinyl compounds, Aminobenzimidazole quinolinone (ABIQ) compounds (US 6,605,617, W002/18383), Hydrapthalamide compounds, Benzophenone compounds, Isoxazole compounds, Sterol compounds, Quinazilinone compounds, Pyrrole compounds (W02004/018455), Anthraquinone compounds, Quinoxaline compounds, Triazine compounds, Pyrazalopyrimidine compounds, and Benzazole compounds (W003/082272).
= Compounds disclosed in W02006/00242, including 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, and nucleoside analogs.
= An aminoalkyl glucosaminide phosphate derivative, such as RC-529 (Johnson et al.
(1999) Bioorg Med Chem Lett 9:2273-227, Evans et al. (2003) Expert Rev Vaccines 2:219-22).
= A phosphazene, such as poly[di(carboxylatophenoxy)phosphazene] ("PCPP") as described, for example, in Andrianov et al. (1998) Biomaterials 19:109-115 and Payne et al. (1998) Adv Drug Delivery Review 31:185-196.
= Small molecule immunopotentiators (SMIPs) such as:
N2-methyl-l-(2-methylpropyl)-1 H-imidazo[4,5-c]quinoline-2,4-diamine N2,N2-dimethyl-l-(2-methylpropyl)-1 H-imidazo [4,5-c]quinoline-2,4-diamine N2-ethyl-N2-methyl- l -(2-methylpropyl)-1 H-imidazo[4,5-c]quinoline-2,4-diamine N2-methyl-l-(2-methylpropyl)-N2-propyl-1 H-imidazo[4,5-c]quinoline-2,4-diamine 1-(2-methylpropyl)-N2-propyl-1 H-imidazo [4,5-c]quinoline-2,4-diamine N2-butyl-l-(2-methylpropyl)-1 H-imidazo[4,5-c]quinoline-2,4-diamine N2-butyl-N2-methyl-l-(2-methylpropyl)-1 H-imidazo[4,5-c]quinoline-2,4-diamine N2-methyl-l-(2-methylpropyl)-N2-pentyl-1 H-imidazo [4,5-c]quinoline-2,4-diamine N2-methyl- l -(2-methylpropyl)-N2-prop-2-enyl-1 H-imidazo [4,5-c]quinoline-2,4-diamine 1-(2-methylpropyl)-2-[(phenylmethyl)thio]-1 H-imidazo[4,5-c]quinolin-4-amine 1-(2-methylpropyl)-2-(propylthio)-1 H-imidazo[4,5-c]quinolin-4-amine 2-[[4-amino-l-(2-methylpropyl)-1 H-imidazo[4,5-c]quinolin-2-yl] (methyl)amino]ethano l 2-[[4-amino-l-(2-methylpropyl)-1 H-imidazo[4,5-c]quinolin-2-yl](methyl)amino]ethyl acetate 4-amino-l-(2-methylpropyl)-1,3-dihydro-2H-imidazo [4, 5-c]quinolin-2-one N2-butyl-l-(2-methylpropyl)-N4,N4-bis(phenylmethyl)-1 H-imidazo[4,5-c]quinoline-2,4-diamine N2-butyl-N2-methyl-l-(2-methylpropyl)-N4,N4-bis(phenylmethyl)-1 H-imidazo [4,5-c]quinoline-2,4-diamine N2-methyl-l-(2-methylpropyl)-N4,N4-bis(phenylmethyl)-1 H-imidazo[4,5-c] quinol ine-2,4-diamine N2,N2-dimethyl-l-(2-methylpropyl)-N4,N4-bis(phenylmethyl)-1 H-imidazo [4,5-c]quinoline-2,4-diamine 1-{4-amino-2-[methyl(propyl)amino]-1 H-imidazo[4,5-c]quinolin-l-yl} -2-methylpropan-2-ol 1-[4-amino-2-(propylamino)-1 H-imidazo[4,5-c]quinolin-l-yl]-2-methylpropan-2-ol N4,N4-dibenzyl-l-(2-methoxy-2-methylpropyl)-N2-propyl-1 H-imidazo [4, 5-c]quinoline-2,4-diamine.
= Saponins [chapter 22 of Vaccine Design: The Subunit and Adjuvant Approach (eds.
Powell & Newman) Plenum Press 1995 ISBN 0-306-44867-X], which are a heterologous group of sterol glycosides and triterpenoid glycosides that are found in the bark, leaves, stems, roots and even flowers of a wide range of plant species. Saponin from the bark of the Quillaia saponaria Molina tree have been widely studied as adjuvants.
Saponin can also be commercially obtained from Smilax ornata (sarsaprilla), Gypsophilla paniculata (brides veil), and Saponaria officianalis (soap root). Saponin adjuvant formulations include purified formulations, such as QS21, as well as lipid formulations, such as ISCOMs. QS21 is marketed as StimulonTM. Saponin compositions have been purified using HPLC and RP-HPLC. Specific purified fractions using these techniques have been identified, including QS7, QS17, QS18, QS21, QH-A, QH-B and QH-C. Preferably, the saponin is QS21. A method of production of QS21 is disclosed in US 5,057,540.
Saponin formulations may also comprise a sterol, such as cholesterol (W096/33739).
Combinations of saponins and cholesterols can be used to form unique particles called immunostimulating complexes (ISCOMs) [chapter 23 of Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN 0-306-44867-X)]. ISCOMs typically also include a phospholipid such as phosphatidylethanolamine or phosphatidylcholine. Any known saponin can be used in ISCOMs. Preferably, the ISCOM includes one or more of QuilA, QHA & QHC. ISCOMs are further described in W096/33739, EP-A-0 109942 and W096/1 1 71 1.
Optionally, the ISCOMS may be devoid of additional detergent (W000/07621). A review of the development of saponin based adjuvants can be found in Barr et al. (1998) Advanced Drug Delivery Reviews 32:247-271 and Sjolanderet et al. (1998) Advanced Drug Delivery Reviews 32:321-338.
= Bacterial ADP-ribosylating toxins (e.g. the E.coli heat labile enterotoxin "LT", cholera toxin "CT", or pertussis toxin "PT") and detoxified derivatives thereof, such as the mutant toxins known as LT-K63 and LT-R72 (Sjolanderet et al. (1998) Advanced Drug Delivery Reviews 32:321-338). The use of detoxified ADP-ribosylating toxins as mucosal adjuvants is described in W095/1721 and as parenteral adjuvants in W098/42375.
= Bioadhesives and mucoadhesives, such as esterified hyaluronic acid microspheres (Singh et al] (2001) JCont Release 70:267-276) or chitosan and its derivatives (W099/2796).
= Microparticles (i.e. a particle of -100nm to -150gm in diameter, more preferably -200nm to -30 m in diameter, or -500nm to -10 m in diameter) formed from materials that are biodegradable and non-toxic (e.g. a poly(a-hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone, etc.), with poly(lactide-co-glycolide) being preferred, optionally treated to have a negatively-charged surface (e.g. with SDS) or a positively-charged surface (e.g. with a cationic detergent, such as CTAB).
= Liposomes (Chapters 13 & 14 of Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN 0-306-44867-X)). Examples of liposome formulations suitable for use as adjuvants are described in US
5,916,588, 6,090,406 and EP-A-0626169.
= Polyoxyethylene ethers and polyoxyethylene esters (W099/52549). Such formulations further include polyoxyethylene sorbitan ester surfactants in combination with an octoxynol (WO01/21207) as well as polyoxyethylene alkyl ethers or ester surfactants in combination with at least one additional non-ionic surfactant such as an octoxynol (WO01/2115). Preferred polyoxyethylene ethers are selected from the following group:
polyoxyethylene-9-lauryl ether (laureth 9), polyoxyethylene-9-steoryl ether, polyoxytheylene-8-steoryl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether.
= Muramyl peptides, such as N-acetylmuramyl-L-threonyl-D-isoglutamine ("thr-MDP"), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylglucsaminyl-N-acetylmuramyl-L-Al-D-isoglu-L-Ala-dipalmitoxy propylamide ("DTP-DPP", or "TheramideTM), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine ("MTP-PE").
= An outer membrane protein proteosome preparation prepared from a first Gram-negative bacterium in combination with a liposaccharide (LPS) preparation derived from a second Gram-negative bacterium, wherein the outer membrane protein proteosome and LPS
preparations form a stable non-covalent adjuvant complex. Such complexes include "IVX- 908", a complex comprised of Neisseria meningitidis outer membrane and LPS.
= Methyl inosine 5'-monophosphate ("MIMP") (Signorelli & Hadden (2003) Int Immunopharmacol 3(8):1177-86).
= A polyhydroxlated pyrrolizidine compound (W02004/064715), such as one having formula:
HO ~ ~Jw Ra....._.~ OH
cHZcaH
where R is selected from the group comprising hydrogen, straight or branched, unsubstituted or substituted, saturated or unsaturated acyl, alkyl (e.g.
cycloalkyl), alkenyl, alkynyl and aryl groups, or a pharmaceutically acceptable salt or derivative thereof.
Examples include, but are not limited to: casuarine, casuarine-6-a-D-glucopyranose, 3-epi-casuarine, 7-epi-casuarine, 3,7-diepi-casuarine, etc.
= A gamma inulin (Cooper (1995) Pharm Biotechnol 6:559-80) or derivative thereof, such as algammulin.
= A compound of formula I, II or III, or a salt thereof:
xt~~,--Y~ /X~~"Y~
( HE)a ~CHZIo 0-P-OH X.~ -0 O=P-O' 1! Z2 A: \N
WO ~-0 mm R= ~ ~ b=
1 Ctl~jq tw. a X ~
NT' ~ Fi2)C ~~ 2)a` F+~' p2 fif ~ Rz W\ rowy~. t 5~ ~
R2 Ff ~~ [ a3c \~~~ a ~~(~Hz1a (GW2}e' ir da' ~
~, 4 pa G2 !_ C'`pa ~ pa He y as defined in W003/011223, such as `ER 803058', `ER 803732', `ER 804053', ER
804058', `ER 804059', `ER 804442', `ER 804680', `ER .804764', ER 803022 or `ER
804057' e.g.:
o" 'Cõ[1zs a =
p- I1-C)~(T
/_j () Na [Iti ,,[IJ,3 ~ (:
HN
O-P-QO' v `G,H~s [23 () Va [iN Y-Y C;i.F
( ) 0 N
A
J _O(O 0 0 O 1~~ ER-803022:
p, A
= Derivatives of lipid A from Escherichia coli such as OM-174 (described in Meraldi et al.
(2003) Vaccine 21:2485-2491, Pajak et al. (2003) Vaccine 21:836-84.
= A formulation of a cationic lipid and a (usually neutral) co-lipid, such as aminopropyl-dimethyl-myri stoleyloxy-propanaminiumbromide-diphytanoylphosphatidyl-ethanolamine ("VaxfectinTM") or aminopropyl-dimethyl-bis-dodecyloxy-propanaminiumbromide-dioleoylphosphatidyl-ethanolamine ("GAP-DLRIE:DOPE"). Formulations containing ( )-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradeceneyloxy)-1-propanaminium salts are preferred (US patent 6586409) = Compounds containing lipids linked to a phosphate-containing acyclic backbone, such as the TLR4 antagonist E5564 (Wong et al. (2003) J Clin Pharmacol 43(7):735-42, US2005/0215517):
0 0 0 ,oPO(orn, C1Ia(> U U
(CIIiIgCII.j - If These and other adjuvant-active substances are discussed in more detail in references Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN
0-306-44867-X) and Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan.
Compositions may include two or more of said adjuvants.
Antigens and adjuvants in a composition will typically be in admixture.
Oil-in-water emulsion adjuvants Oil-in-water emulsions are particularly useful as adjuvants. Various such emulsions are known, and they typically include at least one oil and at least one surfactant, with the oil(s) and surfactant(s) being biodegradable (metabolizable) and biocompatible. The oil droplets in the emulsion are generally less than 5 m in diameter, and may even have a sub-micron diameter, with these small sizes being achieved with a microfluidizer to provide stable emulsions. Droplets with a size less than 220nm are preferred as they can be subjected to filter sterilization.
The invention can be used with oils such as those from an animal (such as fish) or vegetable source. Sources for vegetable oils include nuts, seeds and grains. Peanut oil, soybean oil, coconut oil, and olive oil, the most commonly available, exemplify the nut oils.
Jojoba oil can be used e.g.
obtained from the jojoba bean. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil and the like. In the grain group, corn oil is the most readily available, but the oil of other cereal grains such as wheat, oats, rye, rice, teff, triticale and the like may also be used. 6-10 carbon fatty acid esters of glycerol and 1,2-propanediol, while not occurring naturally in seed oils, may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils. Fats and oils from mammalian milk are metabolizable and may therefore be used in the practice of this invention. The procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art. Most fish contain metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein. A number of branched chain oils are synthesized biochemically in 5-carbon isoprene units and are generally referred to as terpenoids.
Shark liver oil contains a branched, unsaturated terpenoids known as squalene, 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene, which is particularly preferred herein. Squalane, the saturated analog to squalene, is also a preferred oil. Fish oils, including squalene and squalane, are readily available from commercial sources or may be obtained by methods known in the art. Other preferred oils are the tocopherols (see below). Mixtures of oils can be used.
Surfactants can be classified by their `HLB' (hydrophile/lipophile balance).
Preferred surfactants of the invention have a HLB of at least 10, preferably at least 15, and more preferably at least 16.
The invention can be used with surfactants including, but not limited to: the polyoxyethylene sorbitan esters surfactants (commonly referred to as the Tweens), especially polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), and/or butylene oxide (BO), sold under the DOWFAXTM tradename, such as linear EO/PO block copolymers;
octoxynols, which can vary in the number of repeating ethoxy (oxy-1,2-ethanediyl) groups, with octoxynol-9 (Triton X-100, or t-octylphenoxypolyethoxyethanol) being of particular interest;
(octylphenoxy)polyethoxyethanol (IGEPAL CA-630/NP-40); phospholipids such as phosphatidylcholine (lecithin); polyoxyethylene fatty ethers derived from lauryl, cetyl, stearyl and oleyl alcohols (known as Brij surfactants), such as triethyleneglycol monolauryl ether (Brij 30); and sorbitan esters (commonly known as the SPANs), such as sorbitan trioleate (Span 85) and sorbitan monolaurate. Preferred surfactants for including in the emulsion are Tween 80 (polyoxyethylene sorbitan monooleate), Span 85 (sorbitan trioleate), lecithin and Triton X-100.
Mixtures of surfactants can be used e.g. Tween 80/Span 85 mixtures, or Tween80/Triton-X100 mixtures. A combination of a polyoxyethylene sorbitan ester such as polyoxyethylene sorbitan monooleate (Tween 80) and an octoxynol such as t-octylphenoxypolyethoxyethanol (Triton X-100) is also suitable. Another useful combination comprises laureth 9 plus a polyoxyethylene sorbitan ester and/or an octoxynol.
Preferred amounts of surfactants (% by weight) are: polyoxyethylene sorbitan esters (such as Tween 80) 0.01 to 1%, in particular about 0.1 %; octyl- or nonylphenoxy polyoxyethanols (such as Triton X-100, or other detergents in the Triton series) 0.001 to 0.1 %, in particular 0.005 to 0.02%; polyoxyethylene ethers (such as laureth 9) 0.1 to 20 %, preferably 0.1 to 10 % and in particular 0.1 to 1% or about 0.5%.
Specific oil-in-water emulsion adjuvants useful with the invention include, but are not limited to:
= A submicron emulsion of squalene, Tween 80, and Span 85. The composition of the emulsion by volume can be about 5% squalene, about 0.5% polysorbate 80 and about 0.5%
Span 85. In weight terms, these ratios become 4.3% squalene, 0.5% polysorbate 80 and 0.48% Span 85. This adjuvant is known as `MF59' (W090/14837, Podda & Del Giudice (2003) Expert Rev Vaccines 2:197-203, and Podda (2001) Vaccine 19: 2673-2680), as described in more detail in Chapter 10 of Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 of Vaccine Adjuvants:
Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series).
The MF59 emulsion advantageously includes citrate ions e.g. 10mM sodium citrate buffer.
= An emulsion of squalene, a tocopherol, and Tween 80. The emulsion may include phosphate buffered saline. It may also include Span 85 (e.g. at 1%) and/or lecithin. These emulsions may have from 2 to 10% squalene, from 2 to 10% tocopherol and from 0.3 to 3% Tween 80, and the weight ratio of squalene:tocopherol is preferably <1 as this provides a more stable emulsion. One such emulsion can be made by dissolving Tween 80 in PBS to give a 2% solution, then mixing 90m1 of this solution with a mixture of (5g of DL-a-tocopherol and 5ml squalene), then microfluidising the mixture. The resulting emulsion may have submicron oil droplets e.g. with an average diameter of between 100 and 250nm, preferably about 180nm.
= An emulsion of squalene, a tocopherol, and a Triton detergent (e.g. Triton X-100). The emulsion may also include a 3d-MPL (see below). The emulsion may contain a phosphate buffer.
= An emulsion comprising a polysorbate (e.g. polysorbate 80), a Triton detergent (e.g. Triton X-100) and a tocopherol (e.g. an a-tocopherol succinate). The emulsion may include these three components at a mass ratio of about 75:11:10 (e.g. 750 g/ml polysorbate 80, ll0 g/ml Triton X-100 and 100 g/ml a-tocopherol succinate), and these concentrations should include any contribution of these components from antigens. The emulsion may also include squalene. The emulsion may also include a 3d-MPL (see below). The aqueous phase may contain a phosphate buffer.
= An emulsion of squalane, polysorbate 80 and poloxamer 401 ("PluronicTM
L121"). The emulsion can be formulated in phosphate buffered saline, pH 7.4. This emulsion is a useful delivery vehicle for muramyl dipeptides, and has been used with threonyl-MDP
in the "SAF-1" adjuvant (Allison & Byars (1992) Res Immunol 143:519-25), (0.05-1% Thr-MDP, 5% squalane, 2.5% Pluronic L121 and 0.2% polysorbate 80). It can also be used without the Thr-MDP, as in the "AF" adjuvant (Hariharan et al. (1995) Cancer Res 55:3486-9) (5%
squalane, 1.25% Pluronic L121 and 0.2% polysorbate 80). Microfluidization is preferred.
= An emulsion having from 0.5-50% of an oil, 0.1-10% of a phospholipid, and 0.05-5% of a non-ionic surfactant. As described in W095/11700, preferred phospholipid components are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, sphingomyelin and cardiolipin.
Submicron droplet sizes are advantageous.
= A submicron oil-in-water emulsion of a non-metabolizable oil (such as light mineral oil) and at least one surfactant (such as lecithin, Tween 80 or Span 80). Additives may be included, such as QuilA saponin, cholesterol, a saponin-lipophile conjugate (such as GPI-0100, described in US patent 6,080,725, produced by addition of aliphatic amine to desacylsaponin via the carboxyl group of glucuronic acid), dimethyidioctadecylammonium bromide and/or N,N-dioctadecyl-N,N-bis (2-hydroxyethyl)propanediamine.
= An emulsion in which a saponin (e.g. QuilA or QS21) and a sterol (e.g. a cholesterol) are associated as helical micelles (W02005/09718).
= An emulsion comprising a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol, and a non-ionic hydrophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene-polyoxypropylene block copolymer) (W02006/113373).
= An emulsion comprising a mineral oil, a non-ionic hydrophilic ethoxylated fatty alcohol, and a non-ionic lipophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene-polyoxypropylene block copolymer) (W02006/11337).
The emulsions may be mixed with antigen extemporaneously, at the time of delivery. Thus the adjuvant and antigen may be kept separately in a packaged or distributed vaccine, ready for final formulation at the time of use. The antigen will generally be in an aqueous form, such that the vaccine is finally prepared by mixing two liquids. The volume ratio of the two liquids for mixing can vary (e.g. between 5:1 and 1:5) but is generally about 1:1.
Aluminum salt adjuvants The adjuvants known as aluminum hydroxide and aluminum phosphate may be used.
These names are conventional, but are used for convenience only, as neither is a precise description of the actual chemical compound which is present (e.g. see chapter 9 of Vaccine Design: The Subunit andAdjuvant Approach (eds. Powell & Newman) Plenum Press 1995). The invention can use any of the "hydroxide" or "phosphate" adjuvants that are in general use as adjuvants.
The adjuvants known as "aluminium hydroxide" are typically aluminium oxyhydroxide salts, which are usually at least partially crystalline. Aluminium oxyhydroxide, which can be represented by the formula AlO(OH), can be distinguished from other aluminium compounds, such as aluminium hydroxide Al(OH)3, by infrared (IR) spectroscopy, in particular by the presence of an adsorption band at 1070cm I and a strong shoulder at 3090-3100cm 1[chapter 9 of Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995]. The degree of crystallinity of an aluminium hydroxide adjuvant is reflected by the width of the diffraction band at half height (WHH), with poorly-crystalline particles showing greater line broadening due to smaller crystallite sizes. The surface area increases as WHH increases, and adjuvants with higher WHH values have been seen to have greater capacity for antigen adsorption. A fibrous morphology (e.g. as seen in transmission electron micrographs) is typical for aluminium hydroxide adjuvants. The pI of aluminium hydroxide adjuvants is typically about 11 i.e. the adjuvant itself has a positive surface charge at physiological pH.
Adsorptive capacities of between 1.8-2.6 mg protein per mg Al+' at pH 7.4 have been reported for aluminium hydroxide adjuvants.
The adjuvants known as "aluminium phosphate" are typically aluminium hydroxyphosphates, often also containing a small amount of sulfate (i.e. aluminium hydroxyphosphate sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt.
Hydroxyphosphates generally have a P04/Al molar ratio between 0.3 and 1.2.
Hydroxyphosphates can be distinguished from strict A1PO4 by the presence of hydroxyl groups.
For example, an IR spectrum band at 3164cm'1 (e.g. when heated to 200 C) indicates the presence of structural hydroxyls [ch.9 of Vaccine Design: The Subunit and Adjuvant Approach (eds.
Powell & Newman) Plenum Press 1995.
The PO4/A13+ molar ratio of an aluminium phosphate adjuvant will generally be between 0.3 and 1.2, preferably between 0.8 and 1.2, and more preferably 0.95+0.1. The aluminium phosphate will generally be amorphous, particularly for hydroxyphosphate salts. A
typical adjuvant is amorphous aluminium hydroxyphosphate with PO4/Al molar ratio between 0.84 and 0.92, included at 0.6mg A13+/ml. The aluminium phosphate will generally be particulate (e.g. plate-like morphology as seen in transmission electron micrographs). Typical diameters of the particles are in the range 0.5-20 m (e.g. about 5-l04m) after any antigen adsorption.
Adsorptive capacities of between 0.7-1.5 mg protein per mg Al at pH 7.4 have been reported for aluminium phosphate adjuvants.
The point of zero charge (PZC) of aluminium phosphate is inversely related to the degree of substitution of phosphate for hydroxyl, and this degree of substitution can vary depending on reaction conditions and concentration of reactants used for preparing the salt by precipitation.
PZC is also altered by changing the concentration of free phosphate ions in solution (more phosphate = more acidic PZC) or by adding a buffer such as a histidine buffer (makes PZC more basic). Aluminium phosphates used according to the invention will generally have a PZC of between 4.0 and 7.0, more preferably between 5.0 and 6.5 e.g. about 5.7.
Suspensions of aluminium salts used to prepare compositions of the invention may contain a buffer (e.g. a phosphate or a histidine or a Tris buffer), but this is not always necessary. The suspensions are preferably sterile and pyrogen-free. A suspension may include free aqueous phosphate ions e.g. present at a concentration between 1.0 and 20 mM, preferably between 5 and 15 mM, and more preferably about 10 mM. The suspensions may also comprise sodium chloride.
The invention can use a mixture of both an aluminium hydroxide and an aluminium phosphate. In this case there may be more aluminium phosphate than hydroxide e.g. a weight ratio of at least 2:1 e.g. >5:1, >6:1, >7:1, >8:1, >9:1, etc.
The concentration of AI~ in a composition for administration to a patient is preferably less than 10mg/ml e.g. <5 mg/ml, <4 mg/ml, <3 mg/mi, <2 mg/ml, <1 mg/ml, etc. A
preferred range is between 0.3 and 1 mg/ml.
Kits of the invention Where a composition includes two components for delivery to a patient, such as an Env/Tat mixture and an adjuvant, these may be mixed during manufacture, or they may be mixed extemporaneously, at the time of delivery. Thus the invention provides kits including the various components ready for mixing. The kit allows the adjuvant and the complex to be kept separately until the time of use. This arrangement is particularly useful when using an oil-in-water emulsion adjuvant.
The components are physically separate from each other within the kit, and this separation can be achieved in various ways. For instance, the two components may be in two separate containers, such as vials. The contents of the two vials can then be mixed e.g. by removing the contents of one vial and adding them to the other vial, or by separately removing the contents of both vials and mixing them in a third container.
In a preferred arrangement, one of the kit components is in a syringe and the other is in a container such as a vial. The syringe can be used (e.g. with a needle) to insert its contents into the second container for mixing, and the mixture can then be withdrawn into the syringe. The mixed contents of the syringe can then be administered to a patient, typically through a new sterile needle. Packing one component in a syringe eliminates the need for using a separate syringe for patient administration.
In another preferred arrangement, the two kit components are held together but separately in the same syringe e.g. a dual-chamber syringe, such as those disclosed in W02005/089837, W000/07647, W099/17820, EP-A-0520618, W098/01174, US patents 6,692,468, 5,971,953, 4,060,082. When the syringe is actuated (e.g. during administration to a patient) then the contents of the two chambers are mixed. This arrangement avoids the need for a separate mixing step at the time of use.
The kit components will generally be in aqueous form. In some arrangements, a component (typically the antigen component rather than the adjuvant component) is in dry form (e.g. in a lyophilised form), with the other component being in aqueous form. The two components can be mixed in order to reactivate the dry component and give an aqueous composition for administration to a patient. A lyophilised component will typically be located within a vial rather than a syringe. Dried components may include stabilizers such as lactose, sucrose or mannitol, as well as mixtures thereof e.g. lactose/sucrose mixtures, sucrose/mannitol mixtures, etc. One possible arrangement uses an aqueous adjuvant component in a pre-filled syringe and a lyophilised antigen component in a vial.
Methods of treatment, and administration of vaccines The invention provides a method of raising an immune response in a patient, comprising the step of administering a composition of the invention to the patient. The compositions of the invention are particularly suitable for administration to human patients, but can also be administered to other mammals for investigational purposes, for raising antisera, etc.
The invention also provides a kit or composition of the invention for use as a medicament.
The invention also provides the use of an Env/Tat mixture of the invention in the manufacture of a medicament for raising an immune response in a patient.
Compositions of the invention can be administered in various ways. The most preferred immunization route is by injection (e.g. intramuscular, subcutaneous, intravenous), but other available routes include, but are not limited to, intranasal, oral, intradermal, transcutaneous, transdermal, pulmonary, etc.
Treatment can be by a single dose schedule or a multiple dose schedule.
Multiple doses may be used in a primary immunization schedule and/or in a booster immunization schedule. In a multiple dose schedule the various doses may be given by the same or different routes e.g. a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, etc.
Administration of more than one dose (typically two doses) is typical. Multiple doses will typically be administered at least 1 week apart (e.g. about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, etc.).
General The term "comprising" encompasses "including" as well as "consisting" e.g. a composition "comprising" X may consist exclusively of X or may include something additional e.g. X + Y.
The word "substantially" does not exclude "completely" e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.
The term "about" in relation to a numerical value x means, for example, x+10 /a.
Unless specifically stated, a process comprising a step of mixing two or more components does not require any specific order of mixing. Thus components can be mixed in any order. Where there are three components then two components can be combined with each other, and then the combination may be combined with the third component, etc.
Where animal (and particularly bovine) materials are used in the culture of cells, they should be obtained from sources that are free from transmissible spongiform encaphalopathies (TSEs), and in particular free from bovine spongiform encephalopathy (BSE). Overall, it is preferred to culture cells in the total absence of animal-derived materials.
Where a protein or a complex "binds specifically" to a particular target (e.g.
to CD4 or to a monoclonal antibody), it will typically bind to that.target with at least 10-fold greater affinity than to a control protein e.g. than to CD3 or than to an anti-Rev antibody.
Specific binding and non-specific binding can be distinguished by standard techniques e.g. by checking the effect of control proteins on the interaction, by checking dose-responsiveness, etc.
The term "polypeptide" refers to amino acid polymers of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acid components. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. Polypeptides can occur as single chains or associated chains. Polypeptides of the invention can be naturally or non-naturally glycosylated (i.e. the polypeptide has a glycosylation pattern that differs from the glycosylation pattern found in the corresponding naturally occurring polypeptide).
Env and Tat polypeptides for use with the invention can be prepared in many ways e.g. by chemical synthesis (in whole or in part), by digesting longer polypeptides using proteases, by translation from RNA, by purification from cell culture (e.g. from recombinant expression), from the organism itself (e.g. after bacterial culture, or direct from patients), etc. A preferred method for production of peptides <40 amino acids long involves in vitro chemical synthesis (Bodanszky (1993) Principles of Peptide Synthesis (ISBN: 0387564314), Fields et al.
(1997) Meth Enzymol 289: Solid-Phase Peptide Synthesis. ISBN: 0121821900). Solid-phase peptide synthesis is particularly preferred, such as methods based on tBoc or Fmoc (Chan & White (2000) Fmoc Solid Phase Peptide Synthesis. ISBN: 0199637245) chemistry. Enzymatic synthesis (Kullmann (1987) Enzymatic Peptide Synthesis. ISBN: 0849368413) may also be used in part or in full. As an alternative to chemical synthesis, biological synthesis may be used e.g:
the polypeptides may be produced by translation. This may be carried out in vitro or in vivo.
Biological methods are in general restricted to the production of polypeptides based on L-amino acids, but manipulation of translation machinery (e.g. of aminoacyl tRNA molecules) can be used to allow the introduction of D-amino acids (or of other non natural amino acids, such as iodotyrosine or methylphenylalanine, azidohomoalanine, etc.) (Ibba (1996) Biotechnol Genet Eng Rev 13:197-216). Where D-amino acids are included, however, it is preferred to use chemical synthesis.
Polypeptides of the invention may have covalent modifications at the C-terminus and/or N-terminus.
Env and Tat polypeptides can take various forms (e.g. native, fusions, glycosylated, non-glycosylated, lipidated, non-lipidated, phosphorylated, non-phosphorylated, myristoylated, non-myristoylated, monomeric, multimeric, particulate, denatured, etc.). For Env, oligomeric glycosylated polypeptides are preferred.
Env and Tat polypeptides are preferably provided in purified or substantially purified form i.e. substantially free from other polypeptides (e.g. free from naturally-occurring polypeptides), particularly from other HIV or host cell polypeptides, and are generally at least about 50% pure (by weight), and usually at least about 90% pure i.e. less than about 50%, and more preferably less than about 10% (e.g. 5% or less) of a composition is made up of other expressed polypeptides.
EXAMPLES
The full-length SF162 strain Env sequence has the following amino acid sequence (SEQ ID NO:
38):
MRVKGIRKNYQHLWRGGTLLLGMLMICSAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWAT
HACVPTDPNPQEIVLENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTK
SSNWKEMDRGEIKNCSFKVTTSIRNKMQKEYALFYKLDWPIDNDNTSYKLINCNTSVITQACPKVSFEP
IPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEGWIRSENFTDNAK
TIIVQLKESVEINCTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHCNISGEKWNNTLKQIVTKLQAQF
GNKTIVFKQSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEV
GKAMYAPPIRGQIRCSSNITGLLLTRDGGKEISNTTEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPT
KAKRRVVQREKRAVTLGAMFLGFLGAAGSTMGARSLTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT
VWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLDQIWNNMTWMEWEREIDNYT
NLIYTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYIKIFIMIVGGLVGLRIVFTVLSIVNRVR
QGYSPLSFQTRFPAPRGPDRPEGIEEEGGERDRDRSSPLVHGLLALIWDDLRSLCLFSYHRLRDLILIAA
RIVELLGRRGWEALKYWGNLLQYWIQELKNSAVSLFDAIAIAVAEGTDRIIEVAQRIGRAFLHIPRRIRQ
GFERALL
For expression purposes, the leader (amino acids 1-27; SEQ ID NO: 47) can be replaced by a leader sequence from tpa (SEQ ID NO: 48, MDAMKRGLCCVLLLCGAVFVSP).
The gp160 sequence can be modified to a gp140 form (SEQ ID NO: 39):
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWAT
HACVPTDPNPQEIVLENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTK
SSNWKEMDRGEIKNCSFKVTTSIRNKMQKEYALFYKLDVVPIDNDNTSYKLINCNTSVITQACPKVSFEP
IPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPWSTQLLLNGSLAEEGVVIRSENFTDNAK
TIIVQLKESVEINCTRPNNNTRKSITIGPGRAFYATGDIIGDIRQAHCNISGEKWNNTLKQIVTKLQAQF
GNKTIVFKQSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEV
GKAMYAPPIRGQIRCSSNITGLLLTRDGGKEISNTTEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPT
KAKRRVVQREKRAVTLGAMFLGFLGAAGSTMGARSLTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT
VWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLDQIWNNMTWMEWEREIDNYT
NLIYTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYIT"'T''T""TV^^T "^T DTT' '"VT
nrWrnsro GFEP.A.Lb It can be further modified to include five amino acid mutations at the cleavage site, to produce oligomeric gp140. This sequence (SEQ ID NO: 43) is known as `gp140mut7':
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVTTSIRNKM
QKEYALFYKLDWPIDNDNTSYKLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPC
TNVSTVQCTHGIRPWSTQLLLNGSLAEEGVVIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRKSITI
GPGRAFYATGDIIGDIRQAHCNISGEKWNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGGE
FFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTRD
GGKEISNTTEIFRPGGGDMRDNWRSELYKYKWKIEPLGVAPTKAISSVVQSEKSAVTLGAMFLGFLGAA
GSTMGARSLTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIW
GCSGKLICTTAVPWNASWSNKSLDQIWNNMTWMEWEREIDNYTNLIYTLIEESQNQQEKNEQELLELDKW
ASLWNWFDISKWLWYI
The V3 loop of SEQ ID NO: 39 can be replaced with SEQ ID NO: 23, in which a central 22mer has been deleted and a flexible sequence inserted (SEQ ID NO: 40; 627mer):
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVTTSIRNKM
QKEYALFYKLDVVPIDNDNTSYKLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPC
TNVSTVQCTHGIRPVVSTQLLLNGSLAEEGVVIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRGAGQA
HCNISGEKWNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNTIG
PNNTNGTITLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGKEISNTTEIFRPGGGDM
RDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVTLGAMFLGFLGAAGSTMGARSLTLTVQARQLL
SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWS
NKSLDQIWNNMTWMEWEREIDNYTNLIYTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYI
A construct encoding SEQ ID NO: 40 (`gp140dV3-22') can be expressed in 293T
cells and purified. Proteins are initially purified using GNA lectin, and are then re-purified using a ceramic hydroxyapatite column (CHAP). Small-scale and large-scale purifications are performed.
A modified form of SEQ ID NO: 40 (`gp1400V2dv3-22') in which the V2 loop is replaced by SEQ ID NO: 42 (CSFKVGAGKLINC) is prepared in the same way. Its sequence is SEQ
ID NO:
41:
SAVEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKN
NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVGAGKLINC
NTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLA
EEGVVIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRGAGQAHCNISGEKWNNTLKQIVTKLQAQFGNK
TIVFKQSSGGDPEIVMHSFNCGGEFFYCNSTQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEVGKA
MYAPPIRGQIRCSSNITGLLLTRDGGKEISNTTEIFRPGGGDMRDNWRSELYKYKWKIEPLGVAPTKAI
SSWQSEKSAVTLGAMFLGFLGAAGSTMGARSLTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG
IKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLDQIWNNMTWMEWEREIDNYTNLI
YTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYI
This protein is purified in the same manner as described above.
Equivalent Env-derivatives re also made for strain TV 1.
Example 1 After confirming purity, oligomerization and CD4-binding activity for both gp140dV3-22 and gp1400V2dv3-22 proteins using HPLC, are assayed for both CD4- and tat-binding activity using the BIACORETM system. Results using immobilized CD4, immobilized tat or immobilized tat-cys (a mutant of tat that still binds to env (Ensoli et al. (2005) Microbes Infect 7:1392-9) are summarized below:
Parameter Off rate (s-1 x 10=5) Half life (hours) Ligand CD4 Tat Tat-cys CD4 Tat Tat-cys 9p140sF162 5.30 + 0.76% 3.88 + 3.13% 0.13 + 96.4% 3.64 4.96 150.1 gp140AV2sF162 7.60 + 0.67% 5.50 + 1.37% 4.02 + 1.80% 2.53 3.50 4.79 gp140dV3-22sF162 5.48 + 0.63% 6.24 + 2.03% 4.61 + 1.82% 3.51 3.08 4.17 gp140Tv, 6.48 + 0.82% 10.0 + 1.22% 7.38 + 1.69% 2.97 1.92 2.61 gp140dV3-22Tvj 3.47 + 0.67% 6.98 + 2.82% 3.84 + 4.35% 5.55 2.76 5.01 Thus all the trimeric variants of Env bound to both CD4 and the tat polypeptide. Monomeric gp120 binds to CD4 as expected, but binding to tat is not observed.
BIACORETM can also be used to test binding of the SF162-derived proteins to (i) CD4, (ii) neutralizing antibody b12, which binds to gp120's CD4-binding site (Zwick et al. (2003) J Virol 77:5863-76), and (iii) non-neutralizing antibody 4.8d, which binds to a conformational epitope on gp120. Dissociation constants (M-1 x 10-10) and Rmax values (using 4.8d & CD4) are as follows:
CD4 Kd b1 Kd 4.8d Kd x Up-reg 4.8d* Rmax gp120 770 970 40 1.7 416 gp140AV2 160 34 3.8 2.6 281 gp140dV3-22 180 200 75 1.4 660 gp140 AV2 dV3-22 650 1000 79 1.8 602 4.8d is a CD4 inducible epitope antibody. It recognizes env alone at a low level, once env has undergone its conformational change due to CD4 binding. The `x 4.8d up-reg' figure indicates the BlAcore signal observed for env mixed with CD4 as a function of the signal observed for env without CD4, on the 4.8d antibody.
Thus the modifications that are introduced into Env do not substantially alter its CD4-binding properties. Moreover, monoclonal antibody binding remained at reasonable levels for all variants.
Example 2 Tat-binding for the SF162-derived proteins (with or without CD4) is also tested by a Far-Western assay. Results are shown in Figure 1. Thus both in a kinetic experimental environment (i.e.
BlAcore) and under conditions of equilibrium (i.e. Far Western analysis), trimeric envelope and its variants are able to bind to tat. Monomeric gpl20 does not generally show any evidence of binding to the tat polyprotein in either experiment, unless the V2 loop is deleted as in gpI20AV2.
Overall, the data show no significant difference between the magnitude of binding of Tat to the AV2 and dV3-22 forms of Env. However, the off rate for the dV3-22 trimeric Env was faster (i.e.
shorter half-life) when compared to the AV2 trimeric protein.
Example 3 Alternative V3 loop substitutions may be designed. Alignment of SEQ ID NO: 44 with SEQ ID
NOS: 25 to 29 suggests that the middle of the V3 loop is more variable than the outer flanking regions. In mutant loop SEQ ID NO: 15, the middle portion is deleted and the flanking regions remain intact. In SEQ ID NOs: 16 and 17 the N- or C- terminus flanking region is deleted. In SEQ ID NOs: 18 to 21 contact sites for monoclonal antibody 447D are removed.
In SEQ ID NO:
22, the loop is replaced with a flexible Gly-Ala-Gly sequence. In SEQ ID NO:
23 this flexible sequence is also inserted into the SEQ ID NO: 21 loop. In SEQ ID NO: 24, a different V3 loop is substituted into SF162.
SF162dV3-20 CTRPNNN------------------GAGDIRQAHC (SEQ ID NO: 15) SF162dV3-9 CT--------- ITIGPGRAFYATGDIIGDIRQAHC (SEQ ID NO: 16) SF162dV3-6 CTRPNNNTRKSITIGPGRAFYAT--------QAHC (SEQ ID NO: 17) SF162dV3-10 CTRPNNNTR----------FYATGDIIGDIRQAHC (SEQ ID NO: 18) SF162dV3-12 CTRPNNNTR--------------GDIIGDIRQAHC (SEQ ID NO: 19) SF162dv3-17 CT----------------- FYATGDIIGDIRQAHC (SEQ ID NO: 20) SF162dV3-22 CTRPNNNTR----------------------QAHC (SEQ ID NO: 21) SF162dV3-28sub CTRPNNNTR------------------- GAGQAHC (SEQ ID NO: 23) SF162dV3-28 CT----------------------------GAGHC (SEQ ID NO: 22) SF162V3sub CTRPNNNTRKSITIGPGRAFYATGDIIGNMRQAHC (SEQ ID NO: 24) The deleted peptide sequences (SEQ ID NOS: 30 to 37) are synthesized and evaluated for their ability to bind to Tat.
Example 4 Biologically active Tat binds the HIV Env through high affinity interactions with the V3 loop.
This requires exposure and/or conformational transitions of the V3 loop that are induced upon Env oligomerization or V2 loop deletion. Shortening of the Vl-V2 loop is a key feature of virus isolates emerging during early infection, which, however, are much more sensitive to neutralization. These data point to a key role of Tat in shielding these isolates from the mounting humoral immune response. Further, binding of the V3 loop of Env to Tat resembles the interaction of Env with the CCR5 co-receptor, a process that is also potentially enhanced by V1-V2 deletion or shortening. This indicates that the Tat-Env complex may impact virus entry and transmission to T cells, in particular the low CCR5 expressing CD4+ T cells that appear to be early targets of infection in mucosal tissues.
It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.
Claims (20)
1. A mixture of (i) a HIV Tat polypeptide and (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop.
2. The mixture of claim 1, wherein polypeptides (i) and (ii) form a complex.
3. The mixture of claim 2, wherein polypeptides (i) and (ii) are covalently linked to each other.
4. A process for preparing the mixture of claim 1, comprising a step of mixing (i) a HIV Tat polypeptide with (ii) a HIV Env polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop.
5. A process comprising a step of: combining a HIV Env polypeptide with a HIV
Tat polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop.
Tat polypeptide, wherein the Env polypeptide has one or more mutations in its V3 loop.
6. The process of claim 5, comprising a further step of: determining if the Env and Tat polypeptides have formed a complex.
7. A HIV Env polypeptide having a mutant V3 loop sequence, wherein the mutant sequence is selected from the group consisting of SEQ IDs 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24.
8. The mixture, process or polypeptide of any preceding claim, wherein the Env polypeptide includes one or more mutation(s) outside the V3 loop.
9. The mixture, process or polypeptide of any preceding claim, wherein the Env polypeptide lacks the wild-type transmembrane domain and cytoplasmic tail.
10. The mixture, process or polypeptide of any preceding claim, wherein the Env polypeptide includes one or more deletion(s) within the V2 loop.
11. The mixture, process or polypeptide of any preceding claim, wherein the Env polypeptide has a V3 loop with an amino acid sequence selected from group consisting of SEQ ID
NOs: 15 to 24.
NOs: 15 to 24.
12. The mixture, process or polypeptide of any preceding claim, wherein the Env polypeptide has a V3 loop with amino acid sequence SEQ ID NO: 29.
13. A mixture of (i) a HIV Tat polypeptide and (ii) a polypeptide comprising a fragment of a V3 loop of a HIV Env polypeptide, wherein the polypeptide of (ii) is no longer than 100 amino acids and includes at least 5 consecutive amino acids from a HIV Env polypeptide V3 loop.
14. The mixture of claim 13, wherein the polypeptide of (ii) is <=30 amino acids long.
15. The mixture of claim 13 or claim 14, wherein the polypeptide of (ii) is cyclic.
16. The mixture of any one of claims 13 to 15, wherein the fragment of (ii) has an amino acid sequence selected from group consisting of SEQ ID NOs: 30 to 37.
17. The mixture, process or polypeptide of any preceding claim, wherein the Tat polypeptide has amino acid sequence SEQ ID NO: 12.
18. A pharmaceutical composition comprising the mixture of any one of claims 1-3 or 8-17.
19. The pharmaceutical composition of claim 18, including a vaccine adjuvant.
20. A method of raising an immune response in a patient, comprising the step of administering a composition of claim 18 or claim 19 to the patient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96604807P | 2007-08-24 | 2007-08-24 | |
US60/966,048 | 2007-08-24 | ||
PCT/US2008/074179 WO2009029569A1 (en) | 2007-08-24 | 2008-08-25 | Hiv env proteins with modifications in the v3 loop |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2697370A1 true CA2697370A1 (en) | 2009-03-05 |
Family
ID=39884817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2697370A Abandoned CA2697370A1 (en) | 2007-08-24 | 2008-08-25 | Hiv env proteins with modifications in the v3 loop |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2192918A1 (en) |
JP (1) | JP2010536885A (en) |
BR (1) | BRPI0815743A2 (en) |
CA (1) | CA2697370A1 (en) |
WO (1) | WO2009029569A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013279456A1 (en) * | 2012-06-18 | 2014-12-18 | Glaxosmithkline Biologicals Sa | Stabilized gp120 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019785A1 (en) * | 1992-04-01 | 1993-10-14 | Merck & Co., Inc. | Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection |
US6710173B1 (en) * | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
WO2001024810A1 (en) * | 1999-10-05 | 2001-04-12 | Epimmune Inc. | Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions |
CA2357906A1 (en) * | 2001-09-28 | 2003-03-28 | Institut Pasteur | Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections |
AU2003241103A1 (en) * | 2002-04-23 | 2003-11-10 | Umberto Dianzani | Compositions containing anti-hiv peptides and methods of use |
GB0405480D0 (en) * | 2004-03-11 | 2004-04-21 | Istituto Superiore Di Sanito | Novel tat complexes,and vaccines comprising them |
-
2008
- 2008-08-25 CA CA2697370A patent/CA2697370A1/en not_active Abandoned
- 2008-08-25 BR BRPI0815743-0A2A patent/BRPI0815743A2/en not_active IP Right Cessation
- 2008-08-25 EP EP08798605A patent/EP2192918A1/en not_active Withdrawn
- 2008-08-25 WO PCT/US2008/074179 patent/WO2009029569A1/en active Application Filing
- 2008-08-25 JP JP2010522101A patent/JP2010536885A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2009029569A1 (en) | 2009-03-05 |
JP2010536885A (en) | 2010-12-02 |
BRPI0815743A2 (en) | 2015-02-18 |
EP2192918A1 (en) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8936789B2 (en) | Immunoenhancer-linked oligomeric HIV envelope peptides | |
US8790898B2 (en) | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies | |
CA2942450A1 (en) | Mutant staphylococcal antigens | |
DK2464658T3 (en) | Detoxified escherichia coli immunogens | |
US20080300385A1 (en) | Covalently-linked complexes of HIV Tat and Env proteins | |
CA2697370A1 (en) | Hiv env proteins with modifications in the v3 loop | |
PT99063B (en) | PROCESS FOR THE PRODUCTION OF A GLYCOPROTEIN AND VACCINES THAT CONTAINS IT | |
JP2015512394A (en) | Stable peptidomimetics of the HIV-1GP41 prehairpin intermediate | |
EP2019686B1 (en) | Combined mucosal and parenteral immunization against hiv | |
CA2750067C (en) | Splitting gp41 | |
AU2007249937B2 (en) | HIV-1 immunogenic compositions | |
CA2750058C (en) | Novel gp41 antigens | |
AU2010210071B2 (en) | Novel gp41 antigens | |
Sellhorn et al. | JVI Accepts, published online ahead of print on 26 October 2011 | |
AU2013203188A1 (en) | Detoxified Escherichia coli immunogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20130826 |
|
FZDE | Discontinued |
Effective date: 20150825 |